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Summary 
Y. pseudotuberculosis is a human pathogenic bacterium that is responsible for several 
gastrointestinal diseases commonly called yersiniosis. The pathogen is generally ingested as 
contaminated food or water. Once in the intestine, Yersinia enters the lymphatic system 
through the M-cells of the small intestine to colonize and invade their hosts.  
Yersinia has several multifunctional adhesins on its surface that contribute to its 
pathogenicity. These virulence factors are in turn controlled by complex regulatory networks 
that control the expression of these genes, which help Yersinia to survive and adapt to their 
rapidly changing environment. The projects presented here involve the structural and 
functional characterization of adhesins and the virulence regulator RovC of 
Y. pseudotuberculosis. 
Enteropathogenic Yersiniae express three important adhesins, belonging to different protein 
classes: Invasin, YadA and Ail. Invasin-like proteins represent a subgroup of the adhesin 
family that specifically interacts with receptors on the host cell plasma membrane. The C-
terminal domain of Invasins provides specificity for interaction with host-derived factors. 
Invasin (InvA) is the major adhesion factor of Y. pseudotuberculosis and it promotes binding 
of Yersinia to epithelial cells. In addition to InvA, three additional Invasins InvB, InvC and 
InvD have been identified in Y. pseudotuberculosis YPIII. Unlike InvB and InvC whose C-
terminal domain share high sequence similarity with InvA and thus are likely to share a 
common fold, InvD C-terminal domain shares no sequence homology with any of the other 
three Invasins. The aim of this work was to get insight into the structure and function of the C-
terminal domain of InvD.  
To achieve this, InvD construct with two BIg-like domains and the adhesion domain was 
cloned, expressed, purified and crystallized. The structure was solved to 2.6 Å resolution by 
combining molecular replacement with single wavelength anomalous dispersion (MR-SAD). 
The overall shape seen in the crystal structure was confirmed in solution by Small Angle X-
ray Scattering (SAXS). The N-terminal domains of crystallized InvD reveal similarities to the 
Immunoglobulin Superfamily (IgSF) fold. In contrast, the C-terminal domain adopts a novel 
fold. The surface of the adhesion domain clearly shows two highly conserved patches that 
might be involved in targeting the host molecule. Fab fragment of immunoglobulins was 
identified as the host interaction partner of InvD by pull downs and microscale 
thermophoresis (MST) experiments. Phage display panning, pull downs and MST 
experiments confirmed the specificity of InvD towards VH3/VK1 fragment of the antibody. 
Furthermore, fluorescent activated cell sorting experiments revealed that InvD binds 
specifically to B-cell population while no binding was observed with the other immune cells. 
                                                                                                                               Summary 
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In addition to InvD, a novel Invasin, InvE has been identified in the IP31758 strain of 
Y. pseudotuberculosis. First 1730 aa of InvE are highly homologous to that of InvD, but the 
C-terminal domain is significantly different. Hence, the aim of this project was to gain insights 
into the structure of InvE. To achieve this, InvE construct with two BIg-like domains and the 
adhesion domain was cloned, expressed, purified and crystallized. The crystals obtained 
diffracted to approx. 8 Å resolution. Any attempts to improve the crystal quality were not 
successful. Therefore, surface entropy reduction (SER) approach was used to alter 
crystallization behavior. The crystals obtained with SER mutant diffracted to 1.7 Å and the 
structure was solved by using a Seleno-Methionine (Se-Met) variant of InvE SER mutant. 
The rod shaped structure of InvE was confirmed in solution by SAXS. The N-terminal 
domains of crystallized InvE reveal similarities to the IgSF fold. In contrast, the C-terminal 
domain adopts a C-type lectin like fold and share high structural similarity with the C-type 
lectin like domain of InvA and Intimin, even though there exists no sequence homology 
among these proteins.  
YadA of Y. enterocolitica (ent) and Y. pseudotuberculosis (pstb) exhibit differences in their 
specificity of extracellular matrix (ECM) substrate binding. This difference is due to a unique 
N-terminal 31 aa sequence which is present in YadApstb and absent in YadAent. The goal of 
this work was to provide the structural basis for the functional transition by solving the 
structure of YadApstb and to compare it with the known YadAent structure. For that purpose, 
the head region of YadApstb was cloned, expressed, purified and crystallized. The structure 
was solved to 2.3 Å resolution by molecular replacement. However, due to the high flexibility, 
this insertion was only partially visible in the crystal structure. Despite of the partial flexibility, 
the results show that the insertion region is located at the tip, which is likely to change the tip 
surface and influence ECM specificity.  
A novel virulence regulator, RovC has been recently identified in Y. pseudotuberculosis that 
activates Type6 secretion system-4 transcription. RovC is highly conserved among Y. pestis 
and Y. pseudotuberculosis, but does not exhibit homology to any other known protein. The 
aim of this work was to get insights into the structure and DNA binding activity of this novel 
regulator. For that purpose, full length RovC was cloned, expressed, purified and crystallized. 
The structure was solved to 2.3 Å resolution by using a Se-Met variant of RovC. Crystallized 
RovC consists of two domains- the N-terminal domain comprised of α-helices and β-strands 
that adopts a distinct fold, and the C-terminal domain containing a helix-turn-helix motif. 
SAXS analysis of RovC revealed the hexameric ring-shaped structure which was validated 
by multi angle light scattering and site-directed mutagenesis experiments. Furthermore, site-
directed mutagenesis approach and MST were used to characterize the DNA binding activity 
and the model has been proposed in which DNA wraps around the surface of hexameric 
RovC. 
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1 Introduction 
In order to survive in their niche, bacterial pathogens armor themselves with a variety of 
virulence factors that are needed by them to adhere and invade the host tissues, escape and 
modulate the host immune system. The expression of these virulence factors is in turn 
controlled by complex regulatory networks. This helps bacteria to survive and adapt to their 
rapidly changing environment (Erhardt and Dersch, 2015). 
1.1 The genus Yersinia 
The genus Yersinia was named after a swiss-born French physician Alexandre Jean Emile 
Yersin (1863-1943) who discovered the plague bacillus in 1894 (Hawgood, 2008). 
The genus Yersinia comprises seventeen different species of which Yersinia pestis, Yersinia 
pseudotuberculosis and Yersinia enterocolitica are pathogenic to humans (Savin et al., 
2014). All these species show high tropism for lymphatic tissues and the ability to protect 
themselves against the host immune system (Balada-Llasat and Mecsas, 2006). 
Y. pestis is commonly transmitted to humans by the bites of infected fleas and causes 
plague, while Y. pseudotuberculosis and Y. enterocolitica are enteropathogenic to humans. 
Y. pseudotuberculosis and Y. pestis have a nearly identical chromosomal DNA sequence. Y. 
pestis genome shares 83% homology to Y. pseudotuberculosis (Moore and Brubaker, 1975) 
and it is now evident that Y. pestis has evolved from Y. pseudotuberculosis (Achtman et al., 
1999). Although the life cycle and the character of disease caused by Y. pestis is very 
different from that of Y. pseudotuberculosis, these two species are so closely related that Y. 
pestis is classified as a pseudotuberculosis subspecies.  
1.2 Mode of infection of Y. pestis 
Y. pestis is a causative agent for a systemic infectious disease known as plague. The major 
carriers of Y. pestis are ground dwelling rodents which transmit disease to humans through 
infected flea bites (Figure 1). Y. pestis then resides in the lymphatic tissues, which leads to 
bubonic plague. This is the most commonly occurring form of plague. In some cases, inhaling 
Y. pestis particles present in the air can lead to pneumonic plague which affects the lungs. 
Pneumonic plague is the most uncommon, but the most deadly form of plague. In rare cases, 
when Y. pestis multiplies in the blood stream, it can also lead to septicemic plague (Heroven 
and Dersch, 2014). 
When Y. pestis invades the host skin, it encounters macrophages and other immune cells at 
the site of invasion. To escape the host immune system, it survives and replicates within the 
host macrophages during the early stages of infection. This intracellular growth is necessary 
for the pathogenesis of bacteria. When the bacterium reaches the lymph nodes, it escapes 
      Introduction  
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from the macrophages, develops resistance to phagocytosis and survives extracellularly. At 
this point, the bacteria use several Type 3 Secretion System (T3SS) effector proteins to inject 
into the target cell, to further modulate the host immune system (Li and Yang, 2008; Mikula et 
al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Mode of infection of Y. enterocolitica and Y. pseudotuberculosis 
Y. enterocolitica and Y. pseudotuberculosis are food-borne pathogens that cause several 
gastrointestinal diseases (yersinioisis) which further lead to enteritis, acute mesenteric 
lymphadenitis and terminal ileitis. Both of these species exhibit 55% sequence identity at the 
nucleotide level (Snellings et al., 2001). For Y. enterocolitica, swine is the most common 
reservoir from which pathogenic strains have regularly been isolated (Bottone, 1999). Y. 
pseudotuberculosis pathogenic strains are on the other hand isolated from different sources 
such as water, soil, fresh vegetables and wild animals (Heroven and Dersch, 2014). These 
are generally ingested as contaminated food or water and traverse the gastrointestinal tract 
(Figure 1). 
Once Yersinia reaches the small intestine, it encounters microfold cells (M cells). M cells are 
specialized epithelial cells of the follicle-associated epithelium (FAE) of the gastrointestinal 
tract and are responsible for the uptake of antigens and microorganisms and delivery to the  
 
Figure 1: Infection routes of pathogenic Yersinia. The main reservoirs for Y. pseudotuberculosis and Y. 
enterocolitica are pork and fresh vegetables. Once ingested, the bacteria cross the epithelial barrier and enter 
the lymphatic system. In contrast to the two enteropathogenic Yersinia species, Y. pestis enters the human 
lymphatic system by the bite of an infected flea and causes bubonic plague (Adapted from (Heroven and Dersch, 
2014)). 
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immune cells of the lymphoid tissues (Kucharzik et al., 2000). To invade epithelial cells, 
Yersinia binds to at least five different β1- integrin receptors (α3β1, α4β1, α5β1, α6β1 and αvβ1) 
expressed on the surface of M cells (Isberg and Leong, 1990). The adhesion is mediated by 
the outer membrane protein Invasin (InvA), which is the very first virulence factor required by 
Yersinia during the early stages of infection. This interaction further induces the interaction of 
cytoplasmic β1 chain with focal adhesion kinases (FAKs), Src and Rac-1-Arp2/3 complex 
which leads to cytoskeletal rearrangement, a prerequisite for bacterial uptake. This process is 
called zipper mechanism. Yersinia internalized by zipper mechanism, remains intracellular 
surrounded by the vacuole. The bacterium is released from the vacuole into the dome region 
of FAE. Once Yersinia has translocated across the epithelial barrier, it is exposed to a variety 
of immune cells such as dendritic cells, macrophages and lymphocytes. At this stage, 
Yersinia injects several Yop (Yersinia outer proteins) into the macrophages which provides 
resistance to bacteria against phagocytosis and help it to survive extracellularly. Furthermore, 
virulence factors of Yersinia like YadA (Yersinia adhesion A) and Ail (Adherence and 
Invasion Locus) provide resistance against complement mediated lysis (Barnes et al., 2006; 
Reis and Horn, 2010) (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
1.4 Virulence factors of Yersinia 
To survive and replicate inside the host, Yersinia carries several essential plasmids and 
chromosome encoded virulence factors. 
All the pathogenic strains of Yersinia carry a 70 kb virulence plasmid termed pYV (plasmid for 
Yersinia virulence) which differentiates pathogenic from non-pathogenic strains. The pYV 
plasmid is also called low calcium response plasmid (pLCR) as it restricts the growth of 
 
Figure 2: Route of infection of 
enteropathogenic Yersinia. Via consumption 
of contaminated food or water, the pathogen is 
ingested and reaches the small intestine. Once 
in the intestine, it binds to β1- integrins present 
on the M cells, which resulted in the uptake of 
bacteria by zipper mechanism. Once the 
bacteria reach the dome region of FAE, it is 
exposed to a variety of immune cells. Thereby 
Yersinia uses several of its virulence factors 
such as (Yop and T3SS) to escape the host 
system (Adapted from (Reis and Horn, 2010)). 
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Yersinia in calcium deficient media. This plasmid is essential for virulence in all the three 
species of Yersinia (Hu et al., 1998; Huang et al., 2006). 
The pYV plasmid codes for YadA, T3SS and several Yops which are essential for bacterial 
replication in the host. YadA is a multifunctional surface exposed protein that binds to 
extracellular matrix proteins and also provides resistance to serum complement lysis. The 
pYV encoded T3SS injects different Yops into the host cell which interferes with the host 
signal transduction pathway, provides resistance to Yersinia against phagocytosis by 
macrophages and polymorphonuclear leukocytes and also promotes the survival of Yersinia 
inside the cell by blocking the inflammatory response of cells to infection (Cornelis, 2002). 
Besides the plasmid associated pathogenicity factors, Yersinia also harbors inv and ail which 
are chromosomally encoded virulence genes. inv codes for Invasin, which is an essential 
protein required by Yersinia to get entry inside the cell during the initial stages of Y. 
pseudotuberculosis and Y. enterocolitica infection. ail codes for Ail protein, which plays a 
significant role in immune evasion (Biedzka-Sarek et al., 2008). In contrast to inv, ail is only 
found in Y. enterocolitica. Strains that lack the virulence plasmid remain invasive indicating 
that the factors responsible for invasion are located on the chromosome of Yersinia (Portnoy 
et al., 1981). 
Pathogenic species of Yersinia also possess a large chromosomal fragment known as the 
High Pathogenicity Island (HPI) which encodes for yersiniabactin system and is involved in 
siderophore mediated iron-uptake (Perry and Fetherston, 2011). 
Two specific plasmids that are unique to Y. pestis, and are not shared by the 
enteropathogenic species of Yersinia are pMT1/pFra and pPCP1/pPst. The 100 kb 
pMT1/pFra encodes for murine toxin and F1 capsular antigen, former is required for survival 
of Y. pestis in the flea gut, while the latter provides resistance against phagocytosis. The 9.6 
kb plasmid pPCP1/pPst encodes for the Plasminogen activator (Pla) which is required by Y. 
pestis for efficient dissemination in host tissues (Du et al., 2002; Huang et al., 2006; Rajanna 
et al., 2010). 
The uncharacterized plasmid pVM82 has been reported in the strain of Y. 
pseudotuberculosis IP31758. It could be shown that pVM82 provides antiphagocytic and 
immunosuppressive capabilities to Y. pseudotuberculosis. It also codes for type IVB icm/dot 
secretion system. This system is only present in IP31758 strain of Y. pseudotuberculosis and 
might mediate its intracellular survival in epithelial cells (Eppinger et al., 2007). 
1.5 Yersinia adhesins 
In order to infect a cell, Yersinia possesses multifunctional adhesins (Figure 3) on its surface. 
These are not only required by bacteria to get entry inside the cell but are also required for 
efficient colonization and infection. 
Introduction                                                                          
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1.5.1 Invasin-like proteins 
Invasin or Invasin-like proteins of Y. pseudotuberculosis belong to the family of adhesins that 
share a common architecture (Figure 4A). They consist of i) an N-terminal highly homologous 
β-barrel-like domain, which is responsible for the attachment of Invasins to the outer 
membrane region of bacteria, ii) repetitive Ig-like domains, which vary significantly in number 
among Invasins and iii) typically a C-terminal C-type lectin domain, often described as the 
capping or adhesion domain, which provides specificity for interaction with host-derived 
factors (Pisano et al., 2012).  
The arrangement of domains present in Invasins is similar to that found in classical 
autotransporters (Va). However, the order of domains is reversed in Invasins (Figure 4B); 
because of this arrangement, Invasins are categorized in Inverse autotransporter (Ve) family 
(Leo et al., 2014; Oberhettinger et al., 2012).  
 
InvasinA 
Invasin (InvA) is only expressed by the two enteropathogenic species of Yersinia, 
Y. pseudotuberculosis and Y. enterocolitica (Simonet et al., 1996). The inv gene codes for 
InvA which has a molecular weight of 92 kDa and 106 kDa in Y. enterocolitica and 
Y. pseudotuberculosis, respectively (Isberg and Leong, 1990). InvA is expressed at low 
temperatures, e.g. in stored foods which is beneficial for rapid ingestion of Yersinia by the 
host cells (Grassl et al., 2003).  
  
 
Figure 3: Schematic overview of different outer membrane proteins expressed by pathogenic Yersinia.                
A) Adhesins of Y. pseudotuberculosis and Y. enterocolitica. B) Adhesins of Y. pestis. ECM stands for 
extracellular matrix, OM stands for Outer membrane. (Adapted from (Mikula et al., 2012)). 
 
A B 
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Y. pseudotuberculosis InvA is responsible for binding to β1- integrins and causes bacterial 
uptake. The crystal structure of InvA with four BIg like domains and the adhesion domain has 
already been solved (Hamburger, 1999) (Figure 5). The crystal structure is composed of four 
domains (D1-D4), which adopt a fold that is typical of the eukaryotic Immunoglobulin 
superfamily (IgSF) fold. The D5 domain has a folding topology related to the C-type lectin 
domain. 
Although InvA does not possess the RGD motif, the overall topology and the substrate 
specificity of the D5 domain are similar to that of fibronectin. Both D4 and D5 together form a 
superdomain that is essential and constitutes the minimum motif required for integrin binding 
(Leong et al., 1990). InvA binds to integrins with the affinity that is ~100 times higher than 
that of fibronectin binding.  
The D2 domain of InvA is responsible for homotypic interaction which increases the efficiency 
of bacterial uptake by multimerization. In contrast, this domain is absent in Y. enterocolitica; 
Figure 4: Invasin-like proteins of Y. pseudotuberculosis. A) Domain architecture of Invasin-like inverse 
autotranspoter proteins of YPIII and IP31758 strain of Y. pseudotuberculosis. Their N terminus region consists of 
an export signal peptide (SP; in black) followed by the β-barrel (gray). The part that projects out from the β-barrel 
consists of repetitive Ig-like domains (blue/green) and a C-terminal domain. B) Comparison of Inverse 
autotransporters (Type Ve) with classical autotransporters (Type Va). Type Va autotransporters consist of an N-
terminal signal peptide which mediates the export of polypeptide into the periplasm, followed by the passenger 
domain (red), which forms the extracellular domain, the linker (brown) and the β-barrel which is responsible for 
translocation of the passenger domain. Type Ve contains the same domains but in reversed order. 
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hence InvA of Y. enterocolitica is unable to form multimers and the invasion process is much 
less efficient as compared with Y. pseudotuberculosis invasion (Dersch and Isberg, 2000).  
 
 
 
 
 
 
 
 
 
The expression pattern of InvA is temperature regulated with the maximum expression at 
lower temperature (20-25°C) and minimal expression at 37°C. Regulation occurs at the 
transcriptional level by RovA. RovA belongs to MarR/SlyA family of the transcriptional 
regulators found in Enterobacteriaceae (Revell and Miller, 2000). Binding of RovA to the AT 
rich region of the inv promoter at 25°C activates inv expression (Heroven et al., 2004). 
Binding of RovA is temperature dependent and is subject to silencing by the nucleoid-
associated H-NS protein. At higher temperatures, RovA gets partially defolded which reduces 
its DNA binding capability. Transcription of RovA is also repressed by RovM. RovM belongs 
to the LysR type transcriptional regulator family. It interacts with the DNA region 30 bp 
upstream of rovA promoter, which represses RovA transcription. RovM in turn is controlled 
by global post transcriptional acting system of Yersinia called Carbon Storage Regulator 
(Csr) system (Heroven and Dersch, 2006; Heroven et al., 2008). 
 
InvasinB 
InvasinB (InvB) was recently identified in YPIII. It encodes for 1075 aa protein and consists of 
an N-terminal β-barrel domain, three BIg-like domains and the C-terminal adhesion domain 
(Figure 4A). InvB is also present in IP31758, IP32953 and PB1/+ strain of Y. 
pseudotuberculosis but is absent in Y. pestis. Due to its high sequence similarity with InvA 
and Intimin, this protein is termed as Ifp (Intimin family protein) in IP32953 strain. Intimin is 
the adhesin expressed by enteropathogenic E. coli (EPEC) and enterohaemorrhagic E. coli 
(EHEC). The C-terminal domain of Intimin adopts a C-type lectin like fold and also shares 
structural similarity with that of InvA. InvB is expressed at 37°C and binds to human, murine 
and porcine intestinal cells. Furthermore, it plays a role in pathogenesis by promoting 
 
Figure 5: Crystal structure of InvA. Cartoon representation of the crystal structure of InvA (PDB ID:1CWV) 
consisting of the N-terminal BIg domains (D1-D3, shown in blue and D4, shown in green) and the C-terminal C-
type lectin domain (D5, shown in red) (Hamburger, 1999).  
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invasion and replication in lymphatic tissues and organs (Pisano et al., 2012; Strong et al., 
2011). 
 
InvasinC 
A very large protein InvasinC (InvC), comprising of 5337 aa was identified in the YPIII strain 
of Y. pseudotuberculosis. It consists of an N-terminal β-barrel domain, 47 BIg-like domains 
and the C-terminal adhesion domain (Figure 4A). It is present in IP31758, IP32953 and 
PB1/+ strain of Y. pseudotuberculosis, but the number of BIg-like domains varies significantly 
in different strains. InvC is highly homologous to Y. pestis Ilp (Intimin/Invasin-like protein). 
Like InvB, InvC was also shown to promote binding to epithelial cells. Deletion of InvC from 
Y. pseudotuberculosis does not significantly affect the host cell binding while deletion of Ilp 
reduces the dissemination capability of Y. pestis (Pisano et al., 2012; Seo et al., 2012). 
 
In addition to InvA, InvB and InvC, two novel Invasins have been recently identified in the 
strains YPIII and IP31758 of Y. pseudotuberculosis. Bioinformatics analysis reveals that the 
C-terminal domain of these Invasins shares no sequence similarity with the other three 
Invasins. Apart from that, not much analysis has been done (Pisano et al., 2012).  
 
InvasinD from YPIII strain of Y. pseudotuberculosis 
InvasinD (InvD) was recently identified in YPIII strain of Y. pseudotuberculosis. It is a 1976 aa 
protein, comprising of an N-terminal β-barrel domain, 13 Ig-like domains and a unique C-
terminal adhesion domain (Pisano et al., 2012) (Figure 4A). 
 
InvasinD from IP31758 strain of Y. pseudotuberculosis 
In addition to InvB, InvC and InvD (YPIII strain), invD gene encoding 2795 aa protein has 
been identified in IP31758 strain of Y. pseudotuberculosis. The first 1730 aa of InvD of Y. 
pseudotuberculosis IP31758, corresponding to BIgs, are highly homologous to InvD from Y. 
pseudotuberculosis YPIII, but the C-terminal domain is significantly different (Pisano et al., 
2012) (Figure 4A). Due to the significant difference in the C-terminal domain, which in 
adhesins typically mediates interaction with host molecules, InvD Y. pseudotuberculosis 
IP31758 will hereafter be referred to as (InvasinE) InvE, a novel member of the Invasin-
family. 
1.5.2 YadA 
YadA is a lolli-pop shaped protein present on the cell surface of Yersinia that belongs to the 
family of trimeric autotransporters (TAA) (Hoiczyk et al., 2000). YadA is located on the 70 kb 
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virulence plasmid of Yersinia and is expressed by Y. enterocolitica and Y. 
pseudotuberculosis at 37°C immediately after Yersinia crosses the intestinal barrier. yadA in 
Y. pestis is not expressed due to single nucleotide deletion which leads to a frame shift 
mutation and a premature stop codon. Inactivation of YadA in Y. enterocolitica leads to a 
virulence in mouse infection model whereas inactivation of YadA in Y. pseudotuberculosis 
does not affect virulence (Rosqvist et al., 1988). 
YadA consists of an N-terminal extracellular region called the ‘’passenger region’' followed by 
a C-terminal membrane anchor. The passenger region consists of the head domain, followed 
by the neck and a rigid coiled-coil pillar like stalk domain. The structure of the head along 
with the neck region of YadA from Y. enterocolitica (YadAent) has been solved (Nummelin et 
al., 2004). The head domain of YadAent (aa 24-196) is solely composed of β-sheets that adopt 
a left-handed parallel β roll (LPBR) arrangement. The LPBR is composed of a 13-16 residue 
repeat motif, containing an NSVAIGXXS repeat with a highly conserved G. NSVAIGXXS 
motif forms the hydrophobic interior of the trimer. The neck region connects the LPBR region 
to the coiled coil stalk domain (Figure 6A) (Nummelin et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YadA is a multifunctional protein. In Y. enterocolitica, YadA mediates binding to extracellular 
matrix (ECM) components such as laminin, collagen and fibronectin. It preferably binds to 
collagen I, II, III and V. YadAent-collagen interaction is quite stable and can tolerate extremes 
of pH, temperature and is resistant to proteases and chaotropic agents (Emody et al., 1989). 
Binding affinity of YadAent to other ECM components, such as fibronectin and laminin is low 
 
Figure 6: Structure of Y. enterocolitica YadA. A) Cartoon model of the trimeric YadAent crystal structure (PDB 
ID:1P9H) consisting of the N-terminal head and the C-terminal neck region (Nummelin et al., 2004). B) 
Alignment of the N-terminal section of the head domain of YadA of Y. enterocolitica (serotype O:8) and Y. 
pseudotuberculosis. 31 aa insertion that is unique to YadApstb is marked in an orange box. 
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as compared to collagen. YadAent does not bind to plasma fibronectin but only to cellular 
fibronectin (Emody et al., 1989; Heise and Dersch, 2006). 
In contrast, YadA of Y. pseudotuberculosis (YadApstb) preferentially binds fibronectin and 
mediates cell invasion. This is due to the presence of an additional 31 aa (amino acids 53-83) 
at the N-terminal region of the head domain of YadApstb (Figure 6B). Deletion of this region 
results in the loss of cell invasion property of Y. pseudotuberculosis and bacteria gains high 
affinity for collagen and laminin binding and hence this region has been named as “uptake 
domain” but the structural basis for this is unclear (Heise and Dersch, 2006). In contrast to 
InvA, YadA- β1 integrins interaction is not direct and occurs via an ECM bridging mechanism. 
YadA interaction with the ECM molecules which are present on the epithelial cells, triggers 
signaling cascades via the β1- integrin receptors bound to the ECM molecules (Eitel and 
Dersch, 2002). 
Besides its function as an adhesin, YadAent also provides protection to the bacteria by 
blocking the innate immune system. It provides serum resistance to Yersinia by binding to 
complement factors like factor H, C3b and C4BP thereby preventing complement mediated 
lysis (Biedzka-Sarek et al., 2008a; Kolodziejek et al., 2010).  
1.5.3 Ail 
Ail is a 17 kDa outer membrane protein, chromosomally located and present in all three 
pathogenic Yersinia species. It is responsible for host cell adhesion and evading host 
immune response. Ail is expressed at 37°C during the stationary phase (Pierson and Falkow, 
1993). The crystal structure of Ail from Y. pestis has been solved (Yamashita et al., 2012) 
(Figure 7).  
 
 
 
 
 
 
 
 
It forms an eight stranded anti-parallel β-barrel structure that spans the outer membrane with 
four extracellular loops that are responsible for cell adhesion. It is structurally similar to the E. 
coli invasion protein OmpX (Yamashita et al., 2012) (Figure 7). 
In Y. enterocolitica and Y. pestis, Ail mediates attachment to ECM proteins such as laminin, 
fibronectin and heparin sulfate, while Y. pseudotuberculosis Ail does not mediate binding to 
 
Figure 7: Crystal structure of Ail. Structure of Ail 
(PDB ID:3QRA) shown in cartoon model 
(Yamashita et al., 2012). 
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ECM (Miller et al., 2001). Ail is responsible for binding C4BP and factor H, thus blocks the 
complement activation pathway which leads to bacterial survival. Unlike YadA, it can be 
masked by the lipopolysaccharide O antigen in Y. pseudotuberculosis and Y. enterocolitica 
due to the small size of the extracellular regions of Ail. Thus the serum resistance, adhesion 
and internalization activity of Ail is dependent on the LPS core structure (Biedzka-Sarek et 
al., 2008; Kolodziejek et al., 2010). 
1.5.4 Pla 
Plasminogen activator (Pla) is the outer membrane protein of Y. pestis that belongs to the 
family of OM proteases/adhesins. It is encoded by pCP1 plasmid of Y. pestis. Deletion of this 
gene reduces the virulence of Y. pestis in supporting pneumonic plague and bubonic plague. 
The structure of Pla (312 aa) forms a narrow β-barrel and is composed of ten antiparallel β-
strands. The strands are connected by short turns at the periplasmic side (bottom) and by 
loops at the extracellular side (top) (Eren et al., 2010) (Figure 8). Pla is actively associated 
with virulence as it cleaves plasminogen to plasmin and in turn activates matrix 
metalloproteinases which leads to degradation of networks in extracellular matrices.  
 
 
 
 
 
 
 
 
This activity helps in dissemination of bacteria from the primary infection site by preventing 
the formation of fibrin around them and also in inhibiting the formation of microabscesses. Pla 
has also been shown to cleave complement protein C3, providing resistance to bacteria 
against complement mediated lysis. However, Y. pestis strain that lacks Pla is resistant to 
this complement system indicating that this is not its major function (Sodeinde et al., 1992). 
At 37°C, Pla could mediate translocation of Yop proteins to host cells by positioning the 
T3SS in such a manner that Yop proteins could be injected into the host cell (Felek et al., 
2010). 
1.5.5 PsaA 
PsaA (pH six antigen A) is encoded by the chromosomal region of Yersinia and contributes to 
its virulence. Several subunits of 15 kDa PsaA form a fibrillary structure called pH6 antigen. 
 
Figure 8: Crystal structure of Pla. 
Structure of Pla (PDB ID: 2X55) shown in 
cartoon model (Eren et al., 2010). 
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The structure of PsaA adopts an Ig-like fold and consists of seven β-strands (Bao et al., 
2013) (Figure 9). It is produced inside the macrophages in an acidic intracellular environment 
and extracellular environment in abscesses such as buboes (Lindler and Tall, 1993; Lindler 
et al., 1990). pH6 of Y. pestis and Y. pseudotuberculosis promotes hemagglutination and 
also promotes thermoinducible binding to tissue culture cells (Yang et al., 1996). 
 
 
 
 
 
 
 
 
 
 
pH6 of Y. pestis binds to lipoproteins which prevents recognition of the bacteria by the host 
immune system (Makoveichuk et al., 2003). Y. enterocolitica possesses Myf, a homologue of 
pH6 which also forms a fibrillary structure. The exact function of Myf is however not clear 
(Yang and Isberg, 1997). 
1.6 Bacterial secretion system 
Gram-negative bacteria possess a variety of secretion machines to export wide ranges of 
substrates, including DNA, proteins, and small molecules across the bacterial cell envelope. 
In Gram-negative bacteria, these nano-machines are of six different types clustered in two 
subgroups (Figure 10)- 
i) Secretion machines that span the double membrane- Type 1 Secretion System (T1SS), 
T2SS, T3SS, T4SS and T6SS.  
ii) Secretion machine that spans only the outer membrane (OM) of the bacteria- T5SS 
(Abdallah et al., 2007). 
 
1.6.1 T1SS 
The T1S system delivers a large variety of molecules from the cytoplasm to the extracellular 
environment in a single step, independent of the SecYEG translocon. This system is 
composed of three components: i) IMC (Inner Membrane Component) that belongs to the 
ATP binding cassette transporter, ii) a periplasmic adaptor protein and iii) TolC, which forms 
 
Figure 9: Crystal structure of PsaA. 
Structure of PsaA (PDB ID: 4F8O) shown in 
cartoon model (Bao et al., 2013). 
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the outer membrane channel. Binding of substrates to the IMC triggers the sequential 
assembly of IMC, periplasmic adaptor and TolC. This leads to the opening of TolC and the 
substrate is released into the extracellular space (Costa et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6.2 T2SS 
The T2S system is composed of 12-15 components that transport a variety of proteins (such 
as toxins, hydrolyzing enzymes that are mainly involved for bacterial survival in their niche) to 
the extracellular environment in two steps. In the first step, unfolded polypeptides are 
transported to the periplasm by the SecYEG translocon. Folded proteins are then transported 
from the periplasm to the extracellular space in a separate step which is mediated by the 
secreton. The secreton is formed by the OM component (secretin) and the IM component 
that pushes the substrate through the OM pore (Costa et al., 2015; Sandkvist, 2001). All 
pathogenic and non-pathogenic species of Yersinia possess one or two copies of T2SS, but 
not much is known about the role of this system in Yersinia (von Tils et al., 2012). 
1.6.3 T3SS 
T3SS, also called injectisome, is found in a variety of pathogenic Gram-negative bacteria. 
T3SS is structurally and functionally analogous to bacterial flagella (Blocker et al., 2003). It 
 
 
Figure 10: Bacterial secretion systems.  
Type 1 secretion system is composed of the inner membrane (IM) component, membrane fusion protein and the 
outer membrane (OM) component. Substrates are transported into the extracellular space by a one-step 
mechanism.             
Type 2 secretion system spans the double membrane of the bacteria. Substrate is transported to the periplasm 
by the Sec translocon machinery. Proteins fold in the periplasm and are transported to the extracellular space. 
Type 3 secretion system forms a channel that spans the double membrane and extends to contact host cell‘s 
plasma membrane. 
Type 4 secretion system also transports substrate directly to the host cell by a one or a two-step mechanism. 
In Type 5 secretion system, the SEC translocon is used to transfer substrates to the periplasm. A β-barrel 
domain inserts into the OM and the passenger domain is translocated through the β-barrel. 
Type 6 secretion system spans the cell envelope of bacteria. The mechanism of secretion resembles the 
contraction mechanism of phage tails. (Adapted from (Abdallah et al., 2007)). 
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transfers bacterial effector proteins directly into the host cell cytoplasm, bypassing the 
extracellular environment in a Sec-independent manner. Within the host cell, these effector 
proteins modulate or interfere with the host cell processes and promote bacterial invasion 
and colonization. The system is made up of 20 different bacterial components that form a 
syringe like structure which spans the inner membrane, periplasm and the outer membrane 
of bacteria, with the needle extending out of the bacteria. Secretion of bacterial proteins 
occurs, when the tip of the complex contacts the host cell plasma membrane. This contact 
triggers the release of translocator proteins that form pores in the host cell plasma 
membrane. The needle tip attaches to the pore, thus completing a channel through which 
effector proteins are passed from the cytoplasm into the host cell (Galán et al., 2014). All 
pathogenic species of Yersinia use this system to deliver effector proteins into the host cell, 
thereby they gain resistance to phagocytosis and escape the host immune system (Cornelis, 
2002).  
1.6.4 T4SS 
T4SS is composed of twelve different proteins that together form the entire double membrane 
spanning secretion apparatus. T4SS is classified into three subfamilies depending on its 
function. The first subfamily delivers DNA to other bacteria, fungi or plant cells by cell to cell 
contact. The second subfamily involves DNA uptake from and release into the extracellular 
environment and promotes genetic exchange. The third system is the effector translocator 
system that contributes to transfer of effector proteins to eukaryotic cells (Cascales and 
Christie, 2003). 
1.6.5 T5SS 
T5SS also called as the autotransporter system, is a single membrane spanning secretion 
system. This machine requires the SecYEG translocon to mediate export of proteins to the 
periplasm. Proteins that transport through this mechanism consist of a β-barrel domain also 
called translocation domain, that inserts into the OM and the passenger domain is secreted 
through the pore of the β-barrel. This system is divided into five subclasses-Va, Vb, Vc, Vd 
and Ve (Leo et al., 2012). 
Va secretion system- It uses a classical form of autotransport in which the protein is 
transported to the periplasm by the Sec machinery via its N-terminal signal peptide. In the 
periplasm, various chaperones such as SurA, Skp, FkpA and DegP are involved in quality 
control of the transported protein. The signal peptide is cleaved off and the C-terminal β-
barrel domain inserts into the OM with the help of Bam complex. The linker region then forms 
a hairpin inside the pore of the barrel which enables the transport of the passenger domain 
into the extracellular space through the pore of the β-barrel (Leo et al., 2012). 
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Vb secretion system- This system is also known as the Two-Partner Secretion System 
(TPSS). As the name suggests, the passenger domain (referred to as TpsA) and the 
translocation domain (TpsB) are present as separate polypeptide chains which are 
transported to the periplasm by the Sec machinery. In the OM, TpsB protein folds into a β-
barrel structure. TpsA protein contains the two-partner secretion (TPS) domain that targets 
the protein to TpsB, TpsA protein is then translocated through the OM into the extracellular 
space (Henderson et al., 2004; Leo et al., 2012). 
Vc secretion system- This secretion system is also called trimeric autotransporters, the 
prototype of which is YadA. As the name suggests, these are homotrimeric proteins, with the 
translocation domain and the passenger domain being made up of three polypeptide chains. 
The system follows a similar transport mechanism like the Va system, but the major 
difference is the presence of three instead of one polypeptide chain (Leo et al., 2012). 
Vd secretion system-This system is similar to that of Vb secretion system, the major 
difference being that the two polypeptides are fused in a single polypeptide (Leo et al., 2012). 
Ve secretion system–This system is known as the inverse autotransporter family, the 
prototype of which is the Invasins. In contrast to Va autotransporters, their topology is 
inverted. Their translocation domain is at the N-terminus while the C-terminus contains the 
passenger domain (Figure 4B) (Henderson et al., 2004; Leo et al., 2014). 
1.6.6 T6SS 
T6SS can secrete proteins into both prokaryotic and eukaryotic cells (Gueguen et al., 2013). 
The role of T6SS has been reported in virulence, host immunomodulation, stress-sensing 
and biofilm formation (Weber et al., 2009). T6SS was earlier considered to play a role in 
virulence but recent research also points out the role of T6SS in interbacterial interactions 
(Schwarz et al., 2010). 
Bacterial T6SS is structurally analogous to a bacteriophage (Ho et al., 2014). Although the 
overall architecture of T6SS is well conserved, this system has different functions depending 
on the need of individual species.  
Most of the Gram-negative bacteria have one or two copies of the T6SS cluster in their 
genome, but Y. pseudotuberculosis and Y. pestis have 4-5 clusters, suggesting multiple 
functions or specificities of T6SS in different hosts (Bingle et al., 2008). In Y. 
pseudotuberculosis, there are four complete and two incomplete loci, while in Y. 
enterocolitica only one copy is present (Zhang et al., 2011). To respond to various 
environmental changes, T6SS clusters of Yersinia are regulated at transcriptional, post-
transcriptional and translational levels by a variety of proteins. T6SS4 is under control of one 
single promoter, while T6SS1, T6SS2 and T6SS3 clusters are divided into two to three 
putative operons (Zhang et al., 2011). T6SS4 promotes survival of Yersinia in high osmolarity 
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conditions and also provides resistance to deoxycholate. This system in turn is regulated by 
the response regulator OmpR which binds and activates the promoter region of T6SS4 
(Gueguen et al., 2013). T6SS expression is temperature dependent. T6SS2, T6SS3 and 
T6SS4 of Yersinia are strongly induced at moderate temperature in contrast to T6SS1 loci 
which is expressed at 37°C (Zhang et al., 2011). 
1.7 Csr system of Yersinia 
To achieve efficient infection, the virulence factors must be expressed at the correct condition 
and at the correct time. These changes are governed by complex regulatory networks in 
Yersinia that control the expression of these factors depending on the condition. This is 
achieved by regulation at transcriptional, post-transcriptional and post-translational levels by 
a variety of regulatory systems. 
One such system is the Csr (Carbon storage regulator) system in Yersinia. This is a post-
transcriptional regulatory system of Yersinia that is composed of the RNA binding protein 
referred to as CsrA, and two non-coding RNAs CsrB and CsrC (Figure 11). 
CsrA is a homodimer that regulates the translation of its target mRNAs by blocking the 
ribosome binding site at or near the Shine-Dalgarno (SD) sequence, and thus competes with 
binding of the 30S ribosomal subunit, thereby blocking translation. CsrA activity is controlled 
by two non-coding RNAs CsrB and CsrC that can bind multiple CsrA molecules, thus 
controlling the availability of CsrA in the cell and preventing binding of CsrA to its target 
mRNA.  
Csr is a part of the regulatory RovM-RovA-InvasinA cascade. CsrA positively regulates RovM 
by a not clearly known mechanism, thus blocking the expression of RovA, which in turn 
blocks the expression of InvA (Heroven et al., 2008, 2012) (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Csr system of Yersinia. Two non-coding RNAs 
CsrB and CsrC antagonize CsrA function and also counter-
regulate each other. Up-regulation of CsrA increases the 
expression level of RovM, leading to RovA repression and 
hence InvA synthesis is sequestered. Dashed lines indicate 
indirect interaction while solid lines indicate direct 
interaction (modified from (dissertation Stephanie Christine 
Seekircher, 2014)). 
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1.8 RovC 
A novel transcriptional regulator has been identified in Prof. Petra Dersch’s group (HZI) that 
represses the transcription of CsrC and thus designated as regulator of virulence associated 
with CsrC (RovC). This protein is unique to Yersinia. It is highly conserved in Y. pestis and in 
Y. pseudotuberculosis and shares no sequence homology to any other protein in the 
database and also has no conserved DNA binding domain. RovC sequesters CsrC 
transcription, which leads to increased CsrA levels, thus positively affecting RovM expression 
which in turn represses RovA and hence InvA. RovC is thermoregulated and shows maximal 
expression at 25°C in stationary growth phase. It requires factors for its expression that are 
specific for Yersinia. RovC is located directly downstream of T6SS4 gene, encoded in 
opposite direction and activates T6SS4 transcription (dissertation Stephanie Christine 
Seekircher, 2014) (Figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 12: RovC regulation in Yersinia. RovC 
represses the transcription of CsrC but activates T6SS4 
system (modified from dissertation Stephanie Christine 
Seekircher, 2014). 
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2 Aims 
Yersinia pseudotuberculosis armour themselves with a variety of virulence factors that enable 
them to adhere to host cells and colonize host tissues for their survival. Their expression 
levels in Yersinia are regulated by several regulatory proteins in response to the rapidly 
changing environment. Thus, the aims of the project were to structurally and functionally 
characterize adhesins and the virulence regulator of Y. pseudotuberculosis.  
As outlined above, InvA is a major virulence factor of enteropathogenic Yersinia required for 
adhesion to and invasion of epithelial cells. InvA has been extensively characterized at both 
structural and functional levels. The first objective of this work was to structurally and 
biochemically characterize the two recently identified Invasins, InvD and InvE, that share no 
sequence similarity with other known Invasins. Since Invasins share a common architecture, 
the molecular details of the adhesion domain are needed to provide the functional 
information. Thus, the aim was to gain atomic and molecular insights into the structure of 
InvD and InvE by X-ray crystallography and to identify their host-interaction partner by 
various biochemical and molecular biology experiments. The identified interactions should be 
analyzed in vitro, and if confirmed, InvD/InvE should be co-crystallized with their respective 
targets to characterize the interaction surface. These studies will increase our knowledge of 
the diverse Invasins of Yersinia, and will contribute to the understanding of the role of 
Invasins in their host system during infection. 
The second aim of this work was to provide the molecular mechanism for the differences in 
the function of YadA present in Y. pseudotuberculosis and Y. enterocolitica. For that purpose, 
the structure of the head domain of YadApstb should be solved by X-ray crystallography and 
compared to known YadA structure from Y. enterocolitica. The differences in two structures 
should be analyzed in the context of their function. 
The third goal of this work was to structurally and biochemically characterize the virulence 
regulator RovC in the context of DNA binding. For that purpose, RovC should be produced in 
high purity and quantity for crystallization experiments. Then, the structure of RovC alone and 
in complex with DNA should be solved to understand its DNA binding mechanism. 
Additionally, biochemical and biophysical methods should be used to characterize RovC and 
its DNA binding activity. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Buffers and solutions 
Table 1: Buffers and solutions. 
 
Ni-NTA Lysis buffer 50 mM TRIS-HCl pH 8,  
200 mM NaCl, 
1 mM Imidazole pH 8, 
5 mM β-mercaptoethanol (βME), 
5 mM MgCl2,  
1 mM PMSF,
 
DNAse (40 µl at 1 mg/ml per litre of culture) 
 Ni-NTA wash buffer 50 mM TRIS-HCl pH 8,   
200 mM NaCl,  
5 mM Imidazole pH 8, 
5 mM βME 
Ni-NTA elution buffer 50 mM TRIS-HCl pH 8,   
200 mM NaCl,  
250 mM Imidazole pH 8, 
5 mM βME  
Streptactin Lysis buffer 50 mM TRIS-HCl pH 8,  
200 mM NaCl, 
5 mM βME, 
5 mM MgCl2,  
1 mM PMSF,
 
DNAse (40 µl at 1 mg/ml per litre of culture) 
Streptactin wash buffer 50 mM TRIS-HCl pH 8,   
200 mM NaCl,  
5 mM βME 
Streptactin elution buffer 50 mM TRIS-HCl pH 8,   
200 mM NaCl,  
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5 mM βME, 
3 mM D-Desthiobiotin  
TEV protease cleavage buffer 50 mM TRIS pH 8 
200 mM NaCl, 
5 mM βME 
Gel filtration buffer 20 mM HEPES pH 7.4,  
200 mM NaCl,  
5 mM DTT 
Lysine methylation dialysis buffer 50 mM HEPES pH 7.5,  
500 mM NaCl,  
5% Glycerol,   
5 mM βME 
Lysine methylation gel filtration buffer 20 mM TRIS-HCl pH 7.5,  
500 mM NaCl, 
5 mM βME 
Dialysis buffer 50 mM TRIS-HCl pH 8, 
200 mM NaCl,  
5 mM βME 
PBS buffer (10x) 
 
1.4 M NaCl,  
30 mM KCl,  
120 mM Na2HPO4, 
20 mM KH2PO4, 
pH 7.4 
PBS-T  1x PBS, 
 0.1% (v/v) Tween-20 
MPBST PBST, 
2% skim milk 
TBS (10x) 100 mM TRIS-HCl pH 7.5,  
1.5 M NaCl  
TBS-T 1x TBS, 
 0.1% (v/v) Tween-20 
Transfer buffer 25 mM TRIS-Base pH 8.0, 
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192 mM Glycine,  
10% Methanol (v/v)  
Blocking buffer 5% (w/v) Skim milk in TBS-T 
Alkaline Phosphatase (AP) buffer 100 mM TRIS-HCl pH 9.5, 
100 mM NaCl, 
5 mM MgCl2 
Alkaline Phosphatase staining 
solution 
 
10 ml AP buffer,  
66 µl NBT substrate (stock solution-50 mg/ml),  
33 µl BCIP substrate (stock solution-50 mg/ml) 
Coupling buffer 0.2 M NaHCO3 pH 8.6, 
0.5 M NaCl 
TAE buffer (50x) 2 M TRIS-Base,  
1 M Acetic acid,  
50 mM EDTA 
DNA loading buffer (10x) 10 mM TRIS-HCl pH 7.5, 
0.05%(w/v) Bromphenol blue, 
1 mM EDTA, 
5% Glycerol 
SDS loading buffer (2x) 100 mM TRIS-HCl pH 6.8,  
4% (w/v) SDS,  
20% (v/v) Glycerol,  
200 mM DTT,  
0.2% (w/v) Bromophenol blue 
SDS-PAGE running buffer 25 mM TRIS-Base pH 8.5, 
192 mM Glycine, 
0.1% (w/v) SDS 
Coomassie blue staining solution 0.1% (w/v) Coomassie brilliant blue R-250,  
40% (v/v) Ethanol,  
10% (v/v) Acetic acid 
Destaining solution 40% (v/v) Ethanol  
10% (v/v) Acetic acid 
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3.1.2 Culture media and antibiotics 
Table 2: Media and antibiotics used in this work. 
 
Luria Bertani (LB) medium 10 g/L Bacto-tryptone, 
5 g/L Yeast extract, 
7 g/L NaCl 
Terrific Broth (TB) medium 12 g/L Bacto-tryptone, 
24 g/L Yeast extract, 
4 ml/L Glycerol, 
12.54 g/L K2HPO4, 
2.31 g/L KH2PO4 
double Yeast Trypton Broth (dYT) medium 16 g/L Bacto-tryptone, 
10 g/L Yeast extract, 
5 g/L NaCl 
LB plate-Agar 10 g/L Bacto-tryptone, 
5 g/L Yeast extract, 
7 g/L NaCl, 
16 g/L Bacto-Agar 
SOC medium 20 g/L Bacto-tryptone, 
5 g/L Yeast extract, 
0.5 g/L NaCl,  
2.5 mM KCl, 
10 mM MgCl2 
20 mM Glucose 
dYT-GA medium  
 
dYT medium, 
100 mM Glucose,  
100 µg/ml Ampicillin  
Minimal medium 
 
 
 
Additional solution 
1 g/900 ml NH4Cl, 
3 g/900 ml KH2PO4, 
4 g/900 ml Na2HPO4 
 
22 g/100 ml Glucose, 
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Se-Met Medium  
0.61 g/100 ml MgSO4, 
11.2 mg/100 ml Thiamine-HCl, 
10.4 mg/100ml Fe2(SO4)3.7H2O 
 
Minimal Medium + Additional solution 
RPMI 1640 medium Ordered from Gibco Life technologies, 
Contains 1% Glutamax-1 
HEp-2 medium RPMI 1640 (supplemented with 1% 
Glutamax-1),  
10% Newborn Calf Serum (NCS) 
Antibiotics 
Kanamycin (1000x) 
Chloramphenicol (1000x) 
Ampicillin (1000x) 
 
30 µg/ml in deionized water 
34 µg/ml in 70% Ethanol (v/v) 
30 µg/ml in deionized water 
3.1.3 Enzymes 
All enzymes listed in Table 3 were used according to manufacturer´s instructions. 
Table 3: Enzymes used in this work. 
 
KOD Hot Start DNA Polymerase Novagen 
T4 DNA ligase New England Biolabs 
Restriction Enzymes New England Biolabs 
Calf Intestinal Phosphatase New England Biolabs 
DNaseI Roche 
T4 Polynucleotide Kinase Thermo Fischer Scientific Inc. 
2x Red PCR Master Mix pjk GmbH 
3.1.4 Bacterial strains 
Table 4: E. coli strains used in this work. 
 
Name Description Source 
DH5α F-Φ80lacZ∆M15 ∆(lacZYA-argF) U169 
recA1endA1hsdR17 (rk-, mk+) phoAsupE44λ -thi-
1gyrA96 relA1 
Invitrogen 
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Rosetta2 DE3 F- ompThsdSB(rB- mB-) gal dcm (DE3) pRARE2 
(CamR) 
Invitrogen 
 
3.1.5 Antibodies 
Antibodies used in western blot and enzyme linked immunosorbent assays. 
Table 5: Antibodies used in this work. 
 
His-AP conjugate Amersham Bioscience 
Anti-rabbit HRP coupled Jackson Immuno Research  
Anti-flag antibody produced in rabbit Sigma Aldrich 
9E10 mouse anti-myc antibody Yumab GmbH, Braunschweig 
Goat anti-mouse IgG-HRP coupled antibody Sigma Aldrich 
 
Antibodies used for flow cytometry experiments 
Fluorochrome-conjugated anti-CD3 (17A2), anti-CD19 (6D5), anti-CD11b (M1/70), anti-
CD11c (N418), anti-CD49b (DX5), anti-γδTCR (eBioGL3) and anti-flag (L5, DYKDDDDK tag 
epitope) were purchased from eBioscience (San Diego, CA, USA) and Biolegend (San 
Diego, CA, USA). 
3.1.6 Protein and nucleotide standards 
Applied size standards are indicated in Table 6. 
Table 6: Molecular size standards. 
 
Gene Ruler DNA ladder mix Thermo Scientific 
PageRuler unstained protein ladder Fermentas 
PageRuler Plus prestained protein ladder Fermentas 
3.1.7 Columns and resins 
Table 7: Resins used in this work. 
 
Ni Sepharose® 6 Fast Flow GE Healthcare 
Strep-Tactin® Sepharose® 50% suspension Iba 
Strep-Tactin® Macroprep® 50% suspension Iba 
Anti-Flag M2 magnetic beads Sigma Aldrich 
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Table 8: Columns used in this work. 
 
HiLoad 16/600 Superdex 200 prep grade GE Healthcare 
HiLoad 16/600 Superdex 75 prep grade GE Healthcare 
Superdex 200 10/300 GE Healthcare 
Superdex 75 10/300 GE Healthcare 
3.1.8 Kits 
All kits listed in Table 9 were used according to manufacturer’s instructions. 
Table 9: Commercial kits used in this work. 
 
QIAquick PCR purification kit Qiagen 
QIAquick Gel extraction kit Qiagen 
QIAprep Spin Miniprep kit Qiagen 
Proti-Ace Hampton Research 
Proti-Ace-II Hampton Research 
Lanthanide Phasing kit Jena Bioscience 
3.1.9 Crystallization screens 
Table 10: List of crystallization screens used. 
 
Additive screen Hampton Research 
AmSO4 Qiagen 
Anion Qiagen 
Cation Qiagen 
Cryo Qiagen 
Index Hampton Research 
JCSG CoreI Qiagen 
JCSG CoreII Qiagen 
JCSG CoreIII Qiagen 
JCSG CoreIV Qiagen 
JCSG+ Qiagen 
Midas Molecular Dimensions 
Morpheus Molecular Dimensions 
Nucleix screen Qiagen 
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PEGs Qiagen 
Protein Complex Qiagen 
Silver bullet Hampton Research 
3.1.10 Oligonucleotides 
List of oligonucleotides used in this work to amplify gene of interest are listed in Table 11. 
Oligonucleotides used to insert mutations are listed in Table 12. Oligonucleotides that were 
used for sequencing of constructs or plasmids are listed in Table 13. Table 14 depicts the 
oligonucleotides used to modify plasmids. All the primers were purchased from Eurofins 
Genomics. 
Table 11: Oligonucleotides used for DNA amplification. 
 
Oligo name Sequence 5´3´ Restriction 
site 
InvD   
InvD_G1640_notI_f aagaatgcggccgcggcaacctgagcaccacgaac NotI 
InvD_N1976_pstI_r ttttctgcagttagttagatccgg PstI 
InvD_P1738_notI_f aagaatgcggccgcggtgcattagatgctgcgcgc NotI 
Ig_G1839_pstI_r ttttctgcagttaccccggcgttattgtcaccatc PstI 
 
InvA 
  
InvA_P500_notI_f aagaatgcggccgccctcagttgacattaacggcggcc NotI 
InvA_I985_pstI_r ttttctgcagttatattgacagcgcacagagcgg PstI 
 
InvE 
  
InvE_G2448_notI_f aagaatgcggccgcggcaacctgagcaccacgaac NotI 
InvE_A2547_notI_f aagaatgcggccgcgctcctgttgatctaacggtattaac NotI 
InvE_L2795_kpnI_r ggggtaccttatagagaacagcttacattgtagtttc KpnI 
InvE_G2536_notI_f aagaatgcggccgcggcacaacaccagcaacgattaatg NotI 
InvE_P2539_notI_f aagaatgcggccgcccagcaacgattaatgtcattcctg NotI 
InvE_V2544_notI_f  aagaatgcggccgcgtcattcctgctcctgttgatctaac NotI 
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RovC   
RovC_M1_notI_f aagaatgcggccgcatgagaaagaagctatataatgacttc NotI 
RovC_D40_notI_f aagaatgcggccgcgattctgaattaatccaatcagag NotI 
RovC_S47_notI_f aagaatgcggccgctcagagctggatttgaatgcag NotI 
RovC_S80_notI_f aagaatgcggccgcagtaaccgttcagttagagttaaactc NotI 
RovC_M103_notI_f aagaatgcggccgcatgtccaacctaccaggagtcaaac NotI 
RovC_L247_kpnI_r ggggtaccttagaggaagttcaggtagccg NotI 
 
YadA 
  
YadA_E26_notI_f aagaatgcggccgcgaggagcccgaggatggcaac NotI 
YadA_E253_kpn_r ggggtaccttattcagccatttctttctttaattg kpnI 
 
 
Table 12: Oligonucleotides used to insert mutations/deletions in the gene of interest. 
 
Oligo name Sequence 5´3´ 
InvE  
InvE_E2695A/K2696A_f Gcagcggcgccaggcacaataggcaccaatgttgaaaac 
InvE_ E2695A/K2696A _r Gcctggcgccgctgctgccaagtatgggcgtttgaac 
InvE_E2648A_f Aaagcggcgagcggtgatatggaaaatactaatgtcacc 
InvE_E2648_r Accgctcgccgctttagccctaagggttgtttgcac 
InvE_K2646A_f Agggctgcggcggaaagcggtgatatggaaaatactaatg 
InvE_ K2646A _r Ttccgccgcagccctaagggttgtttgcacaccaatacc 
InvE_E2505A/Q2506A_f Gtgaccgcggcggccagtggcctctataccgcgacc 
InvE_E2505A/Q2506A _r Ggccgccgcggtcacattgtccagcgtccctagagtg 
 
RovC 
 
RovC_K181A/E182A/E183A_f Tgcgcggcggcgcaatatttaggtctcttgaagaccatag 
RovC_ K181A/E182A/E183A _r Ttgcgccgccgcgcattccacctctattttgtgattaac 
RovC_K233A/K234A _f Cgtatagcggcggcgaatgcacttattaattacggctacctg 
RovC_ K233A/K234A_r Attcgccgccgctatacgatagcggatttttgctctgac 
RovC_K56E_f Gaaaaagaatggggagtaatgaaatatattgatccttataactctg 
RovC_K56E_r Tactccccattctttttctgcattcaaatccagctctgattg 
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RovC_R225E_f tgggtcgaagcaaaaatccgctatcgtataaagaaggcg 
RovC_R225E_r ttttgcttcgacccaactgtcagcagaccattcattttttac 
RovC_R229E_f aaaatcgaatatcgtataaagaaggcgaatgcacttattaattac 
RovC_R229E_r tatacgatattcgatttttgctctgacccaactgtcagc 
RovC_I150P_f ctctatccttatatccctttgaaccttgaatctgatgtttttg 
RovC_I150P_r agggatataaggatagaggtttgaatcatcttttaatgcatctgc 
RovC_I150P/Y151P_f ctctatccttatatccctttgaaccttgaatctgatgtttttg 
RovC_I150P/Y151P_r agggataggaggatagaggtttgaatcatcttttaatgcatctgc 
RovC_A237E_f aaggcgaatgaacttattaattacggctacctgaacttcctc 
RovC_A237E_r attaataagttcattcgccttctttatacgatAgcggattttcg 
RovC_G242E_kpn_r ggggtaccttagaggaagttcaggtattcg 
RovC_S219E/A220E_f gaatgggaagaagacagttgggtcagagcaaaaatccgc 
RovC_S219E/A220E_r actgtcttcttcccattcattttttaccagttccttacC 
 
 
Table 13: Oligonucleotides used for sequencing. 
 
Oligo name Sequence 5´3´ 
DuetUP1 ggatctcgacgctctccct 
DuetDOWN1 gattatgcggccgtgtacaa 
MHLacZ-Pro_f ggctcgtatgttgtgtgg 
 
 
Table 14: Oligos used to modify plasmids (to insert tags). 
 
Oligo name Sequence 5´3´ 
Inserting 3xflag tag at 
the N terminus in 
pVP009 
Modified vector is 6xHis_TEV_3xflag_MCS1 
 
3xFlag_notI_2f aaagatgacgatgacaagggcggccgcctgcagggtac 
3xFlag_notI_4r cgtcatggtctttgtagtcgccac 
3xFlag_notI_1f ggccgtggcgactacaaagaccatgacggtgattataaagatcatgatatcgattac 
3xFlag_notI_3r cctgcaggcggccgcccttgtcatcgtcatctttgtaatcgatatcatgatctttataatcac 
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Inserting SUMO tag 
at the N terminus in 
pVP009 
Modified vector is 6xHis_SUMO_TEV_MCS1 
SUMO_TEV_notI_r Attcttgcggccgcctccctggaagtagaggttctcgtcgacaccaatctgttctctgtg 
SUMOHis_ncoI_f catgccatgggccatcatcatcaccatcattcggactcagaagtcaatcaag   
3.1.11 Plasmids 
Table 15: Plasmids used in this work. 
 
Plasmid name Description Source 
pVP009 modified pCOLA Duet, KanR, N-His6 Own lab 
pVP008 modified pCOLA Duet, KanR, N-Strep Own lab 
pPS018 modified pCOLADuet, KanR, N-His6_TEV_3xflag Own lab 
pPS041 modified pCOLADuet, KanR, N-His6_SUMO_TEV Own lab 
pPS001 pET28derived, InvD_P1737-N1976, KanR, N-His6-
Thrombin 
Prof. Petra 
Dersch’s 
laboratory, HZI 
pPS003 pCOLADuet (pVP009), InvD_G1640-N1976, KanR, N-
His6-TEV 
This study 
pPS004 pCOLADuet (pVP009), InvD_P1838-N1976, KanR, N-
His6-TEV 
This study 
pPS005 pCOLADuet (pVP008), InvD_G1640-N1976, KanR, N-
Strep-TEV 
This study 
pPS016 pCOLADuet (pVP009), InvE_A2547-L2795, KanR, N-
His6-TEV 
This study 
pPS017 pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
His6-TEV 
This study 
pPS019 pCOLA Duet (pPS018), InvD_G1640-N1976, KanR,  
N-His6_TEV_3xflag 
This study 
pPS020 pCOLA Duet (pPS018), InvD_G1640-G1839, KanR,  
N-His6_TEV_3xflag 
This study 
pPS021 pCOLA Duet (pPS018), InvA_P500-I985, KanR,  
N-His6_TEV_3xflag 
This study 
pPS022 pCOLA Duet (pPS018), InvE_G2448-L2795, KanR,  This study 
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N-His6_TEV_3xflag 
pPS027 pCOLA Duet (pVP009), YadA_E26-E253, KanR, N-
His6-TEV 
This study 
pPS029 pCOLADuet (pVP008), InvD_G1640-N1839, KanR, N-
Strep-TEV 
This study 
pPS031 
 
pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
Strep-TEV 
This study 
pPS032 pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
His6-TEV (Surface entropy mutation at aa 2695,2696) 
This study 
pPS033 pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
His6-TEV (Surface entropy mutation at aa 2646) 
This study 
pPS034 pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
His6-TEV (Surface entropy mutation at aa 2505, 2506) 
This study 
pPS035 pCOLADuet (pVP009), InvE_G2448-L2795, KanR, N-
His6-TEV (Surface entropy mutation at aa 2648) 
This study 
pVK14 /pPS036 pET28 derived, RovC_R2-L247, KanR, N-His6-SUMO Prof. Petra 
Dersch’s 
laboratory, HZI 
pPS037 pCOLA Duet (pVP009), RovC_D40-L247, KanR, N-
His6-TEV 
This study 
pPS038 pCOLA Duet (pVP009), RovC_S80-L247, KanR, N-
His6-TEV 
This study 
pPS042 pCOLA Duet (pPS041), RovC_M1-L247, KanR, N-
His6-SUMO-TEV 
This study 
pPS047 pCOLA Duet (pPS041), RovC_M1-L247, KanR, N-
His6-SUMO-TEV (Surface entropy mutation at aa 
181,182,183 aa) 
This study 
pPS048 pCOLA Duet (pPS041), RovC_M1-L247, KanR, N-
His6-SUMO-TEV (Surface entropy mutation at aa 233, 
234 aa) 
This study 
pPS085 pCOLA Duet (pPS041), RovC_M1-L247 
(S219E/A220E), KanR, N-His6-SUMO-TEV 
This study 
pPS092 pCOLA Duet (pPS041), RovC_M1-L247 
(I150P/Y151P), KanR, N-His6-SUMO-TEV  
This study 
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pPS093 pCOLA Duet (pPS041), RovC_M1-L247 (I150P), KanR, 
N-His6-SUMO-TEV  
This study 
pPS099 pCOLA Duet (pPS041), RovC_M1-L247 (R229E), 
KanR, N-His6-SUMO-TEV  
This study 
pPS100 pCOLA Duet (pPS041), RovC_M1-L247 (K56E), KanR, 
N-His6-SUMO-TEV  
This study 
pPS102 pCOLA Duet (pPS041), RovC_M1-L247 (R225E), 
KanR, N-His6-SUMO-TEV  
This study 
pPS107 pCOLA Duet (pPS041), RovC_M1-L247 
(K211E/K215E), KanR, N-His6-SUMO-TEV 
This study 
3.1.12 Laboratory equipments 
The technical equipments used in this study are given in Table 16. 
Table 16: Technical equipments. 
 
Equipment Manufacturer 
ÄKTApurifier GE Healthcare 
BP2100S, I2000D(Balance) Sartorius AG  
BandelinSonopuls HD 200(Ultrasonic 
Homogenizer) 
BANDELIN electronic GmbH & Co. KG 
CO8000 Cell Density Meter Biochrom Ltd. 
EmulsiFlex-C3(Homogenizer) Avestin Inc. 
Fujifilm scanner Fujifilm Co-Kamera LAS-3000 
Formulator(Liquid handling system) Formulatrix Inc. 
Gel Logic 212 Pro Gel documentation system Carestream Health Inc. 
Heraeus microbiological incubator Thermo Fisher Scientific Inc 
HerasafeMultifuge X3R(Centrifuge) Thermo Fisher Scientific Inc 
Heraeus Fresco 21(Centrifuge) Thermo Fisher Scientific Inc 
Honeybee 961 (Protein crystallization robot) Digilab Inc. 
LSM510Meta Confocal microscope  Carl Zeiss 
Monolith NT.115 Nanotemper Technologies GmbH 
Multitron Standard (Incubation shaker) Infors AG 
Mini-PROTEAN(SDS-gel running system) Bio-Rad Laboratories 
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Milli-Q Advantage A10 (Water purification 
system) 
Merck KGaA 
Micro Star 17(R) (Centrifuge) VWR International 
Micromax-007 HF (X-ray generator) Rigaku Corp. 
NanoDrop 2000(UV-Vis spectrophotometer) Thermo Fisher Scientific Inc 
ND1000(UV-Vis spectrophotometer) Thermo Fisher Scientific Inc 
OryxNano (Protein crystallization robot) Douglas Instruments Ltd 
PowerPac 300/Basic (Power Supply) Bio-Rad Laboratories 
Peqgradient Thermocycler (PCR machine) Peqlab 
R-963 (Microwave) Sharp K.K. 
Rock Imager 182/1000 Formulatrix Inc 
SteREO Discovery.V8 Stemi SV 8 
(Stereomicroscope) 
Carl Zeiss AG 
SZ40 (Stereomicroscope) Olympus 
Sorvall RC6 Plus(Centrifuge) Thermo Fisher Scientific Inc 
Saturn 944+ R-AXIS IV++(X-ray detector) Rigaku Corp. 
SevenEasy pH meter Mettler-Toledo International Inc. 
Thermomixer Eppendorf AG 
Trans-Blot Turbo (Western blot transfer 
system) 
Bio-Rad Laboratories 
UV Transilluminator Intas Science Imaging 
UV cuvettes semimicro BrandTech Scientific, Inc 
Variomag Mono Direct (Magnetic stirrer) H+P Labortechnik GmbH 
XB6200D(Balance) PrecisaGravimetrics AG 
XS204(Balance) Mettler-Toledo International Inc. 
3.2 Molecular biology methods 
3.2.1 Polymerase chain reaction  
The gene of interest was amplified in a peqstar2x Thermocycler by using the PCR approach. 
Reaction components as listed in table 17 were assembled on ice and the PCR program 
listed in table 18 was run to selectively amplify the desired DNA. 
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Table 17: PCR reaction mix. 
 
Component Volume (µl) 
Sterile water 31 
MgSO4 (25 mM) 3 
dNTPs (2 mM) 5 
Primer forward (10 pm/µl) 2 
Primer reverse (10 pm/µl) 2 
KOD hot Start DNA Polymerase buffer (10x) 5 
Template DNA (10 ng/µl) 1 
KOD Hot Start Polymerase 1 
 
Table 18: PCR program steps. 
 
Cycle step Temperature (°C) Time (s) Number of 
cycles 
Initial denaturation 95 120 1 
Final denaturation 
Annealing           
Extension 
95 
55 
70  
30 
15 
60 
 
40   
 
Final extension 70 10 1 
Hold 4 ∞ 1 
 
To introduce mutations in the gene of interest, a two-step PCR was performed. Two 
independent PCR reactions were performed as described above to generate two primary 
PCR products in the first step. For the second step, 0.5 µl of both the purified PCR products 
from step 1 were used as a template and PCR reaction was performed using the flanking 
primers as described above. 
3.2.2 DNA agarose gel electrophoresis and gel extraction purification 
PCR products were visualized after loading them on 0.8% or 1.2% agarose gel (depending 
on the size of the product). 1x TAE was used as a running buffer. 9 volumes of sample were 
mixed with 1 volume of 10x DNA loading buffer. Agarose gels were stained with Roti gel stain 
(Carl Roth) according to the manufacturer´s instructions. Gels were visualized under UV light 
                                                                                                           Materials and methods 
 
41 
  
using Kodak Gel logic 212 Imaging system. Gel extraction was performed with the QIAquick 
gel extraction kit according to the manufacturer’s instructions. 
3.2.3 Restriction digest 
Cloning vector and PCR products were digested with the restriction enzymes from NEB in an 
appropriate NEB buffer according to the manufacturer´s instructions. 2-3 µg of PCR product 
(50 µl), 5 µl of Cut smart NEB buffer (10x), 1 µl of enzyme 1, 1 µl of enzyme 2 were mixed 
and incubated at 37°C for 1 h. To dephosphorylate the plasmid, digested vector was treated 
with 1 µl of CIP and the reaction was further incubated at 37°C for 1 h. Digested products 
were loaded on the agarose gel. Band of interest was excised and purified as described 
above. Concentration of purified DNA was determined by NanoDrop spectrometer. 
3.2.4 Annealing of oligonucleotides 
Small fragments generated on annealing of the oligonucleotides were used to insert 
tags/protease cleavage site in the vector or study DNA-protein interaction by electrophoretic 
mobility shift assay (EMSA) and microscale thermophoresis (MST). 
To insert tags/protease cleavage site in the vector, complementary oligonucleotides were first 
phosphorylated at their 5’ end followed by annealing. Reaction components as listed in table 
19 were assembled. The mixture was incubated at 37°C for 30 mins followed by incubation at 
65°C for 20 mins to heat inactivate the enzyme. 
 
Table 19: Reaction mix to phosphorylate oligonucleotide. 
 
Component Volume (µl) 
Sterile water 14 
T4 DNA ligase buffer (10x) 5 
Oligo (10 pm/µl) 30 
T4 polynucleotide kinase 1 
 
Phosphorylated oligonucleotides were diluted (8 µl oligonucleotide + 32 µl water) and 5 µl of 
each of the diluted complementary oligonucleotide were mixed. Program listed in table 20 
was run to anneal the oligos. 
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Table 20: Program to anneal complementary oligonucleotide. 
 
Cycle step Temperature (°C) Time (s) Number of cycles 
Step 1 95 120 1 
Step 2 95 (-1°C/cycle) 60 85 
Step 3 4 ∞ 1 
For MST/EMSA, complementary oligonucleotides were mixed and annealed with the program 
listed in table 20. 
3.2.5 Ligation 
For ligation, 3 µl of digested and dephosphorylated plasmid, 1 µl of purified and digested 
insert (or 5 µl of phosphorylated and annealed oligos), 2 µl of T4 DNA ligase buffer (10x) and 
1 µl of T4 DNA ligase were mixed and the reaction was kept at room temperature for 1 h. As 
a negative control, ligation without insert DNA was performed. 
3.2.6 Transformation 
For transformation, 100 µl of chemicompetent cells were thawed on ice, to which either 10 µl 
of the ligation reaction or 1 µl of the purified DNA was added and incubated on ice for 30 
mins. It was followed by a heat shock at 42°C for 90 s with short cooling on ice (90 s). After 
addition of 1 ml of SOC media, reaction was incubated at 37°C for 45 mins at 600 rpm. The 
mixture was centrifuged for 1 min at 3000 rpm. 800 µl of supernatant was discarded and the 
cells were resuspended in the remaining 300 µl of media. 300 µl of the cells were plated on 
LB agar plate containing the appropriate antibiotics. 
3.2.7 Colony PCR 
Colony PCR was performed to determine the presence or absence of insert DNA directly 
from E.coli colonies. Either vector specific or combination of insert-vector specific primers 
were used.  
Table 21: Colony PCR reaction mix. 
 
Component Volume (µl) 
Sterile water 6 
2x Red PCR Master Mix 10 
Primer forward (10 pm/µl) 2 
Primer reverse (10 pm/µl) 2 
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For the detection of positive clones, an isolated bacterial colony was touched with the sterile 
tip and dipped into the PCR reaction tube, with gentle twirling of the tip 3-4 times. PCR run 
listed in table 22 was performed. In parallel, 500 µl of LB media in Eppendorf was inoculated 
as pre-culture with the same tip and tubes were incubated at 37°C for 1.5 h.  
 
Table 22: Colony PCR program steps. 
 
Cycle step Temperature (°C) Time (s) Number of cycles 
Initial denaturation 95 300 1 
Final denaturation 
Annealing           
Extension 
95 
55 
70  
30 
15 
70 
 
25 
 
Final extension 70 10 1 
Hold 4 ∞ 1 
 
The presence of insert was determined by loading the PCR product on 0.8% agarose gel 
along side a DNA size marker. If the clones were positive, 8-50 ml of culture was inoculated 
with the pre-culture from Eppendorf tube and incubated overnight in a shaker at 37°C. 
Plasmid DNA was isolated for sequencing using QIAprep Spin Miniprep kit according to the 
manufacturer´s instructions.  
3.2.8 Sequencing of DNA 
600 ng of isolated plasmid mixed with 2 µl of sequencing primer (forward or reverse) was 
sent to MWG-Biotech or in-house sequencing service to obtain the sequence of interest. 
DNA sequences were analyzed by Chromas and Serial Cloner softwares. 
3.2.9 Storage of bacteria 
For permanent storage of bacterial clone, 500 µl of freshly grown overnight culture was 
mixed with 500 µl of 86% glycerol. Glycerol stocks were stored at -80°C. 
3.3 Protein expression and purification 
3.3.1 Small scale test-expression of recombinant genes in E. coli 
Single bacterial colony of E.coli Rosetta2 (DE3) harboring protein of interest was used to 
inoculate 10 ml LB culture supplemented with the appropriate antibiotics. Culture was grown 
overnight in a shaker at 37°C. 300 ml of LB media was inoculated with the overnight culture 
to optical density at 600 nm (OD600) of about 0.05 with the suitable antibiotics and the culture 
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was grown at 37°C until the OD600 reached 0.6-0.7. The culture was split into six small 
cultures with the volume of 40 ml each. To determine the optimum condition of expression of 
the protein of interest, a variety of parameters such as concentration of inducer and post 
induction incubation temperature were optimized. Cultures were induced with two different 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Carbosynth) concentrations (50 µM and 200 
µM). The expression was tested at 16°C/18°C/20°C, 25°C and 37°C and the bacterial pellet 
was collected after 3 h and overnight incubation by taking 10 ml of cells (per condition) and 
centrifugation at 4000 rpm for 10 mins at 4°C. Bacterial cells were resuspended in 1 ml of 
lysis buffer. Cells were lysed by using ultrasound sonication (3x for 10sec @ 50% MS73D) 
followed by centrifugation at 13000 rpm at 4°C for 30 mins. Pellet was boiled in 30 µl of SDS-
loading buffer to analyze the samples on SDS gel. Also 20 µl of supernatant was taken from 
each sample and mixed with 20 µl of SDS loading buffer. Cleared lysate was incubated with 
20 µl of beads (depending on the affinity tag fused to the protein) and allowed to incubate on 
a rotating platform for 30 mins at 4°C. Beads were washed twice with 1 ml of washing buffer 
and SDS loading buffer was added to the beads. Beads sample along with the supernatant 
and pellet samples were analyzed on 15% SDS gel. The expression condition that yields the 
most soluble protein was used for large scale expression and purification.  
3.3.2 Expression of recombinant genes in preparative scale 
4 L of TB or dYT medium (supplied with suitable antibiotics) was inoculated to an OD600 of 
0.05 with the overnight culture and it was grown at 130 rpm, 37°C until the OD600 reached 
0.7. Expression was induced by adding IPTG and changing the incubation temperature 
according to the identified conditions in the test-expression. After incubation, cells were 
harvested by centrifugation at 5000 rpm for 15 mins at 4°C. 
For expression of Se-Met derivative protein, transformed cells were first grown in 2x 500 ml 
of LB medium (supplied with suitable antibiotics) at 37°C, 130 rpm overnight. 500 ml of fresh 
LB medium (supplied with suitable antibiotics) was added to each of the overnight culture and 
cells were grown for another hour at 130 rpm, 37°C. Cells were harvested by centrifugation 
at 6000 rpm, 4°C for 5 mins and washed twice with Minimal Medium (by centrifugation at 
6000 rpm, 5 min at 4°C). Pellet was resuspended in Minimal Medium. With this suspension, 
4 L of Se-Met Medium was inoculated to the OD600 of 1.0, 50 mg/L of selenomethionine 
(Acros Organics) was added and protein production was induced by adding IPTG. Induction 
was performed under the conditions that were obtained in the small-scale test-expression. 
After overnight incubation, cells were harvested by centrifugation at 5000 rpm for 15 mins at 
4°C. 
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3.3.3 Preparative lysis of bacterial cells 
Bacterial cells were resuspended in the lysis buffer and lysed by homogenizing using Avestin 
homogenizer (2 cycles, air pressure 50-60 psi, homogenizing pressure 16000 psi). Lysate 
was cleared by centrifugation at 16000 rpm at 4°C for 60 mins. 
3.3.4 Affinity chromatography 
Affinity chromatography is based on the specific and reversible interaction between the 
molecules. A specific ligand is immobilized to a chromatography matrix. Complex mixture is 
then passed over the column. Molecules that have high specificity towards the ligand will bind 
while the non-binding components are removed using a wash buffer that will not interfere with 
the binding interaction between the ligand and the protein of interest.  
Ni-affinity chromatography 
Polyhistidine-tags are often used for affinity purification of recombinant proteins expressed in 
E. coli and other prokaryotic expression systems. The sample is incubated with affinity media 
such as Ni Sepharose. These matrices coordinate Ni2+ through four of the six coordination 
sites while the two remaining sites are exposed to interact with the polyhistidine tag. The 
protein mixture is passed through the matrix containing bound Ni2+ ions. Imidazole side-chain 
present in histidine will interact with the Ni2+. Non-specific binding can be reduced by using 
low concentrations (1-10 mM) of imidazole in the binding buffer. The resin is then washed 
with the buffer containing slightly higher concentrations of imidazole to remove proteins that 
do not specifically interact with the matrix-bound Ni2+ ions; subsequently histidine-tagged 
proteins are specifically eluted with imidazole which competes with the polyhistidine-tag for 
binding to the resin.  
To purify Histidine-tagged proteins, cleared lysate (after homogenization and centrifugation) 
was loaded onto 3 ml Ni-sepharose gravity column, which was pre-equilibrated with 50 ml of 
Ni-NTA lysis buffer. Ni-NTA resin (GE Healthcare) was allowed to incubate with the protein 
for 1 h at 4°C with gentle shaking. The Ni-NTA column was washed with 60 ml of Ni-NTA 
wash buffer and protein was eluted in Ni-NTA elution buffer. 
After elution of the protein of interest, beads were washed using 2 CV 6M Guanidinium 
Hydrochloride, followed by washing with water and storage in 20% ethanol. 
Strep affinity chromatography 
It is based on the specific and reversible interaction between the strep tag-II (WSHPQFEK) 
and Strep-Tactin, an engineered version of naturally occurring tetrameric bacterial protein 
Streptavidin that has high affinity towards biotin. The short 8 aa tag can be placed at the 
N terminus or C terminus. The tagged protein binds to the immobilized Strep-Tactin during 
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affinity purification. After a short washing step, protein is eluted by addition of D-Desthiobiotin 
that competes for the biotin binding pocket (Schmidt and Skerra, 2007). 
To purify the strep-tagged proteins, cleared lysate (suspended in strep lysis buffer) was 
loaded onto equilibrated 4 ml Strep-Tactin Sepharose beads gravity column. On incubation of 
lysate with the beads, column was washed with strep wash buffer and protein was eluted in 
elution buffer containing 3 mM D-Desthiobiotin (iba-2-1000-005). 
After elution of the protein of interest, beads were washed using 3 CV 0.5 M NaOH and 
stored in 50 mM TRIS pH 8.0, 200 mM NaCl.  
3.3.5 Removal of affinity tag 
If there is a need to remove the fused tag, elution fractions were pooled and concentrated to 
volume of 10 ml using viva-spin concentrators (GE Healthcare) with 10000 molecular weight 
cut-off (MWCO). Concentrated sample was dialyzed in a 3500 Da molecular weight dialysis 
tube (Thermoscientific) in TEV cleavage buffer and the tag was removed by overnight TEV 
cleavage (ratio 1 mg to 30 mg protein) at 4°C for 15 h. The fusion tag, TEV protease and 
uncleaved protein were removed by passing the dialyzed sample again through Ni/strep 
column. 
3.3.6 Concentration of proteins by ultrafiltration 
Protein solutions were concentrated using viva-spin concentrators with 10000 MWCO. 
Centrifugation is carried out at 4000 rpm, 4°C with gentle pipetting of the protein solution 
during concentration to prevent protein precipitation by accumulation of highly concentrated 
protein at the bottom of the filter over the membrane. Proteins larger than the filter cut-off size 
will be retained by the filter. 
3.3.7 Size exclusion chromatography 
Size exclusion chromatography (SEC) is a method of separating protein mixtures on the 
basis of their size and shape. SEC matrix consists of pores of different sizes. The separation 
of the molecule depends on the ability of the protein to enter the channels in the porous 
beads. Small molecules easily enter the porous beads while large molecules are restricted 
and pass between the beads. So, all molecules with size larger than the pore size are 
completely excluded to enter the porous channels and elute together.  
Protein was loaded onto the column that was pre-equilibrated with 1CV of filtered (0.2 µm 
whatman membrane filter-GE Healthcare) and degassed gel filtration buffer. Fractions 
containing the protein were analyzed on SDS-PAGE. Fractions that contain the protein of 
interest were pooled, concentrated, aliquoted and flash frozen in liquid nitrogen and kept at    
- 80°C for further use. 
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3.4 Protein characterization and modification 
3.4.1 Protein concentration according to nanodrop 
Protein concentration was determined by nanodrop at 280 nm using the default settings –
E 0.1 % (1 mg/ml). Spectrophotometric determination of protein concentration depends on 
Beer Lambert´s law which gives the relation between the absorption of light and the amount 
of absorbing substance present. It is expressed as- 
 =  ×  × 	           Equation 1 
where A is the absorbance, c is the concentration of sample in mol L-1, l is the length of path 
light in cm and Ɛ is the molar extinction coefficient or molar absorptivity (expressed in L mol-1 
cm-1) 
Protein concentration obtained by nanodrop was divided by the Absorbance (0.1%= 1 g/L) 
(which is calculated as mass extinction coefficient/Molecular weight) obtained from EXPASY 
Protparam (Gasteiger et al., 2005). 
Table 23: Molecular size and Abs (0.1%=1g/L) of the proteins used in this study. 
 
Protein name Molecular weight (kDa) Abs (0.1%=1g/L) 
InvD G1640-N1976 34.5 0.634 
InvD P1737-N1976 25.0 0.831 
∆AD-InvD 19.7 0.151 
InvA P500 51.2 1.022 
InvE 36.4 0.944 
∆AD-InvE 23.2 0.429 
YadA 23.0 0.194 
RovC M1-L247 28.7 1.960 
3.4.2 Denaturing SDS gel electrophoresis 
It is a technique to separate components of a protein mixture based on their size. It is 
commonly used to determine purity of the protein, protein subunits and protein quantitation. 
Protein is incubated with SDS and DTT (SDS loading buffer) at 95°C for 5 mins. Under these 
conditions protein becomes fully denatured and dissociated from each other. In addition, SDS 
binds to the protein on a weight basis (1.4 g SDS/g of protein or about 1 SDS molecule per 
two amino acids). The SDS-protein complex forms a rod with its length proportional to the 
molecular weight of the protein. The complexes are then separated on the bases of their size 
within resolving gel matrix, where small protein-SDS complex moves faster while larger 
complexes move slowly though the matrix. 
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Electrophoresis was performed in 1x SDS running buffer at a constant voltage of 200 V for 40 
mins. Protein standard is applied to compare the molecular weight. After completion of 
electrophoresis, gels were stained with the staining solution. Gels were destained by 
incubating in the destaining solution for 15-20 mins or boiling the gel in water for 5-7 mins. 
3.4.3 Western blot 
Western blot is a commonly used technique to detect the presence of a specific protein or a 
tag in a complex mixture with high sensitivity. For western blotting, SDS gel was first washed 
with water, and then incubated in transfer buffer for 10 mins. Polyvinylidene difluoride 
membrane (PVDF) (EMD Millipore-IPVH00010) was activated by 100% methanol for 5 s, 
washed with water and then incubated in transfer buffer for 10 mins. Whatman paper was 
also incubated in transfer buffer. Proteins were transferred by semi dry transfer method for 30 
min at 25 V, 1 A. Next, the membrane was washed with TBS-T and then blocked with 5% 
skim milk (in TBS-T) for 1 h at room temperature. Membrane was incubated with the primary 
antibody (1:2000 diluted in TBS-T) for 2 h. Again, the membrane was washed with TBS-T. 
The membrane was incubated with the secondary antibody for 1 h, and washed with TBS-T 
before detection. In case of HRP conjugated antibody, membrane was developed using 
Lumi-light Western Blotting Substrate (Roche-12015200001) and analyzed by Fujifilm LAS-
3000 Imager. In case of AP conjugated antibodies, membrane was developed with Alkaline 
Phosphatase staining solution. 
3.4.4 Limited proteolysis 
Limited proteolysis was performed to either search for the stable subdomains of the protein of 
interest or test protein’s stability in presence of different proteases. This method is based on 
the susceptibility of conformationally flexible and exposed regions of protein to proteases 
whereas the protein core remains resistant to proteases (Dong, 2007). Limited proteolysis 
was performed using Hampton Proti-Ace kit I and II according to manufacturer´s instructions. 
In brief, 0.01 mg/ml of protease solution was mixed with 1 mg/ml or 5mg/ml of protein in 
equal volume and incubated at room temperature, 37°C or 4°C for different time points. 
Reaction was stopped by addition of SDS-PAGE sample loading dye. Subsequently samples 
were analyzed by SDS-PAGE and/or MS. 
3.4.5 Mass spectrometry 
For the identification of protein bands, band of interest was excised from blue silver stained 
or Coomassie stained SDS gel and subjected to mass spectrometry (matrix-assisted laser 
desorption ionization) analysis performed by Mass Spectrometry platform at HZI using 
Ultraflex TOF/TOF (Bruker Daltonics). In-gel tryptic digestion was performed and the size of 
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the resulting fragments was determined by mass spectrometry. Peptide sequences thus 
obtained were searched in protein database to identify the protein. 
3.4.6 Protein labeling 
The accessible primary amine residues of the protein were covalently labeled with Cyanine-5 
NHS ester (GE Healthcare) in PBS according to the manufacturer’s instructions. 20 µM (100 
µl) of protein in 1xPBS was mixed with 60 µM (100 µl) dye in DMSO. This mixture was 
incubated at room temperature in dark for 30 mins. Excess dye was removed by buffer 
exchange column (illustra NAP-5 columns GE Healthcare). The protein:dye ratio was 
determined from the protein absorption at 280 nm and the Cy5-absorption at 647 nm using 
an extinction coefficient of Cy5 of 250000 L mol-1 cm-1. 
3.4.7 Size Exclusion Chromatography-Multi Angle Light Scattering  
In Multi Angle Light Scattering (MALS), a beam of light is focused on the sample in solution. 
Light scattered by the sample is detected at various angles at the same time. The intensity of 
the light scattered is directly proportional to the molecular mass of the macromolecule. Size 
exclusion chromatography (SEC) combined with MALS is used to determine the exact 
molecular weight of the macromolecule in solution regardless of its shape and conformation 
which cannot be determined using UV detector and SEC alone.  
For the molecular mass determination of RovC, an inline SEC (Akta PURE, GE Healthcare) 
coupled with a MALS detector (miniDAWN TREOS, Wyatt Technology) and a differential 
refractometer (RI) (Optilab T-rEX, Wyatt Technology) was used (Prof. Teresa Carlomagno’s 
laboratory). 2.8-3.3 mg/ml of RovC was loaded on Superdex 200 10/300 GL column 
prequilibrated with 100 mM TRIS pH 8, 500 mM NaCl and 5 mM DTT. Molecular weight of 
the eluted protein was analyzed by ASTRA 6 software (Wyatt Technology) by recording RI 
and MALS signals. 
3.4.8 Lysine methylation 
Lysine methylation is an inexpensive, fast and simple process to enhance crystallization by 
methylation of the surface exposed Ɛ-NH2 group of lysines, which changes the protein’s 
biophysical properties. The protocol is adapted from (Walter et al., 2006). RovC (5 mg/ml_1.5 
ml) was dialyzed against lysine methylation dialysis buffer (2 L) at 4°C, overnight. RovC was 
diluted to a concentration of 1 mg/ml and 20 µl 1 M dimethylamine-borane (Sigma Aldrich- 
180238) and 40 µl 1M formaldehyde (37% formaldehyde solution, Carl Roth) per ml of 
protein solution was added. Sample was gently mixed and incubated at 4°C for 2 h. Again, 
20 µl 1M dimethylamine-borane and 40 µl 1M formaldehyde per ml protein solution was 
added and the sample was gently mixed and incubated for 2 h at 4°C. Finally, 10 µl 1 M 
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dimethylamine-borane per ml of protein solution was added and the sample was incubated at 
4°C, overnight. Protein was centrifuged at 4°C, 13000 rpm for 10 mins to remove precipitated 
protein. Protein was purified on gel filtration column (S200 10/300), pre-equilibrated with 
lysine methylation gel filtration buffer. 
3.4.9 Surface entropy reduction  
Protein crystallization is a thermodynamic process and depends on the entropy of the 
system.  
According to Gibb´s Helmholtz equation,  
∆ = ∆ − ∆ + ∆											Equation 2 
Where G, H, T,  and	 are Gibb’s free energy, enthalpy, temperature, protein entropy and 
solvent entropy, respectively. 
Equation 2 represents the free energy change that drives crystallization. A negative ∆	is a 
prerequisite for successful crystallization. When protein crystallizes, there is loss in entropy 
for the protein molecules making ∆ negative, but the release of water molecules during 
protein crystallization contributes to entropy gain of the solvent making	∆ + ∆ highly 
positive, favoring crystallization by an overall negative contribution of −∆ + ∆	to ∆. 
In the Surface Entropy Reduction approach, highly entropic residues on the surface of protein 
(mostly Lys, Gln, Glu) are replaced by less entropic residues (mainly Ala). Due to these 
mutations, the total entropy loss of the mutant protein is smaller compared to its native form. 
With constant 		∆ , the total entropy difference in equation 2 becomes larger 
making 	−∆ + ∆  and therefore also 	∆  more negative, which could enhance the 
crystallization of the protein (Derewenda and Vekilov, 2006). Highly entropic residues were 
predicted by Surface Entropy Reduction prediction software-UCLA MBI (SERp) (Goldschmidt 
et al., 2007). 
3.5 Protein interaction 
3.5.1 Pull downs 
Pull down assays were performed to analyze protein–protein interactions. 5-20 µg of tagged 
bait protein in 1x TBS (or 1x PBS) was first immobilized to 20 µl affinity matrix (specific for 
the tag of the bait). On incubation, beads were washed twice (centrifugation at 2000 rpm, 4°C 
for 2 mins) with 1x TBS (or 1x PBS) to remove any unbound protein. Beads were then 
incubated with 1 ml of homogenized extract of mouse tissue or with 6 µg of purified protein in 
100 µl of 1xTBS (or 1x PBS). Following incubation at 4°C (o/n with homogenized tissue 
extract or 2 h with purified protein), with gentle shaking, beads were washed twice (or 3x) 
with 1xTBS (or 1xPBS) and protein was eluted. Wash, elution fractions and beads were 
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analyzed by SDS-PAGE analysis and stained by blue silver stain (Candiano et al., 
2004)/Coomassie blue staining solution. 
3.5.2 Biopanning 
Phage display panning was performed by Saskia Helmsing in Prof. Michael Hust’s laboratory. 
(Bio-) panning is the procedure of selecting binding partners from phage display library. In 
this affinity-driven selection procedure, protein of interest is incubated with phages, washing 
is done to remove unbound phages and bound phages are eluted. This process is repeated 
for several cycles to enrich the target protein with specifically bound phages (Hammers and 
Stanley, 2014)(Adams et al., 2014).  
HAL9 and HAL10 scFv libraries with size of 1.04*1010 and 4.45*109 respectively were used 
for panning (Kügler et al., 2015). The panning and production of soluble scFv was performed 
according to (Frenzel, Kügler, Wilke, Schirrmann, & Hust, 2014). In brief, 5 µg of strep-
tagged InvD1640 was coated on microtiter plate (U96 PP 0.5 ml, Greiner, Frickenhausen, 
Germany) and incubated with HAL10 library/HAL9+HAL10 library. After a few washings, 
bound phages were eluted with trypsin. The eluted phages were used to infect E.coli culture 
which was then co-infected with the helper phage and grown overnight. Phage particles were 
precipitated in PEG/NaCl and then used for the next round of panning. This process was 
repeated for three rounds and plasmids of isolated clones were purified and inserts 
sequenced.  
Production of soluble scFv 
For the production of soluble scFv, clones were picked from the third round of panning, 
inoculated in dYT–GA media and incubated overnight at 30°C at 250 rpm. Phosphate–
buffered dYT-GA media was inoculated with the overnight culture and grown for 2 h at 37°C 
and 800 rpm. Cells were harvested and pellet was suspended in 2xYT supplemented with 
100 µg/ml ampicillin, 100 mM sucrose and 50 µM IPTG and incubated at 30°C and 800 prm 
overnight. Bacteria were pelleted and supernatant was used for ELISA. 
Enzyme linked immunosorbent assay 
A 96 well microtiter plate was coated with 200 ng of InvD 1640 or ∆AD-InvD (in PBS pH 7.4). 
As a control, four wells were also coated with lysozyme. After overnight incubation at 4°C, 
plates were blocked with MPBST for 1 h followed by three washings with PBST. 100 µl of 
scFv containing supernatant were added to the wells and incubated for 1.5 h at room 
temperature. Wells were washed three times with PBST and incubated with 9E10 mouse 
anti-myc antibody (1:50 dilution in MPBST) (Yumab, Braunschweig) for 1.5 h at room 
temperature. Plates were washed again as described earlier. For detection, goat anti-mouse 
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IgG-HRP coupled antibody (1:1000 dilution in 2% MPBST) (Sigma Aldrich-A0168) was added 
to the wells and incubated for 45 mins at room temperature followed by addition of TMB 
(3,3′,5,5′-Tetramethylbenzidine) and absorbance was measured at 450 nm (620 nm 
reference) by ELISA plate reader (Tecan, Crailsheim, Germany). 
3.5.3 Beads assay 
Coating of latex beads with the protein 
30 µl suspension of amine modified polystyrene, fluorescent yellow-green latex beads 
(L1030; Sigma-Aldrich) were added to 1 ml of 1x PBS. After one washing step with 1x PBS, 
beads were suspended in 1 ml coupling buffer in the absence of light. After centrifugation at 
12000 rpm for 5 mins, beads were resuspended in 100 µl of coupling buffer and 100 µl of 
0.6-1 mg/ml InvA, BSA or InvD1640 were added to it and incubated at 37°C for 1 h. Then 
500 µl of coupling buffer was added and sonicated for 10 seconds. To the coated beads 500 
µl of 30 mg/ml BSA in coupling buffer was added followed by 1 h incubation at 37°C followed 
by washing with 1x PBS in 0.2 mg/ml BSA. Coated beads were resuspended in 1 ml 1xPBS 
0.2 mg/ml BSA and stored at 4°C until use. 
Cultivation of eukaryotic cells 
Human Epithelial cells (HEp-2 cells) were cultivated in 75 cm2 cell culture flasks (Greiner) 
with 20 ml of HEp2 medium at 37°C, 89% humidity and 5% CO2 in a cell incubator (Heracell 
150, Prof. Petra Dersch’s laboratory). HEp-2 cells were passaged every second day. Cells 
were washed with 1x PBS and treated with 2 ml trypsin-EDTA solution for 5 mins at 37°C. 
Trypsinization was stopped by the addition of 8 ml culture medium. 1 ml of this suspension 
was diluted with 19 ml of medium and transferred to a new flask. 
Cell density measurement 
Cell density was measured by Neubauer counting chamber. 10 µl of resuspended cell 
suspension was mixed with 90 µl of trypan blue and loaded onto the counting chamber. 
Trypan blue stains dead cells blue while live cells do not take up the dye. Counting chamber 
was observed under the microscope and live cells were counted in each of the four squares. 
The cell number per ml was calculated by the equation- 
 				 			 = !"#$%&	'(	)%**+∗-,
!"#$%&	'(	)%**+∗/0*"10'!	(2)1'&
          Equation 3 
The cells were resuspended in the appropriate volume of the culture medium to reach the 
desired cell density and seeded into a new flask. 
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Cell adhesion assay 
For cell adhesion assay, 5*104 HEp-2 cells were seeded and grown overnight in individual 
wells of 12-well cell culture plates. Cells were washed three times with PBS and incubated in 
HEp-2 binding buffer. Approximately 2*106 beads were added to the cells and cell culture 
plate was centrifuged for 5 mins at 1000 rpm. Cells were incubated for 1 h at 25°C to check 
for adhesion. After 1 h incubation, cells were washed 3 times with PBS and fixed with 2% 
paraformaldehyde (Sigma-Aldrich-P6184). After 10 mins post-incubation at room 
temperature, cells were washed once with PBS and fixed cells were stained with 4´, 6-
diamidino-2-phenyl indole (DAPI; Roth-6335.1) to visualize the nuclei of the cells. After 
another 4 mins incubation at room temperature, cells were again washed with PBS and after 
addition of 200 µl of PBS, cells were visualized with a Zeiss Axiovert II fluorescence 
microscope and the AxioVision Software (Zeiss). 
3.5.4 Flow cytometry 
Flow cytometry experiments were performed by Jörn Pezoldt in Prof. Jochen Hühn’s 
laboratory. 
Single cell suspensions were obtained by mechanical disruption of the organs through a 
100 µm cell strainer (BD, Franklin Lakes, NJ, USA). To eliminate erythrocytes, spleen cells 
were incubated for 3 mins in erythrolysis buffer (7.8 mM NH4Cl, 10 mM KHCO3, 100 mM 
EDTA). Dead cells were identified using Live/dead fixable blue dead cell stain kit (Invitrogen, 
Waltham, MA, USA). To exclude unspecific binding of antibodies, samples were incubated 
for 15 mins with anti-CD16/CD32 (BioXCell, West Lebanon, NH, USA) and rat IgG (Jackson 
ImmunoResearch, Baltimore, PA, USA). 3xflag tagged InvD1640 and AD-InvD were used at 
100 µg/ml and staining was performed together with the antibodies staining (listed below 
table 5) for 15 mins at 4°C in PBS containing 0.2 % (w/v) bovine serum albumin (BSA, 
Sigma-Aldrich) and 2 mM Ca2+ (Roth, Karlsruhe, Germany). Flow cytometry was performed 
using LSR Fortessa flow cytometer with Diva software (BD), and data were analyzed with 
FlowJo software (TreeStar, Ashland, OR). 
3.5.5 Lipid binding assay 
To assess lipid binding of InvD1640, a protein-lipid assay was performed using Membrane 
Lipid Strips (P-6002; Echelon Biosciences) according to the manufacturer’s 
recommendations. Briefly, membrane was blocked in 3% (w/v) fatty acid-free BSA in TBST 
for 1 h at room temperature in the dark followed by 1 h incubation with 3xflag-tagged 
InvD1640 (1.0 µg/ml in TBST) at room temperature with gentle agitation. After washing the 
membranes three times over a 1 min period in TBST, they were incubated for 1 h with 
0.8 µg/ml rabbit anti-flag polyclonal antibody. Membranes were washed as before and 
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incubated for 1 h with anti-rabbit-HRP conjugate followed by washing as done before and 
detection by Echelon´s K-TMBP. 
3.5.6 Glycan binding assay 
Binding of 3xflag tagged InvD was analyzed by the Consortium for Functional Genomics 
(CFG) Protein-glycan interaction core. Binding of the protein to 609 different glycans on a 
glass slide (version 5.2) was analyzed at a concentration of 200 µg/ml. Protein binding was 
detected by anti-flag antibody and fluorescently labeled  anti-rabbit IgG 488 antibody 
(supplied by the Consortium). The array consists of six replicates of each glycan. The highest 
and lowest point from each set of six replicates has been removed so the average is of four 
values rather than six to eliminate some of the false hits that contain a single very high or low 
point. 20 mM TRIS-HCL pH 7.4, 150 mM sodium chloride, 0.05% Tween 20 and 1% BSA 
was used as the binding buffer. As a washing buffer, 20 mM Tris-HCL pH 7.4, 150 mM 
sodium chloride, 2 mM calcium chloride, 2 mM magnesium chloride, 0.05% Tween 20 and 
1% BSA was used. 
3.5.7 Microscale thermophoresis 
Microscale thermophoresis is based on the movement of molecules in a temperature 
gradient. This process is dependent on the size, hydration shell or charge of the molecule 
which has an influence on the Soret coeffecient (STi). 
30 =
456
46
            Equation 4 
Where 730  is the thermophoretic mobility or thermal diffusion coefficient and 70  is the 
diffusion coefficient. 
One of these parameters gets affected when a molecule binds to its interaction partner hence 
changing the Soret coeffecient. The Microscale thermophoresis technique detects these 
changes in the movement of the molecule upon binding to an interaction partner (Duhr and 
Braun, 2006; Jerabek-Willemsen et al., 2014). 
In this method, one of the interaction partners is fluorescently labeled according to the 
protocol described in section 3.4.6. Constant amount of labeled protein was then titrated with 
the increasing concentration of the unlabeled partner, and the change in thermophoresis of 
fluorescently labeled molecule in presence of unlabeled partner is measured, which leads to 
the measurement of binding constant. 12 or 16 dilutions of unlabeled partner were prepared 
and mixed in a 1:1 ratio with the labeled protein. Samples were then filled in the standard 
treated capillaries. Infrared laser is focused on the capillary to create a temperature gradient 
of 2-6 K. The temperature gradient leads to depletion of molecules in that region which is 
quantified by Soret coefficient.  
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The experiments were performed on Monolith NT.115 at 20% LED with a MST power of 20–
60 %; laser-on time was 30 s, laser-off time 5 s each. Curve fitting was done by MO.Affinity 
Analysis (x64) software (NanoTemperTechnologies) in Thermophoresis + T-jump mode. 
3.6 X-ray crystallographic methods 
3.6.1 Protein crystallization  
To elucidate the structure of proteins by X-ray crystallography, protein crystals are required. 
For the formation of protein crystals, protein in solution is mixed with a precipitant solution to 
decrease the solubility of the protein which leads to supersaturation and hence crystal 
formation. Large supersaturation is required to overcome the activation energy required to 
form crystals. Protein crystallization can be explained by crystallization phase diagram 
(Figure 13). This is a two-dimensional solubility plot with X-axis showing precipitant 
concentration and protein concentration on Y-axis. The solubility curve is divided into two 
zones: the undersaturated and the supersaturated zone. In the undersaturation region 
protein is soluble and no crystal formation will take place. The supersaturation zone starts 
above the solubility curve and is further divided into three zones (Asherie, 2004):  
1) metastable zone-spontaneous nucleation will not occur, crystal growth only occurs from 
pre-existing nuclei. 
2) nucleation zone- supersaturation is large enough that crystal growth can take place. 
3) precipitation zone- supersaturation is too large which leads to precipitation of the protein. 
 
 
 
 
 
 
 
 
As illustrated in the protein crystallization diagram, protein crystallization depends on protein 
as well as precipitant concentration, pH, ionic strength and additives. Apart from these 
factors, temperature has also been shown to be an important variable in protein 
crystallization. Protein solubility can decrease or increase with the temperature depending on 
the type of precipitant used, thus it influences nucleation and crystal growth. Crystallization 
also depends on the geometry of the set-up. Two experimental setups are commonly used in 
crystallization, namely hanging drop and sitting drop (Figure 14). In both methods, protein 
 
Figure 13: Crystallization phase diagram. 
Schematic representation of two-dimensional 
crystallization phase diagram. 
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solution is mixed with the precipitant in a 1:1 ratio and is allowed to equilibrate with the 
precipitant solution (reservoir solution). As the protein drop contains less concentration of 
precipitant as compared to the reservoir solution alone, there is a net transfer of water (by 
vapor diffusion) from the protein drop to the reservoir. Hence, the precipitant and protein 
concentration in the protein drop is steadily increased until equilibrium is established. 
In case of hanging drop, a well is filled with 500 µl of reservoir solution. 500 nl of protein 
solution was mixed with 500 nl of precipitant solution on a cover slip which was flipped over 
the well. The contact area between the coverslip and the well was sealed with silicone 
grease. For this approach, 24 well plates (VDX PlateTM HR3-108) were used. 
In case of sitting drop, 96 intelli plates (Art Robbins Instruments, Hampton Research) were 
used. Screening was performed with Honey bee robot or drops were set manually. With 
honey bee, wells were filled with 60 µl of reservoir solution. The protein drop (200 nl) was 
mixed with reservoir solution (200 nl) and the plate was covered with transparent tape and 
placed in the RockImager for imaging of drops. For manual set-ups, 60 µl of reservoir 
solution was placed in the well and 400 nl of protein was mixed with 400 nl of reservoir 
solution. 
 
 
 
 
 
 
 
 
 
For initial screening, different crystallization screens were used as mentioned in Table 10. 
Protein concentration ranging from 2 mg/ml-30 mg/ml was used in protein crystallization 
experiments and plates were incubated at 20°C and 4°C. 
3.6.2 Cryoprotection 
When the protein crystal reaches a certain size, it is harvested from the drop and flash frozen 
in liquid nitrogen, if the drop contains sufficient amount of cryoprotectant. If this is not the 
case, the crystal is first dipped in a drop of cryoprotectant and then quickly dipped into liquid 
nitrogen. Cryoprotectants prevent the formation of ice crystals as they act as an anti-freezing 
agent and prevent the mother liquor from freezing as amorphous ice. If there are ice crystals 
on the loop, it largely affects the quality of the diffraction. Cryoprotectants used in this study 
are PEG400, glycerol and sodium formate. 
 
Figure 14: Hanging and sitting drop methods. Schematic representation of the hanging drop and sitting drop 
methods for protein crystallization. 
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3.6.3 Structure determination by X-ray crystallography 
When X-rays strike a crystal, they get diffracted upon interaction with the electrons of the 
atom. The diffracted rays consist of reflections of different intensities from sets of parallel 
planes (called Miller planes characterized by three Miller coordinates (h, k and l)) of atoms in 
a crystal. 
According to Bragg´s law, for diffraction to occur, the following rule must be satisfied, 
8 = 2:;              Equation 5 
where n is an integer, λ is the wavelength of the incident wave, d is the spacing between the 
atomic planes and	; is the incident angle (reflection angle) which is the angle between the 
incident beam and the plane. As the crystal consists of an infinite set of Miller planes, each 
plane will diffract X-rays differently. The interference can only be constructive when the path 
difference is equal to the integral number of wavelength (Figure 15). From the X-ray 
diffraction pattern that is generated by these planes, crystal parameters can be calculated. 
 
 
 
 
 
 
 
 
 
 
Intensities of the reflections can be calculated from the experimental data obtained from the 
X-ray experiment. The major step towards determination of a structure is to construct the 
electron density map, which is calculated by Fourier Transformation of the diffraction data. 
The function for electron density ρ(x,y,z) is given as 
∑∑∑
−++⋅−
=
h k l
lzkyhxi
hkl hkleFV
zyx )(21),,( αpiρ
                Equation 6 
Where V is the unit cell volume, hklF  is the structure factor amplitude for each reflection and 
hklα  are the phases for each reflection. 
To calculate the electron density, one needs the information of the intensity of the reflections, 
which is proportional to |=>?*|2, and the phases (@>?*). Intensities are directly measured by the 
detector but the phase information is lost during the measurement. This is known as phase 
problem. In protein crystallography, phases can either be derived from the coordinates of 
structurally similar proteins (called Molecular Replacement (MR)) or experimentally by 
 
Figure 15: Schematic representation of 
Bragg’s law. Two X-ray beams A and A' 
arrive in phase and strike the planes with an 
angleA . The diffracted X-rays can only be 
constructive when the distance between the 
paths ABC and A’B’C’ is an integral number 
of wavelength. 
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determining the positions of heavy atoms that have been added to the protein (methods 
include single/multiple isomorphous replacement (SIR/MIR), single/multiple wavelength 
anomalous dispersion (SAD/MAD). Only SAD and MR will be discussed further in this work. 
3.6.4 Molecular replacement  
Molecular replacement (MR) is based on the assumption that the phases of a homologous 
protein (model) will provide the estimation of the real phases. In MR, the model is oriented 
and positioned in such a manner that it coincides with the crystallized target protein in the 
unit cell. 
To determine the correct orientation and position of the model in the unknown unit cell, three 
rotation angles and three translational directions must be specified. For one molecule in the 
asymmetric unit, the MR problem becomes a 6D problem. To solve this problem, 6D problem 
is divided into two 3D problems. First rotation angles are calculated by the use of Patterson 
function, and then the oriented molecule can be placed in the unit cell by 3D translation 
function. 
If Fourier transformation is applied only on the intensities, a Patterson map is obtained. This 
map gives the information about the interatomic distances within the molecule. This 
information can be used to solve the structure for small molecules, but as the number of the 
peaks in the Patterson function is directly proportional to the square of the number of atoms, 
it is not possible to solve the structure for large molecules. However, this information can be 
used to solve the orientation problem. Patterson function of the model is calculated for every 
possible orientation and is matched with the Patterson function of the unknown structure. 
Once the correct orientation is found, the same method is used to correctly determine the 
position of the molecule in the unit cell. Once the correct solution is obtained, reverse Fourier 
transformation is applied to calculate the phases which are further used to calculate the 
electron density map (Evans and McCoy, 2007). 
3.6.5 Anomalous diffraction 
If the incident X-ray energy is close to the transition energy of the used heavy metal atom, 
the phase and the intensity of the diffracted wave gets affected. Since some of the energy is 
used to bring the atom to an excited state, the intensity of the coherent scattering at this 
wavelength is reduced and also there is a phase change of the scattered X-rays. This effect 
is called anomalous scattering. 
In the presence of anomalous scatterer, the scattering power of that atom at any wavelength 
becomes- 
B = B! +	∆BC + ∆B′′                                                                            Equation 7 
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Where B!  is the normal scattering factor (independent of wavelength), ∆BC  is the real 
component that describes the amount by which the normal scattering is reduced and	∆BCC is 
the imaginary component which is 90° out of the phase with the normally scattered radiation. 
These factors are wavelength dependent and vary with the wavelength used for the 
measurement. 	B	CC  has its maximum value at the peak wavelength, while at the edge 
wavelength BC	is reduced to its lowest possible value. 
Anomalous phasing is based on the violation of Friedel’s law. According to Friedel’s law, 
structure factor Fhkl and its Friedel mate F-h-k-l have the same magnitude but opposite phases. 
In the presence of anomalous scatterers, Fhkl and F-h-k-l have different magnitudes and also 
their phases are different giving rise to an anomalous difference which can be used to locate 
the anomalous scatterer. Once the position of the heavy atom is located in the unit cell by 
Patterson methods, phases can be calculated. 
In SAD (single anomalous diffraction/dispersion), data is calculated at the peak wavelength of 
the anomalous scatterer. In multi wavelength anomalous dispersion (MAD), datasets at three 
different wavelengths are collected: first dataset is collected at the peak wavelength of the 
anomalous scatterer, second at the remote wavelength and third at the inflection wavelength 
(Taylor, 2003). 
In this study, to solve the phase problem by SAD, heavy metals are introduced into the 
preformed crystals by soaking, for the determination of InvD structure. For InvE and RovC, 
Selenomethionine variants of the proteins were expressed, purified and crystallized. Data 
were processed with XDS software package (Kabsch, 2010). Phaser MR was used to 
perform Molecular Replacement (McCoy, 2006). Phaser EP was used for MR-SAD and SAD 
phasing (Read and McCoy, 2011). 
3.6.6 Model building and refinement 
After determination of phases, the calculated electron density is interpreted and model is 
built. To eliminate the conformational or stereo-chemical errors that remained after model 
building, it is necessary to carry out a crystallographic refinement. During refinement, several 
parameters such as B-factors, geometry and model coordinates are refined against 
experimental data to obtain the best fit between the observed and calculated structure factor 
amplitudes. The overall fit is calculated by the following equation 
E =
∑ G|HIJK>,?,*|L|HMNOM>,?,*|GP,Q,O
∑ |HIJK>,?,*|P,Q,O
                                                                  Equation 8 
R or Rwork is a useful factor to assess the progress of the model. However, it can be lowered 
by over-fitting or mis-fitting the data, but this would not improve the model. To avoid this 
problem, Rfree was introduced (Brunger, 1992). Rfree is calculated in the same way as Rwork, 
but for Rfree calculation 5% of the reflections are excluded from the structure refinement. If 
Materials and methods                                                                         
60 
 
there is an over-fit in the model, Rfree will increase or will stop dropping, while Rwork is further 
reduced.
 
The initial model was built using Phenix Autobuild. Wincoot (Emsley et al., 2010) 
and Phenix_refine (Afonine et al., 2012) was used for iterative model building and refinement 
respectively.  
3.7 Small angle X-ray scattering  
Small angle X-ray scattering (SAXS) reveals the structure of macromolecules in solution at a 
resolution of 10-20 Å. SAXS, like X-ray crystallography uses high energy X-rays to obtain 
structural information of the sample. In a SAXS experiment, an incident X-ray beam falls onto 
a thin glass capillary filled with protein solution. Scattered X-rays are recorded by the 
detector. As the molecules are randomly oriented in solution, averaging of these molecules 
leads to loss of information as compared to crystallography where the sample is in crystalline 
form. SAXS experiment gives information about the oligomerization state and also the 
organization of oligomers in solution. It is a useful technique to calculate the low resolution 
envelope of the molecule. SAXS is a contrast method; it depends on the difference in the 
electron density between the molecule and the solvent. Therefore, a buffer blank has to be 
measured and subtracted from the scattering curve of protein + buffer scattering curve to 
obtain the scattering curve of the pure protein. 
The data obtained from SAXS experiments were processed using tools in the ATSAS 
software package. The net protein-scattering data was generated by subtracting scattering of 
buffer from the scattering of protein using PRIMUS (Konarev et al., 2003). The distance 
distribution function was calculated by GNOM (Svergun, 1992). 18-20 independent ab-initio 
models were built using DAMMIF (Franke and Svergun, 2009). These models were then 
averaged with DAMAVER package (Beaucage, 1995) to yield SAXS envelope. Fitting of the 
crystal structure with the experimental SAXS curve was performed using CRYSOL 
(Barberato et al., 1995). Using UCSF Chimera (Yang et al., 2012), the X-ray structure was 
fitted in the SAXS envelope. 
SAXS data were measured for InvD1640 on the P12 beamline at PETRAIII EMBL Hamburg. 
InvD1640 was prepared in a buffer consisting of 20 mM HEPES pH 7.4, 200 mM NaCl and 5 
mM DTT at a protein concentration of 3.5 mg/ml. 
For InvE2448, SAXS data were measured at BM29 of the ESRF in Grenoble, France. 
InvE2448 was prepared in a buffer consisting of 20 mM HEPES pH 7.4, 200 mM NaCl and 5 
mM DTT at a protein concentration of 1 mg/ml.  
For RovC, SAXS data were measured on the P12 beamline at PETRAIII EMBL Hamburg. 
RovC was prepared in a buffer consisting of 50 mM TRIS pH 8.0, 500 mM NaCl, 5 mM DTT 
and 5% glycerol at a protein concentration of 2.5 mg/ml. 
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4 Results 
4.1 InvD from YPIII strain of Y. pseudotuberculosis 
Y. pseudotuberculosis YPIII possesses four different Invasins (InvA, InvB, InvC and InvD) on 
its surface. Unlike InvB and InvC, whose C-terminal domain share high sequence similarity 
with InvA, InvD C-terminal domain shares no sequence homology to any other Invasins. 
Thus, the aim of this part of work was to structurally and functionally characterize the recently 
identified InvD. 
4.1.1 Cloning, expression and purification of InvD 
4.1.1.1 Bioinformatics analysis of InvD 
Sequence analysis of InvD using a combination of BLAST-p, Pfam (ID: 
B1JSC0/A0A0H3B1G5) and Signal-BLAST identified a putative signal peptide (SP in Figure 
16) between residues 32 and 57. This N-terminal sequence stretch is followed by a β-barrel 
domain comprising of residues 146-421, which is required for anchoring the protein to the 
outer membrane of bacteria. The putative β-barrel domain is followed by 13 bacterial Ig-like 
(BIg) domains. BIg1-13 are capped by a predicted C-terminal domain (1829-1976 aa) with no 
similarity to known proteins. Based on these predictions, three constructs, InvD1640 (G1640-
N1976), InvD1737 (P1737-N1976) and InvD1838 (P1838-N1976) were designed (Figure 16). 
 
 
 
 
 
 
 
4.1.1.2 Cloning and expression 
InvD constructs were amplified by PCR from the genomic DNA of Y. pseudotuberculosis 
YPIII and cloned (3.2.1-3.2.7) into a modified pCOLA-Duet vector containing an N-terminal 
6xHis tag (vector pVP009) and TEV cleavage site. After verification of inserts by sequencing 
(3.2.8), bacteria were transformed with the plasmid and tested for expression (3.3.1). Out of 
three constructs, InvD1640 and InvD1737 resulted in soluble protein, while InvD1838 was not 
soluble (Figure 17). 
 
 Figure 16: Domain organization of Y. pseudotuberculosis InvD. Scheme of the domain organization of Y. 
pseudotuberculosis InvD with construct boundaries. 
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4.1.1.3 Culturing and cell disruption 
As described in section 3.3.2-3.3.3, 4 L of TB + kanamycin + chloramphenicol media was 
inoculated with the overnight culture of InvD1640 or InvD1737 expressing bacteria. At an 
OD600 (optical density at 600 nm) of 0.7, expression was induced with 100 µM IPTG and 
cultures were allowed to grow at 20°C, 130 rpm for 21 h. After centrifugation and 
resuspension in lysis buffer, cells were homogenized. 
4.1.1.4 Purification of 6xHis InvD constructs for crystallization 
After clearing of the lysate by centrifugation, affinity chromatography was performed (3.3.4). 
To further purify proteins to homogeneity, size exclusion chromatography was performed 
(3.3.7) in 20 mM HEPES pH 7.4, 200 mM NaCl and 5 mM DTT. For InvD1640, S200 16/60 
column was used, while InvD1737 was purified on S75 16/60 column (Figure 18). 
Purified proteins were identified as Y. pseudotuberculosis YPIII InvD by tryptic digest and 
mass spectrometry. Proteins were concentrated to 40 mg/ml and flash frozen in liquid 
nitrogen. The overall yield of pure InvD1640 and InvD1737 was about 10 mg/L culture. 
4.1.1.5 Protease stability assay  
To assess the stability and flexibility of InvD in solution, InvD1640 and InvD1737 were treated 
with 12 different proteases.  
Apart from treatment with Proteinase-K or Subtilisin, InvD1737 was highly stable with no 
major degradation detectable, and InvD1640 also showed high stability with only minor 
degradation (Figure 19). 
  
 
 
Figure 17: Coomassie stained 15% SDS gel of test expression of 6xHis 
InvD constructs. For both constructs, high yields of soluble protein were 
obtained by overnight incubation of cells at 20°C with 100 µM IPTG. Bands 
corresponding to soluble proteins are marked with the black arrow. 
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Figure 18: Purification of 6xHis tagged InvD constructs. A) Purification of InvD1640 and B) purification of 
InvD1737. Elution profile of the run on size exclusion column (left); Coomassie stained SDS gel of eluted 
fractions (right). Blue bar represents the corresponding elution fractions in the chromatogram that were analysed 
by SDS-PAGE. Absorbance of the protein is measured at 280 nm. 
 
A 
B 
Figure 19: Stability of InvD against proteases. InvD1737 (top) and InvD1640 (bottom) (at a concentration of 
1 mg/ml) were treated with 12 different proteases (BR-Bromelain, TR-Trypsin, EG-C-EndoproteinaseGlu-C, PA-
Papain, TH-Thermolysin, CL-Clostripain, AE-Actinase, PK-Proteinase-K, EL-Elastase, SU-Subtilisin, α-C-α-
Chymotrypsin , PE-Pepsin at a concentration of 0.01 mg/ml) and incubated for 20 h at room temperature. 
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4.1.2 Crystallization and structure solution of InvD 
4.1.2.1 Crystallization of InvD 
To gain insight into the structure of the adhesion domain of InvD, 6xHis tagged InvD1640 and 
InvD1737 were used for initial crystallization screening at 20°C and 4°C using commercially 
available screens. Initial hit with 22 mg/ml of InvD1640 was obtained in the following 
condition- 2 M ammonium dihydrogen phosphate and 0.1 M TRIS-HCl pH 8.5 at 20°C (Figure 
20A). For optimization, crystals were grown using 24 well hanging drop plate at 20°C by 
mixing 0.5 µL of concentrated protein with 0.5 µL of mother liquor. Well diffracting quality 
crystals were obtained under the following condition-1.9 M ammonium dihydrogen phosphate 
and 0.1 M TRIS-HCl pH 8.0 with 18 mg/ml of InvD1640 (Figure 20B). 
Several of these crystals were dissolved in protein buffer (20 mM HEPES pH 7.4, 200 mM 
NaCl, 5 mM DTT) after washing in the reservoir solution and loaded on SDS-PAGE to 
confirm the identity of crystals. As a control, InvD1640 (in solution) was also loaded on the 
gel. The protein band was sent for mass spectrometry analysis which confirmed that the 
band in the gel belongs to InvD1640 (Figure 20C).  
For cryoprotection, the reservoir solution was supplemented with an additional 25% PEG 
400. Crystals were incubated for about 30 s in the cryosolution to ensure exchange of the 
reservoir solution and flash frozen in liquid nitrogen. InvD1640 crystals diffracted to a 
resolution of 3.6 Å in house (λ-1.5418 Å). 
 
 
 
 
 
 
 
 
 
 
  
Figure 20: 6xHis tagged InvD1640 crystals. A) Initial hit (crystals are marked in red circle) B) optimized crystals 
and C) SDS-PAGE analysis of crystals (S=protein in solution, C=protein in crystals). 
 
 
A B C 
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4.1.2.2 Data processing and structure solution 
The native data set was collected at the Swiss Light Source (SLS) at X06DA/PXIII beamline. 
InvD crystals diffracted to 2.6 Å resolution. InvD C-terminal domain shows no significant 
similarity to other sequences in the protein database. Instead, BIg domains 12 and 13 share 
31-53% sequence identity with BIg domains D1, D2 and D3 of InvA (PDB entry 1CWV 
(Hamburger, 1999)). Hence, initial molecular replacement trials were performed with Phaser 
MR by using individual Ig-like domains of InvA as a search template. A partial solution 
containing two Ig-like domains in the asymmetric unit was found. Further attempts to use the 
integrin binding domain of InvA (1CWV) as a search model did not improve the electron 
density. 
Therefore to obtain the additional information on phases, heavy-atom derivatives were 
prepared by soaking the crystals in 1.9 M ammonium dihydrogen phosphate, 0.1 M TRIS-HCl 
pH 8.0 and 25% PEG400 supplemented with 100 mM of Yb-HPDO3A for 1 min, followed by 
flash freezing in liquid nitrogen.  
The anomalous data set (1.38315 Å) was collected at the SLS at X06DA/PXIII beamline. The 
heavy atom soaked crystals diffracted to 3.3 Å. Phaser-EP was employed to calculate the 
phases. SAD alone failed to solve the structure. So, MR-SAD protocol was used in Phaser 
using the "SAD plus MR" mode. The model obtained after MR-SAD was subsequently used 
as the template to solve the native structure by molecular replacement. 
InvD1640 crystallized in space group p43 with two molecules in the asymmetric unit (AU). 
Phenix-Autobuild was used for automated model building. Coot was used for further manual 
model building. The model was refined to 2.6 Å resolution with phenix.refine taking into 
account the twin law (h,-k,-l). Final step of refinement was performed using TLS refinement 
with the TLS groups as were defined by Phenix. Statistics of data collection and refinement 
are depicted in Table 24.The quality of the electron density is shown in Figure 21. 
 
 
 
 
 
 
 
 
  
 
 Figure 21: Quality of the electron density. 2Fo-Fc electron density (contoured at 1 σ) in the A) BIg12 B) BIg13 
and C) the C-terminal domain of InvD. 
A B C 
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Table 24: Data collection and refinement statistics. 
 
DATA COLLECTION InvD (PDB: 5LDY) InvD (Yb-derivative) 
X-ray source PXIII, SLS  PXIII, SLS 
Wavelength [Å] 1.000 1.38315 
Resolution [Å] 44.70-2.60 
(2.70-2.60) 
49.40-3.10 
(3.20-3.10) 
Space group P43 P43 
Cell dimensions  
a, b, c [Å] 
α, β, γ [°] 
 
58.9, 58.9, 274.5 
90.0, 90.0, 90.0 
 
58.7, 58.7, 274.0 
90.0, 90.0, 90.0 
Rmerge[%] 6.3 (41.6) 8.0 (38.8) 
Rmeas[%] 6.6 (43.6) 8.3 (40.4) 
CC1/2 [%] 99.9 (95.7) 99.9 (97.5) 
‹I/σ(I)› 26.6 (5.8) 29.8 (6.8) 
 Completeness [%] 99.9 (99.9) 99.8 (99.5) 
 Unique reflections 28540 (3070) 33168 (3019) 
 Redundancy 11.3 (11.2) 12.4 (12.7) 
REFINEMENT   
Resolution [Å] 44.70-2.60   
No. of reflections 28540  
Rwork 0.230   
Rfree 0.253  
No. of atoms 9725  
Avg. B factor [Å2] 67.0  
R.m.s. deviations       
Bond length [Å]  
Bond angles [°] 
 
0.0024 
0.470 
 
Ramachandran [%] 
(favored/allowed/ 
disallowed) 
90.6/9.4/0.0  
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4.1.3 Structural characterization of InvD 
4.1.3.1 Structure of InvD1640 
The overall structure of the construct is rod-like, with a length of 12.9 nm as shown in Figure 
22. InvD1640 consists of three domains: BIg12 (1640-1736 aa), BIg13 (1737-1837 aa) and 
the C-terminal domain (1838-1976 aa) which is named adhesion domain (AD) hereafter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two molecules in the asymmetric unit (AU) are very similar and they superimpose with an 
rmsd of 0.923 Å. The separate superimposition of BIg13/AD or BIg12 resulted in a lower 
rmsd of 0.814 Å and 0.761 Å, respectively.  
 
Figure 22: Crystal structure of Y. pseudotuberculosis InvD. Cartoon model of the crystal structure of 
InvD1640. InvD1640 consists of the N-terminal BIg12 (blue), BIg13 (green) and the C-terminal adhesion domain 
(AD in orange) shown in two orientations. 
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4.1.3.2 SAXS structure of InvD1640 
With the aim of understanding the structure of InvD in solution, SAXS data for InvD1640 was 
collected at the P12 beamline at PETRAIII EMBL Hamburg. The calculated SAXS envelope 
is highly similar to the crystal structure of InvD1640 although with the N-terminal BIg12 
domain in a different conformation. Manual fitting of InvD1640 crystal structure to the 
envelope was performed by fitting separately the region corresponding to BIg13/AD and the 
N-terminal BIg12 (Figure 23A).  
These small differences that were observed in the orientation of BIg12 suggest that the 
junction between BIg12 and BIg13 allows for minor flexibility. 
The chi value of 1.09 was obtained with CRYSOL on fitting the SAXS data with the crystal 
structure, which indicates that the model is in very good agreement with the calculated 
SAXS-envelope (Figure 23B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
180° 
Figure 23: SAXS envelope of InvD1640. A) Rigid body fitting of the crystal structure into the ab initio 
determined SAXS envelope shown in two orientations. B) Fit of the rigid body model (red) with the experimental 
scattering (blue). Quality of the fit is expressed in terms of chi value. 
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4.1.3.3 Topology of InvD 
BIg12/13 domain 
InvD comprises 13 BIg like domains; of these, the first 12 BIg-domains share high sequence 
identity in the range of 56-97% (72-100% similarity), whereas BIg13 is significantly different 
from BIg1-12 (sequence identity 22-28%; similarity 40-47%) (Figure 24). 
  
 
 
 
 
 
 
Despite the low sequence identity between BIg12 and BIg13, their structures are highly 
similar, each adopting a classical Immunoglobulin Superfamily (IgSF) fold (Figure 26 and 
Figure 27).  
IgSF fold consists of two β-sheets with seven or more strands adopting a greek-key topology. 
IgSF domains have been previously classified into three different sets- C, V and I-set (Figure 
25). The core structure of these domains is similar; variation arises due to the presence of 
different number of strands and their arrangement. The C and V domains are so named due 
to the similarities which they share with the constant and variable domains of antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 25: Topology diagrams of five different sets of the immunoglobulin fold. Variable (V-set), constant1 
(C1-set), constant2 (C2-set), intermediate1 (I1-set) and intermediate2 (I2-set) (modified from (Bodelón et al., 
2013)). 
 
 
Figure 24: Sequence alignment of BIg 1-13 domains of InvD. 100% conserved amino acids are marked in red, 
80% in orange and 60% in yellow. Alignment has been generated with GeneDoc (Nicholas et al., 1996). 
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The C set is further divided into C1 and C2-sets. Structures grouped in C1-set consist of 
strands ABED formed by one β-sheet while the second sheet comprises β-strands G, F and 
C. Structures that belong to C2-set lack the D strand, but contain a C' strand. Structures that 
belong to V set comprise strands ABED forming one β-sheet, whereas the second sheet 
consists of A'GFCC'C'' strands. I-set is intermediate in topology between C and V sets. In I-
set, one β-sheet is composed of the ABED strands while the other sheet comprises A'GFCC' 
strands. Like C-set, I-set is also classified into I1 and I2 sets. Structures that belong to I1-
category have a D strand while members of the I2 do not (Figure 25) (Bodelón et al., 2013; 
Casasnovas et al., 1998).  
In BIg12 and BIg13 domains of InvD, one β-sheet is composed of strands ABED, while the 
second β-sheet is composed of strands A'GFC (Figure 26). Both BIg12 and BIg13 have a 
kink in strand A-A' mediated by cis-Proline (P1653). These results, together with the 
presence of strand D as well as the lack of strand C'' are reminiscent of the I1-set of IgSF 
domains (Figure 25 and Figure 26). Even though BIg12 and BIg13 lack strand C', both BIg12 
and BIg13 were classified in I1-set, in line with the previously observed lack of C' in other I1-
set domains (Tan et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
A B 
Figure 26: Domain architecture of BIg12/13 domains. A) Topology diagram of BIg12 (blue) and BIg13 
(green) of InvD1640. (B) Cartoon representation of the BIg12/13 domains of InvD (β-strands are labeled). 
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Both BIg12 and BIg13 lack the usual disulfide bridge that connects the two sheets of the β-
sandwich fold as well as the core residues conserved in IgSF structures, such as the 
tyrosine-corner or the C-strand tryptophan. The canonical cysteines in strands B/F are 
replaced by an interacting set of hydrophobic residues comprising V1666/L1718 and 
I1764/I1817 for BIg12 and BIg13, respectively (Figure 28) (Jones et al, 1992). 
 
 
 
 
 
 
 
 
 
 
BIg12/13 interface 
The contact area between BIg12 and BIg13 comprises an interface area of 199 Å2 comprising 
a total of 13 interacting residues as determined by the PISA server (Krissinel, 2015) (Figure 
29A, Table 25).  
  
Figure 27: Structural overlay of 
BIg12 and BIg13. Superposition of 
BIg12 (blue) and BIg13 (green) 
shown in two orientations (β-
strands are labeled). They 
superimpose with an rmsd of 
1.58 Å.  
 
A B C D 
Figure 28: Close-up view of the hydrophobic core of BIg12/13 and its comparison with human NCAM 
domain-1. A) Structural overlay of BIg12 (blue), BIg13 (green) and Human NCAM domain1 (brown, PDB code 
5AEA). B) Human NCAM domain-1 adopts a classsical Ig-like fold (Griffiths et al., 2016) and contains a disulfide 
bond formed by C22 and C77 while in C) BIg12 and D) BIg13 cysteines were replaced by hydrophobic amino 
acids. These residues are shown as sticks with sulfur atoms in yellow. 
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Table 25: PISA predicted BIg12-13 and BIg13-AD interacting interface. 
 
 BIg12-BIg13 interface BIg13-AD interface 
Nres 13  
(6 on BIg12 and 7 on BIg13)  
19  
(9 on BIg13 and 10 on AD) 
Nat 47 69 
Interface area (Å2) 199.0 317.1 
NHB 2 4 
NSB 0 0 
∆G (kcal/mol) -1.4 -3.9 
Nres: indicates the number of interfacing residues; Nat: indicates the number of interfacing atoms; 
Interface area: half sum of the buried surface area; NHB: number of hydrogen bonds in the interface 
NSB: number of salt bridges in the interface; ∆G: gain in solvation energy. 
 
 
Apart from contributions from the BIg12-BIg13 linker region (G-A), interface residues on 
BIg12 are located on the interstrand loops A'-B and E-F, whereas on BIg13 interface 
residues cluster exclusively on the B-C interstrand loop (Figure 29A).  
 
 
 
 
 
 
 
 
 
 
 
 
While these interactions stabilize the relative orientation of BIg12-BIg13 and rod-like 
arrangement, flexibility of BIg12 in solution, as seen in the SAXS data (4.1.3.2), can be 
explained by this small interface area. 
Adhesion domain of InvD 
The C-terminal adhesion domain comprises residues 1838-1976 with a molecular weight of 
14.8 kDa. As illustrated in Figure 30A and B, the structure of the AD is composed of β-
Figure 29: BIg12/13 and BIg13/AD domain interface. Detailed description of the inter-domain junctions of the A) 
BIg12–BIg13 and B) BIg13–AD. Residues responsible for forming interface contacts are labeled and shown as 
sticks with oxygen atoms in red and nitrogen atoms in blue. Hydrogen bonds are shown as yellow dashed lines. 
Interstrand loops are labeled. 
 
A B 
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strands with a single α-helix at the tip of the rod shaped protein. The AD shares 37% and 
27% sequence identity to BIg12 and BIg13, respectively. This is also reflected in the high 
degree of structural similarity of the two BIg domains with the core structure of the adhesion 
domain (Figure 30C). InvD AD core is formed by two antiparallel β-sheets reminiscent of the 
IgSF, in which ABE strands form one β-sheet, while the second β-sheet is formed by four 
antiparallel GFCC' strands. The lack of strand A/A' subdivision, lack of strand D combined 
with the presence of strand C' are reminiscent of the C2-set of IgSF. 
 
 
 
 
< 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, various insertions and modifications are observed in the structure of InvD AD apart 
from the canonical IgSF fold: i) an elongated linker region is present between strand A and B; 
ii) a short helix is inserted between strands E and F, that also includes a disulfide bridge 
 
 
A B 
C D 
Figure 30: Topology of the adhesion domain and its comparison with BIg21. A) Cartoon representation of 
the AD of InvD (β-strands are labeled). B) Topology diagram of the AD. C) Structural superposition of BIg13 and 
the AD. They superimpose with an rmsd of 2.5 Å. D) Topology diagram of BIg13. Secondary structure elements 
that are unique to the IgSF fold in the AD are marked in red in (A), (B) and (C). 
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formed between C1859 and C1939; iii) two short antiparallel β-strands (I/I'), that are inserted 
between strands B and C and enlarge the interaction surface with BIg13. In addition, iv) a 
further insertion between strands C and C' composed of two antiparallel β-strands (C'*/C*) is 
present, which in combination with v) the extended strand F form a third antiparallel three 
stranded β-sheet (C'*C*F), sharing strand F with the canonical GFCC' sheet (Figure 30A). 
BIg13/AD interface 
Compared to BIg12-BIg13, the BIg13-AD interdomain interface spans a significantly larger 
area of 317 Å2 attributed to 19 interacting residues in total (Figure 29B, Table 25). Apart from 
contributions from the BIg13-AD linker region (G-A), on BIg13, these interactions are 
clustered on interstrand loop A'-B and E-F, whereas on the AD, residues are clustered in the 
short antiparallel β-strand insertion between strands B and C and in the interstrand linker F-G 
(Figure 29B and Figure 30B). 
4.1.3.5 Structural similarity with InvD-AD 
Search for structural similarity with the AD using PDBefold server (http://www.ebi.ac.uk/msd-
srv/ssm) revealed weak structural (Z-score < 3.2) but no sequence similarity with variety of 
proteins of different functions such as adnectin, a monobody that is engineered to target 
specific proteins (Lipovšek, 2011), PsaA from Y. pestis which is shown to agglutinate red 
blood cells, binds to carbohydrates and lipids and also inhibits phagocytosis by macrophages 
by binding to the Fc part of IgG (Bao et al., 2013) and SafA pilin, a protein involved in biofilm 
formation (Remaut et al., 2006) (Figure 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i) 
Figure 31: Comparison of InvD-AD with other structurally similar proteins. A) Structural Superposition of 
InvD-AD (orange) with (in pink): i) Adnectin (PDB code-4OV6:G) (rmsd 4.3 Å), ii) PsaA (PDB code-4F8O:A) 
(rmsd 3.7 Å) and iii) SafA pilin (PDB code-2CNY:A) (rmsd 3.7 Å), B) Sequence alignment of InvD-AD with 
Adnectin (4OV6:G), PsaA (4F8O:A) and SafA pilin (2CNY:A). (100% conserved amino acids are marked in red, 
80% in orange and 60% in yellow). Alignment is generated with GeneDoc (Nicholas et al., 1996). 
A ii) iii) 
B 
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Despite the structural homology of the AD core to IgSF, taking the insertions into account, the 
AD adopts a distinct fold. These observations made it difficult to assign function of InvD AD 
on the basis of its structural features. 
4.1.4 Functional characterization of InvD 
Rebecca Geyer demonstrated that InvD is expressed during infection and required for 
efficient colonization of the host (Dissertation Rebecca Geyer, 2014). But the information on 
the identity of the host interaction partner to which InvD targets was not known.  
In analogy to InvA, the AD in proteins of the Invasin-family usually represents the domain that 
targets a specific host cell surface molecule (Pisano et al., 2012; Strong et al., 2011). With 
the aim to identify the molecular target and to characterize the function of InvD, binding of 
recombinant InvD protein to carbohydrates, proteins and lipids was systematically tested.  
4.1.4.1 Cloning, expression and purification of InvD and InvA 
Cloning  
For receptor identification, InvD (G1640-N1976) was cloned into a modified pCOLA-Duet 
vector containing N-terminal 6xHis, TEV-protease cleavage site and 3xflag tag (vector 
pPS18) or N-terminal strep affinity tag with TEV cleavage site (vector pVP008). As a negative 
control, InvD construct that lacks the AD, hereafter referred to as ∆AD-InvD (G1640-G1839) 
was designed and cloned into the above mentioned vectors.  
It is known that InvA binds β1- integrins on the surface of human epithelial cells (Isberg et al., 
1987). Therefore, for the beads assay and MST experiments (please refer to 4.1.3.2 and 
4.1.3.5), InvA was used as a control. InvA (P500-I985) was PCR amplified by using pET28 
plasmid containing InvA (kindly provided by Prof. Petra Dersch) and cloned into a vector 
containing a N-terminal 6xHis_TEV_3xflag site. 
Expression of InvA or InvD constructs 
Strep-tagged InvD1640 or ∆AD-InvD, 6xHis_3xflag-tagged InvD1640 or ∆AD-InvD or InvA 
were expressed in 3 L E. coli culture by overnight incubation of cells at 20°C with 100 µM 
IPTG as described in 4.1.1.2.  
Purification of strep tagged InvD1640 
Strep-tagged InvD1640 and ∆AD-InvD were first purified by strep affinity. Elution fractions 
were pooled and loaded on size exclusion column to further purify the protein (Figure 32).  
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Purification of 6xHis_3xflag tagged InvA and InvD constructs 
6xHis_3x flag tagged constructs were first purified by Ni-affinity. Elution fractions were pooled 
and incubated with TEV to remove 6xHis tag. The 3xflag-tag was retained for later 
identification with a highly specific anti-Flag antibody. Cleaved proteins were loaded on size 
exclusion column to purify the protein to homogeneity (Figure 33 and Figure 34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 33: Purification of 3xflag tagged InvD constructs: Elution profile of 3xflag tagged A) InvD1640 on 
S200 16/60 column. B) ∆AD-InvD on S75 16/60 column and corresponding SDS gel showing the purity of 
proteins. Absorbance of the protein is measured at 280 nm. The fractions indicated by the solid blue bar were 
pooled and concentrated. 
A B 
Figure 32: Purification of strep tagged InvD constructs. Elution profile of strep tagged A) InvD1640 on 
S200 16/60 column B) ∆AD-InvD on S75 10/30 column and corresponding SDS gel showing the purity of 
proteins. Absorbance of the protein is measured at 280 nm. The fractions indicated by the solid blue bar were 
pooled and concentrated. 
A B 
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4.1.4.2 InvD attachment to Human epithelial (HEp-2) cells 
To identify if InvD mediates attachment to HEp-2 cells, similar to InvA, the attachment 
efficiency of InvD1640 coated latex beads on HEp-2 cells was analyzed. Significant number 
of beads coated with InvA was found attached on the cell surface, while beads coated with 
InvD or BSA showed no efficient cell attachment (Figure 35A). So, the possibility that InvD 
targets a molecule, which is commonly exposed on the cellular surface of HEp-2 cells, was 
excluded. 
4.1.4.3 InvD binding to lipids and carbohydrates 
Since binding to a factor exposed on the surface of HEp-2 cells could be excluded, binding of 
3xflag tagged InvD1640 to membrane lipid strip was tested. But no binding of InvD1640 was 
observed in a lipid binding assay (data not shown). Similarly, 3xflag tagged InvD1640 was 
screened with the mammalian glycan array (within the Consortium for Functional Glycomics 
(CFG)). Strong signal to glycans 540 (1000 Relative Fluorescence Units (RFU)), 544 (550 
RFU) and 582 (264 RFU) were observed, but these signals were also observed with the 
negative control, showing that overall no binding to glycans was detected (table with raw data 
shown in appendix 8.2.1) (Figure 35B). 
Since no glycan or lipid was identified as the interaction partner, as a next step, InvD binding 
with proteins in a cell extract was tested.  
  
 
Figure 34: Purification of 6xHis_3xflag tagged 
InvA construct. Elution profile on S200 16/60 
column and corresponding SDS gel showing the 
purity of the protein. Absorbance of the protein is 
measured at 280 nm. The fractions indicated by 
the solid blue bar were pooled and concentrated. 
 
Results                                                                         
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.4.4 Pull down experiments with homogenized mice organs 
To investigate if InvD1640 targets proteins as its receptor, pull down experiments using 
3xflag tagged InvD1640 with homogenized extract of uninfected mice peyer´s patches and 
intestine (small intestine, caecum and colon) was performed (3.5.1) (Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: InvD1640 binding to HEp-2 cells, lipids and carbohydrates. A) Latex beads (in green) coated with 
(i) InvA (positive control), (ii) InvD1640 (iii) BSA (negative control) were incubated with HEp-2 cells. (iv) Attached 
beads per cell were quantified after removal of unattached beads. Numbers in brackets correspond to (# beads/ # 
of total cells). B) Glycan binding analysis of 3xflag tagged InvD (left); As a control, binding of anti-flag antibody on 
the array was also analyzed (right). Glycans for which strong signal were observed, are marked with the black 
arrow. 
 
A 
B 
 
Figure 36: InvD interaction with immunoglobulins. Homogenized extract of mice intestines (left) and peyer’s 
patches (right) mixed with 3xflag tagged InvD1640 or ∆AD-InvD were subjected to flag pulldown assay.  
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As a negative control, 3xflag tagged ∆AD-InvD was used. Elution fractions obtained after pull 
downs were analyzed by SDS-PAGE. In InvD1640 elution fraction, a 25 kDa and a less 
prominent 50 kDa bands were observed, while these bands were absent in ∆AD-InvD elution 
fraction. The 25 kDa and 50 kDa proteins were identified as immunoglobulin light and heavy 
chain by mass spectrometry suggesting that InvD targets the immunoglobulins (Figure 36). 
4.1.4.5 Microscale thermophoresis  
To confirm the interaction between InvD and immunoglobulins, MST was used (3.5.7). Cy5-
labelled InvD1640, ∆AD-InvD and InvA were titrated with increasing concentrations of mouse 
IgG, human IgG and human IgA (Figure 37A, B and C). The obtained results confirmed the 
binding of InvD with IgG/IgA with an experimentally determined affinity constant (Kd) in the 
range of 1 to 10 µM. No binding was observed when labeled controls ∆AD-InvD or InvA were 
titrated with human/mouse IgG or human IgA, confirming an AD-dependent specific 
interaction. In order to narrow down the region on immunoglobulins to which InvD binds to, 
binding of Cy5 labeled InvD1640 was tested with IgG Fc and IgG F(ab')2. The results showed 
that InvD specifically targets the F(ab')2 fragment (Figure 37D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: InvD interaction with immunoglobulins. Binding affinities of InvD1640 with mouse IgG (A), human 
IgG (B), human IgA (C) and human F(ab')2 or Fc (D) were determined by Microscale thermophoresis. InvA or 
∆AD-InvD were used as negative control. Individual measurements are shown performed with different 
concentrations of antibodies. 
 
A B 
C D 
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4.1.4.6 InvD specifically binds to B-cell populations isolated from mouse 
Based on MST data (Figure 37D), it was clear that InvD targets the Fab fragment of the 
soluble antibody. Since the antibody structure is also present on B cells in the form of B cell 
receptor, a flow cytometry approach was used to analyze if InvD can target B-cell receptor 
present on B cells apart from targeting soluble antibodies.  
Binding of 3xflag tagged InvD1640 to ex vivo isolated murine B-cell populations was tested 
via flow cytometry (3.5.4) in collaboration with the group of Prof. Jochen Hühn (experiments 
performed by Jörn Pezoldt). Only B cells were enriched for cells bound by InvD1640, 
whereas total T cells, γδT cells, monocytes, NK cells and dendritic cells did not show any 
binding of InvD1640 (Figure 38B), indicating that InvD binds specifically to the F(ab')2 
fragment of the B-cell receptor. Moreover, ∆AD-InvD showed a 10-fold lower signal in 
frequency and intensity, further validating that the binding of InvD1640 relied on the adhesion 
domain (Figure 38A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.4.7 Characterization of Fab binding specificity by phage display panning 
To gain a detailed insight into the specificity of interaction of InvD with Fab, phage display 
panning was performed (3.5.2) in collaboration with the group of Prof. Michael Hust 
(experiments performed by Saskia Helmsing). HAL10 (kappa library) and HAL9+10 
(combination of kappa and lambda library) libraries were separately incubated with 
immobilized strep tagged InvD1640. After three rounds of panning, eluted phages were 
reamplified in E. coli and plated on agar plate. 96 clones were randomly picked and phage 
A B 
Figure 38: Single cell suspensions from indicated organs were analyzed using flow cytometry. A) 
Exemplary dotplots depict frequencies and fluorescence intensity of 3xflag tagged InvD1640 or 3xflag tagged 
∆AD-InvD on living B cells using anti-flag-antibody conjugated to APC. B) Scatterplot summarizes frequencies of 
InvD+ cells of the respective cell population. Pooled data of two independent experiments (n = 2-3). B cells: 
CD19+, T cells: CD3+: γδT cells: CD19-gdTCR+, NK cell: CD49b+, monocytes: CD19-γδTCR-CD11b+CD11c-, 
dendritic cells: CD19-γδTCR-CD11bmedCD11c+. 
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ELISA was performed on immobilized strep tagged InvD1640 and ∆AD-InvD (Figure 39A, B). 
Compared with ∆AD-InvD, 20-60 fold higher absorbance signal was observed with InvD1640 
indicating that the interaction of InvD with scFvs is AD specific. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
Phagemid DNA of 57 and 59 randomly selected individual scFvs after 3rd round of panning on 
InvD1640 with HAL10 and HAL9+HAL10 library, respectively, were sequenced. Sequence 
analysis of scFvs showed high specificity for VK1 subfamily in combination with VH3 
subfamily. While this combination only represents approx. 16% and 6% of the unselected 
HAL10 and HAL9+10 library, 86% and 59% of the clones isolated after panning correspond 
to VH3/VK1, respectively (Figure 40A, B), giving rise to the notion that InvD specifically 
targets antibodies of the VH3/VK1 subfamily. 
  
 
Figure 39: Binding assessment of soluble scFv to InvD1640 by ELISA. Binding of soluble scFv from A) 
HAL10 and B) HAL9+10 library to InvD1640 (Invd strep) and ∆AD-InvD(Neg. control) was analyzed by microtiter 
plate ELISA. Green bar represents the positive control (lysozyme + anti-lysozyme scFv), blue bar represents the 
background signal of the system (streptavidin + E. coli supernatant + components of detection system). 
A 
B 
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4.1.4.8 Pull down and MST experiments using recombinantly purified scFv-Fcs 
To further confirm the interaction between InvD and VH3/VK1 subtype, pull down 
experiments using strep tagged InvD1640 with scFv-Fc fragments (different heavy/light chain 
subtype combinations) were performed. As a negative control ∆AD-InvD was used. Results 
confirm that InvD is specific towards the VH3/VK1 subfamily combination (Figure 41A). To 
determine the affinities between InvD and VH3/VK1 antibody, Cy5 labeled InvD was titrated 
with increasing concentrations of VH3/VK1-Fc or VH1/VL2-Fc antibodies. The obtained result 
confirmed the binding of InvD with VH3/VK1-Fc with an experimentally determined affinity 
constant (Kd) of 731 ± 261 nM (Figure 41B). 
 
 
 
 
Figure 40: InvD targets VH3/VK1 subfamily antibodies. A) Heat map representation of the percentage 
abundance of (left) VH-VK gene pairs in HAL10 (kappa) library composed of 456 different clones and (right) VH-
VK gene pairs obtained from the 3rd round of panning against InvD1640 using HAL10 library (based on sequence 
analysis of 57 clones). B) Heat map representation of the percentage abundance of (left) VH-VK/VL gene pairs in 
HAL9+10 (lambda + kappa) library composed of 1282 different clones and (right) VH-VK/VL gene pairs obtained 
from the 3rd round of panning against InvD1640 using HAL9+10 library (based on sequence analysis of 59 
clones). 
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Figure 41: Interaction of InvD with scFv-Fc antibodies. A) Pulldown based interaction analysis of InvD and 
scFv-Fc antibodies with different heavy/light chain subtype combinations. B) Interaction of InvD1640/∆AD-InvD 
with VH3/VK1 or VH1/VL2 subfamily scFv-Fc antibodies analyzed by MST. Data shown is the average of 
duplicate experiments. 
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4.2 InvE from IP31758 strain of Y. pseudotuberculosis 
Strain IP31758 of Y. pseudotuberculosisis is responsible for Far East scarlet–like fever and 
also leads to toxic shock syndrome, which is not commonly seen for pseudotuberculosis 
infections (Eppinger et al., 2007). A novel Invasin, InvE has been recently identified in this 
strain. The C-terminal domain of InvE has a significantly different sequence from any other 
known Invasin. Thus, the aim of this part of work was to gain insights into the structure of the 
recently identified InvasinE. 
4.2.1 Cloning, expression and purification of InvE 
4.2.1.1 Bioinformatics analysis of InvE 
Sequence analysis of InvE using a combination of BLAST-p, Pfam (A7FEC2/A0A0U1R0I0) 
and Signal-BLAST identified a putative signal peptide (SP in Figure 42) followed by a β-barrel 
domain comprising of residues 146-421, which is required for anchoring the protein to the 
outer membrane region of bacteria. The putative β-barrel domain is followed by 21 bacterial 
Ig-like (BIg) domains. BIg1-21 are capped by a predicted C-terminal domain (2619-2795 aa) 
with no similarity to known proteins. Based on these predictions, two constructs, InvE2547 
(A2547-L2795) and InvE2448 (G2448-L2795) were designed (Figure 42). 
 
 
 
 
 
 
4.2.1.2 Cloning and expression 
InvE constructs were amplified by PCR from the genomic DNA of Y. pseudotuberculosis 
IP31758 and cloned (3.2.1-3.2.7) into a modified pCOLA-Duet vector containing an N-
terminal 6xHis tag (vector pVP009) and TEV cleavage site. After verification of inserts by 
sequencing (3.2.8), bacteria were transformed with the plasmid and tested for expression 
(3.3.1). Out of the two constructs, InvE2448 resulted in soluble protein whereas no 
expression was seen for InvE2547 (Figure 43). 
  
 
 Figure 42: Domain architecture of Y. pseudotuberculosis InvE. Scheme of the domain organization of Y. 
pseudotuberculosis InvE with construct boundaries. 
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4.2.1.3 Culturing and cell disruption 
As described in section 3.3.2-3.3.3, 4 L of TB + kanamycin + chloramphenicol media was 
inoculated with the overnight culture of InvE2448 expressing bacteria. At an OD600 (optical 
density at 600 nm) of 0.7-0.8, expression was induced with 100 µM IPTG and cultures were 
allowed to grow at 18°C, 130 rpm for 21 h. After centrifugation and resuspension in lysis 
buffer, cells were homogenized. 
4.2.1.4 Purification of 6xHis_InvE2448 for crystallization 
After clearing of the lysate by centrifugation, affinity chromatography was performed (3.3.4). 
Elution fractions were pooled and TEV protease was added to remove the 6xHis tag. To 
remove the uncleaved material, reverse Ni-affinity was employed. To further purify the protein 
to homogeneity, size exclusion chromatography was performed (3.3.7) in 20 mM HEPES 
pH 7.4, 200 mM NaCl and 5 mM DTT (Figure 44). 
Purified protein was identified as Y.pseudotuberculosis IP31758 InvE by tryptic digest and 
mass spectrometry. InvE2448 was concentrated to 25 mg/ml and flash frozen in liquid 
nitrogen. 
4.2.1.5 Protease stability assay  
To assess the stability and flexibility of InvE2448 in solution, 5 mg/ml of the protein was 
treated with 12 different proteases.  
Apart from treatment with Proteinase-K and subtilisin, that resulted in stable sub-domain 
fragments, InvE2448 showed high stability with only minor degradation (Figure 45). 
 
  
 
Figure 43: Test expression of 6xHis_InvE2448. Coomassie stained 15% SDS 
gel of test expression of 6xHis_InvE2448 construct. High yields of soluble protein 
were obtained by overnight incubation of cells at 18°C with 100 µM IPTG. Band 
corresponding to soluble InvE is marked with the black arrow.  
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4.2.2 Crystallization and structure solution of InvE 
4.2.2.1 Crystallization of InvE 
To gain insight into the structure of the adhesion domain of InvE, InvE2448 (without tag) was 
used for initial crystallization screening at 20°C and 4°C using commercially available 
screens. Initial crystals obtained with InvE2448 showed only weak diffraction. To improve 
crystal quality, a strategy of mutating surface entropic residues was applied. Using SERp 
server, four surface entropic residues (E2505A/Q2506A, K2646A, E2648A and 
 
 
Figure 45: Stability of InvE2448 against 
proteases. InvE2448 (at a concentration of 
5 mg/ml) was treated with 12 different 
proteases (α-C-α-Chymotrypsin, TR-Trypsin, 
EL-Elastase, PA-Papain, SU-Subtilisin, EG-C-
Endoproteinase Glu-C, PK-Proteinase-K, CL-
Clostripain, PE-Pepsin, TH-Thermolysin, BR-
Bromelain, AE-Actinase, at a concentration of 
0.01 mg/ml) and incubated for 1.5 h at 37°C. 
Figure 44: 6xHis_InvE2448 purification. A) Coomassie stained gel of InvE Ni-affinity chromatography. FT: 
flow through of the column; W: wash fraction (washing with 10 mM imidazole); E1-E5: elution fractions (with 
100 mM imidazole); M: marker; B) Elution profile of the run on S200 16/60 column (left); Coomassie stained gel 
of eluted fractions. Blue bar represents the corresponding elution fractions in the chromatogram that were 
analysed by SDS PAGE. Absorbance of the protein is measured at 280 nm. 
 
 
A Ni-affinity 
B Size-exclusion chromatography 
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E2695A/K2696A) were identified. Out of the four mutants, K2646A was successfully 
expressed and purified in large scale as described for the wild type protein (Figure 46). 
 
 
 
 
 
 
 
InvE2448 (K2646A) (without tag) was crystallized at a concentration of 18 mg/ml in the 
following condition- 0.12 M MgCl2, 0.1 M TRIS pH 8.5, and 26% PEG8000. The crystals were 
grown in sitting drop at 4°C by mixture of 0.2 µL of concentrated protein with 0.2 µL of 
crystallization solution (Figure 47). For cryoprotection, the crystallization solution was 
supplemented with 10% PEG 400.  
 
 
 
 
 
 
The native data set was collected to 1.7 Å at the SLS at X06DA/PXIII beamline. InvE C-
terminal domain shows no significant similarity to other sequences in the protein database. 
Hence, initial molecular replacement trials were performed with Phaser MR by using 
individual Ig-like domains of InvA (PDB entry 1CWV (Hamburger, 1999) as a search 
template, but the approach was not successful. 
Therefore, to solve the phase problem, a Se-Met labeled variant of InvE2448 (K2646A) was 
expressed and purified by Ni-affinity and size-exclusion chromatography (Figure 48). 
Expression and purification conditions were same as described for the native protein. Se-Met 
labeled InvE crystals grew under the same condition as the native crystals.  
 
Figure 47: Crystals of InvE2448 (K2646A). 
 
 
Figure 46: Purification of the surface entropy variant (K2646A) of InvE2448. Elution profile of InvE2448 
(K2646A) on S200 16/60 column (left); Coomassie stained gel of eluted fractions (right). Blue bar represents the 
corresponding elution fractions in the chromatogram that were analysed by SDS PAGE. Absorbance of the 
protein is measured at 280 nm. 
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4.2.2.2 Data collection and structure solution 
Data for Selenomethionine crystals were collected at SLS at X06DA/PXIII beamline to 2.3 Å 
resolution. The data was indexed, integrated and scaled using the XDS program package 
Se-Met InvE crystals belonged to space group P21. The structure was solved by Autosol 
program in Phenix. The model obtained after SAD phasing was subsequently used as the 
template to solve the native structure by molecular replacement. An initial model was 
automatically built using Phenix-autobuild and then manually rebuilt in WinCoot, followed by 
refinement in Phenix-refine. The final model was refined to 1.7 Å resolution. The overall 
electron density was of the high quality as shown in Figure 49. The statistics of data 
collection is shown in Table 26. 
 
 
 
 
 
 
 
 
  
 
Figure 48: Purification of the Se-Met variant of InvE2448 (K2646A). Elution profile of InvE on S200 16/60 
column (left); Coomassie stained gel of eluted fractions (right). Blue bar represents the corresponding elution 
fractions in the chromatogram that were analysed by SDS-PAGE. Absorbance of the protein is measured at 
280 nm. 
 
Figure 49: Quality of the electron density. 2Fo-Fc electron density (contoured at 1 σ) in the A) BIg20, B) 
BIg21 and C) the C-terminal domain of InvE. 
A B C 
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Table 26: Data collection and refinement statistics. 
 
DATA COLLECTION InvE  InvE (Se-Met derivative) 
X-ray source PXIII, SLS  PXIII, SLS 
Wavelength [Å] 1.00000 0.97927 
Resolution [Å] 46.4-1.7 
(1.8-1.7) 
46.3-2.3 
(2.4-2.3) 
Space group P21 P21 
Cell dimensions  
a, b, c [Å] 
α, β, γ [°] 
 
70.26, 27.03, 88.95 
90.00, 107.10, 90.00 
 
70.13, 27.08, 88.83 
90.00, 107.29, 90.00 
Rmerge[%] 7.7 (58.7) 10.9 (30.9) 
Rmeas[%] 8.4 (63.5) 11.1 (31.5) 
CC1/2 [%] 99.9 (90.1) 99.9 (99.4) 
‹I/σ(I)› 16.3 (3.2) 36.1 (15.1) 
 Completeness [%] 99.3 (99.7) 99.9 (100.1) 
 Unique reflections 35804 (5614) 27731 (3324) 
 Redundancy 6.5 (6.8) 27.8 (27.3) 
REFINEMENT   
Resolution [Å] 46.4-1.7  
No. of reflections 35801  
Rwork 0.161   
Rfree 0.194  
No. of atoms 5722  
Avg. B factor protein [Å2] 21.76  
R.m.s. deviations       
Bond length [Å]  
Bond angles [°] 
 
0.003 
0.557 
 
Ramachandran [%] 
(favored/allowed/ 
disallowed) 
98.00/2.00/0.00  
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4.2.3 Crystal structure of InvE 
The overall structure of the construct is rod-like and displays a three domain architecture 
formed by two N-terminal domains BIg20 (aa 2448-2546), BIg21 (aa 2547-2660) and the 
adhesion domain (AD, aa 2661-2795) (Figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3.1 SAXS structure of InvE2448 
With the aim of understanding the structure of InvE in solution, SAXS data for InvE2448 was 
collected at BM29 of the ESRF in Grenoble, France. The calculated SAXS envelope is highly 
similar to the crystal structure of InvE2448 as shown in Figure 51A. 
Figure 50: Crystal structure of Y. pseudotuberculosis IP31758 InvE. Cartoon model of the crystal structure 
of InvE2448. InvE2448 consists of the N-terminal BIg20 (dark blue), BIg21 (cyan) and the C-terminal adhesion 
domain (AD) (shown in green, magenta, orange and red; these elements are described in detail in 4.2.3.2) 
shown in two orientations. 
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The chi value of 1.8 was obtained with CRYSOL on fitting the SAXS data with the crystal 
structure, which indicates that the model is in very good agreement with the calculated 
SAXS-envelope (Figure 51B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3.2 Topology of InvE 
BIg20/21 domains 
Full length InvE consists of 21 BIg like domains, of these BIg1-20 share high sequence 
identity in the range of 56-98%, whereas BIg21 is significantly different from BIg1-20 
(sequence identity 15-18%) as shown in Figure 52. 
BIg20 of InvE adopts a two layer β-sandwich fold in which β-strands ABED form one sheet 
while the second β-sheet is formed by A'GFC (Figure 53). IgSF have previously been 
classified into V, C1, C2, I1 and I2-sets as described in section 4.1.3.3 and Figure 25. 
Presence of the A-A' strand with a kink formed by a cis–Proline (P2461), lack of C'' and 
presence of D strand in BIg20 are characteristics of the I1-set of IgSF (Figure 53). Even 
though it lacks strand C', it is classified in I1-set, since lack of C' has also been observed 
previously in other I1-set domains (Tan et al., 1998). Furthermore, two highly conserved 
cysteine residues forming a disulfide-bridge in the canonical Ig-fold are absent in BIg20 of 
InvE and instead replaced by V2474 (present on strand B) and L2526 (present on strand F). 
 
 
Figure 51: SAXS envelope of InvE2448. A) Rigid body fitting of the crystal structure into the ab initio 
determined SAXS envelope shown in two orientations. B) Fit of the rigid body model (red) with the experimental 
scattering (blue). Quality of the fit is expressed in terms of chi value. 
 
A B 
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In BIg21, the first sheet is formed by ABE strands while the second sheet is formed by 
A'GFC. This type of fold can be categorized in the I2 set of IgSF (Chen et al., 2007) due to 
characteristics of A-A' kink and lack of D strand (Figure 53). Similar to BIg20, the canonical 
cysteines in strands B/F of BIg21 are replaced by the hydrophobic residues L2568/L2643. 
 
Figure 53: Overall structure of BIg20 and BIg21. A) Topology diagram of BIg20 (dark blue) and BIg21 (cyan) 
of InvE2448. (B) Cartoon representation of the BIg20/21 domains of InvE (β-strands are labeled). 
A B 
Figure 52: Sequence alignment of BIg1-21 of InvE. 100% conserved amino acids are marked in red, 80% in 
orange and 60% in yellow. Alignment has been generated with GeneDoc (Nicholas et al., 1996). 
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Structural comparison of BIg20 and BIg21 
As shown in Figure 54, the two domains can be superimposed with a rmsd of 2.6 Å. Although 
BIg21 is topologically similar to BIg20, there are significant differences between the 
structures of two domains. 
 
 
 
 
 
 
 
 
 
 
 
Compared to BIg20, BIg21 has a longer C strand and a uniquely structured C-E interstrand 
loop along with a short helix that connects C strand with E (Figure 53). Conformation of the 
C-E interstrand loop is stabilized by three internal hydrogen bonds as shown in Figure 55.  
 
 
 
 
 
 
 
 
 
 
 
 
The conformation of this loop is unique to BIg21 among structurally characterized BIg’s of 
InvE and InvA (Figure 56). In InvE, this loop is responsible for forming interactions between 
BIg21 and the C-terminal AD as described in the context of the adhesion domain. 
 
Figure 54: Structural overlay of 
BIg20 and BIg21. Superposition of 
BIg20 (dark blue) and BIg21 (cyan) 
shown in two orientations (β-strands 
are labeled). 
 
Figure 55: Stabilization of the C-E interstrand loop. Close up view of the C-E interstrand loop with residues 
stabilizing the loop are shown as sticks with oxygen atoms in red and nitrogen atoms in blue. Hydrogen bonds 
are shown as yellow dashed lines. 
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BIg20/BIg21 interface 
As calculated by PISA, the interface between BIg20/BIg21 spans an area of 319 Å2 involving 
residues in the BIg20 A'-B and E-F interstrand loops and the BIg21 B-C interstrand loop 
(Table 27 and Figure 57A).  
 
Table 27: PISA predicted BIg20-21 and BIg21-AD interacting interface. 
 
 BIg20-BIg21 interface BIg21-AD interface 
Nres 17  
(7 on BIg20 and 10 on BIg21)  
29  
(15 on BIg21 and 14 on AD) 
Nat 63 121 
Interface area (Å2) 319.6  561.0 
NHB 2 6 
NSB 1 5 
∆G (kcal/mol) -3.2 -8.2 
Nres: indicates the number of interfacing residues; Nat: indicates the number of interfacing atoms; 
Interface area: half sum of the buried surface area; NHB: number of hydrogen bonds in the interface 
NSB: number of salt bridges in the interface; ∆G: gain in solvation energy. 
 
  
 
Figure 56: Conformation of the C-E interstrand loop. Structural overlay of BIg20 (dark blue), BIg21 (cyan) 
and D1 (InvA, in olive) (left). BIg domain structures of BIg20 (InvE), BIg21 (InvE) and D1 (InvA PDB ID-1CWV) 
(right).  
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Adhesion domain  
The 1.7 Å crystal structure of InvE adhesion domain reveals resemblance to C-type lectin-like 
domains (CTLD) based on structure similarity search (discussed in detail in 5.2.2).  
The canonical CTLD fold consists of two α-helices, that are oriented orthogonal to each other 
and two antiparallel β-sheets formed by strands β1+β5 and β2+β3+β4. The CTLD fold 
contains two disulfide bridges formed between β5 and α1 as well as between β3 and β5 
(Figure 58).  
 
 
 
 
 
 
 
 
 
 
 
The long loop region (LLR) which is located between strands β2 and β3, plays an important 
role in receptor binding and also involved in Ca2+ binding in true C-type lectins. The CTLDs 
can be structurally subdivided into the canonical CTLD, which contains the LLR and the 
Figure 58: Cartoon representation of rat mannose 
binding protein (PDB ID-1MSB). This protein adopts a 
canonical C-type lectin-like domain fold. Secondary 
structure elements and long loop region (LLR) are labeled 
(Weis et al., 1991). 
 
 
LLR 
 
A 
Figure 57: BIg20/21 and BIg21/AD interface. Detailed description of the inter-domain junctions of the A) 
BIg20–BIg21 and B) BIg21–AD. Residues responsible for forming interface contacts are labeled and shown as 
sticks with oxygen atoms in red and nitrogen atoms in blue. Hydrogen bonds are shown as yellow dashed lines. 
 
B 
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hallmark motif „WIGL“, and into the compact CTLD, which lacks the LLR. Further division into 
sub-groups is based on the presence (long form) or absence (short form) of an N-terminal 
extension (presence of β1') (Torgersen et al., 1998; Zelensky and Gready, 2003, 2005). 
Hence, based on the structural similarity of InvE AD to CTLDs, it is divided into three sections 
(Figure 59)– 
i. a lasso-shaped loop structure (V2661-A2677, orange), which is termed as the 
“adaptor ring” (AR), since it forms a ring-shaped platform that connects BIg21 with 
the residual sections of the AD,  
ii. the “wedge domain” (WD, P2690-M2712, magenta)  
iii. and the C-type lectin-like domain (CTLD, E2678-R2689 and F2713-L2795, green). 
InvE CTLD comprises the canonical strands β1, β3 and β4. Residues usually forming strands 
β2 and β5 are located at the canonical position, however do not adapt to the β-strand 
geometry and are thus shown as coil instead of being displayed as β-strands in Figure 59 
(also labeled in brackets for clarity). InvE CTLD contains two conserved Cysteines (C2722 
and C2793) that link α1 to β5 with a disulfide bond but lacks the second conserved disulfide 
bridge present in between β3 and β5.  
 
 
 
 
 
 
 
 
 
 
 
In addition to two canonical α-helices α1 and α2, InvE CTLD comprises two additional α-
helices, α3 and α4. Due to the presence of β0 as an additional N-terminal extension, it 
belongs to the long form of CTLDs. In addition, InvE lacks the hallmark „WIGL“ motif and its 
Figure 59: Overall structure of InvE adhesion domain. A) Topology of InvE AD. Different subdomains are 
labeled. B) Cartoon representation of InvE AD. Secondary structure elements are labeled. Disulfide bond is 
shown here as sticks with sulfur atoms in yellow. 
 
 
A B 
                                                                                                                                   Results 
 
97 
  
LLR (red) only comprises less than eight residues and is thus classified as short. Thus, the 
CTLD of InvE belongs to the compact, long form CTLD sub-group. 
AD and BIg21 domain interface 
BIg21 and the AD span an extensive contact area interface of 561 Å2. The interface is formed 
by a total of 29 residues from both the domains that make several contacts including five salt 
bridges. A tryptophan residue present in the AD (W2673) clamped between the C-E 
interstrand loop of BIg21, appears to play a major role in stabilizing the interaction between 
the two domains (Table 27 and Figure 57A).  
  
Results                                                                         
98 
 
4.3 YadApstb 
YadA of Y. enterocolitica (ent) and Y. pseudotuberculosis (pstb) exhibit differences in their 
specificity of ECM substrate binding. This difference is due to a unique N-terminal 31 aa 
sequence, which is present in YadApstb and absent in YadAent.The aim of this project was to 
provide the structural basis for the functional transition by solving the structure of YadApstb 
and to compare it with YadAent structure, which has already been solved previously 
(Nummelin et al., 2004).  
4.3.1 Cloning, expression and purification of YadApstb 
4.3.1.1 Bioinformatics analysis of YadApstb 
In Y. pseudotuberculosis, YadA is expressed as 435 aa protein. Sequence analysis of 
YadApstb (Uniprot ID-P10858) and its comparison with homologous YadAent sequence 
(Uniprot ID-P31489) revealed that YadApstb consists of the signal peptide (aa 1-25) that is 
cleaved off during transport to the outer membrane. This N-terminal sequence stretch is 
followed by the surface exposed head (aa 26-240) and stalk (aa 241-364) domains and a C-
terminal membrane anchor domain (aa 365-435) (Heise and Dersch, 2006). To gain insight 
into structural differences between the head domain of YadApstb and YadAent, YadApstb 
construct comprising aa 26-253 was designed. 
4.3.1.2 Cloning and expression of YadApstb 
YadApstb construct (aa 26-253) was amplified by PCR using pET28 plasmid containing 
YadApstb (kindly provided by Prof. Petra Dersch) as a template and cloned (3.2.1-3.2.7) into a 
modified pCOLA-Duet vector containing an N-terminal 6xHis tag and TEV cleavage site 
(vector pVP009). After verification of the sequence of the insert (3.2.8), bacteria were 
transformed with the plasmid. YadApstb resulted in soluble protein when tested for expression 
in E. coli (Figure 60). 
 
 
 
 
 
 
 
 
 
 
Figure 60: Coomassie stained 12% SDS gel of test expression of 6xHis YadApstb. 
Maximum yield of soluble protein was obtained by 3 h incubation of cells at 25°C with 
500 µM IPTG. Band corresponding to soluble YadApstb is marked with the black arrow. 
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4.3.1.3 Culturing and cell disruption 
As described in section 3.3.2-3.3.3, 3 L of TB + kanamycin + chloramphenicol media was 
inoculated with the overnight culture of YadApstb. At an OD600 of 0.7, expression was induced 
with 500 µM IPTG and the culture was allowed to grow at 25°C, 130 rpm for 3 h. After 
centrifugation and resuspension in lysis buffer, cells were homogenized. 
4.3.1.4 Purification of 6xHis tagged YadApstb 
After clearing of the lysate by centrifugation, Ni-affinity chromatography was performed 
(3.3.4) (Figure 61A). YadApstb containing fractions were pooled and incubated with TEV 
protease to remove the tag (3.3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cleavage of tag was monitored by running uncleaved and cleaved samples on SDS-PAGE. 
After complete cleavage, reverse Ni-affinity was performed. Protein was further purified by 
size exclusion chromatography in 10 mM TRIS pH 8 and 300 mM NaCl (Figure 61B). 
Figure 61: 6xHis YadApstb large scale expression and purification. A) Coomassie stained gel of YadApstb Ni-
affinity chromatography. P: pellet; FT: flow through of the column; W: wash fraction (wash with 5 mM imidazole) 
E1-E3: elution fractions (with 100 mM imidazole); B) Elution profile of cleaved YadApstb on S200 16/60 column 
(left); Coomassie stained gel of eluted fractions (right). Gel filtration retention volume indicates that YadApstb 
eluted with an apparent molecular weight of ~75 kDa, suggesting elution as a trimer as expected. Blue bar 
represents the corresponding elution fractions in the chromatogram that were analysed by SDS-PAGE. 
Absorbance of the protein is measured at 280 nm. 
 
A Ni-affinity 
B Size-exclusion chromatography 
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4.3.2 Crystallization and structure solution of YadApstb 
4.3.2.1 Crystallization of YadApstb 
To gain insight into the structure of YadApstb, purified YadApstb (without tag) was used for 
initial crystallization screening at 20°C and 4°C using commercially available screens. 
12 mg/ml of YadApstb crystallized in 50% PEG 200, 0.1 M CHES pH 9.5 at 20°C (Figure 62). 
As the PEG200 concentration in the crystal condition was already sufficient for 
cryoprotection, the crystal was directly harvested from the drop, and flash frozen in liquid 
nitrogen.  
 
 
 
 
 
 
 
 
4.3.2.2 Structure solution of YadApstb 
The native data set (0.91841 Å) was collected at BESSY beamline 14.2. YadApstb crystal 
diffracted to 2.3 Å. The data was processed using XDS and the structure was solved by 
Molecular Replacement using YadAent (PDB ID-1P9H) (Nummelin et al., 2004) as a search 
model. Phenix Autobuild was used to build the model. Coot was used for further manual 
model building. Phenix refine was used for refining the structure. The statistics for data 
collection and refinement are shown in Table 28. 
 
  
 
Figure 62: YadApstb crystal. Crystal is marked 
with a black box. 
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Table 28: Data collection and refinement statistics. 
 
DATA COLLECTION YadApstb  
X-ray source BESSY14.2 
Wavelength [Å] 0.91841 
Resolution [Å] 18.7-2.3 
(2.4-2.3) 
Space group C2 
Cell dimensions  
a, b, c [Å] 
α, β, γ [°] 
 
118.1,68.1,91.5 
90, 94.119, 90 
Rmerge[%] 9.5 (36.0) 
Rmeas[%] 11.7 (45.7) 
CC1/2 [%] 99.2 (87.5) 
‹I/σ(I)› 8.2 (2.7) 
 Completeness [%] 92.0 (82.5) 
 Unique reflections 29835 (3168) 
 Redundancy 2.6 (2.2) 
REFINEMENT  
Resolution [Å] 2.3  
No. of reflections 29817 
Rwork 24.7  
Rfree 29.0 
No. of atoms 3944 
Avg. B factor [Å2] 26.45 
R.m.s. deviations       
Bond length [Å]  
Bond angles [°] 
 
0.003 
0.774 
Ramachandran [%] 
(favored/allowed/ 
disallowed) 
93.6/4.7/1.6 
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4.3.2.3 Crystal structure of YadApstb 
YadApstb crystallized as a trimer in space group C2. Like YadAent (PDB ID-1P9H) (Nummelin 
et al., 2004b), YadApstb consists of the head region that forms a left-handed parallel β-roll and 
the C-terminal domain comprising a short helix (Figure 63A). 12 N-terminal residues 26-37 
are not visible in the crystal structure. However, the 31 aa insertion (53-83 aa) that is unique 
to YadApstb is partially visible (12-16 aa out of 31 aa) (Figure 63B, C). In chain A, 53-64 aa, 
chain B, 53-69 aa, and in chain C, 53-67 aa are visible in the crystal structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
C 
 
A B 
C 
Figure 63: Crystal structure of Y. pseudotuberculosis YadA (YadApstb). A) Cartoon model of the trimeric 
crystal structure. Region that is unique to YadApstb is colored in orange for the chain in red, cyan for the chain in 
blue, and yellow for the chain in green. B) Top view onto the tip with the structured parts of the 31 aa insertion, 
C) 2Fo-Fc electron density (contoured at 1 σ) shown for the insertion region. 
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4.4 RovC 
The aim of this part of work was to structurally and biochemically characterize the DNA 
binding protein RovC (Regulator of virulence associated with CsrC) from Y. 
pseudotuberculosis YPIII. 
4.4.1 Cloning, expression and purification of RovC 
4.4.1.1 Bioinformatics analysis of RovC 
Full length RovC is expressed as 247 aa protein in YPIII strain of Y. pseudotuberculosis. 
BLASTp analysis of RovC sequence (Uniprot ID- A0A0H3B5N9) against the non-redundant 
protein database revealed that all of the hits were annotated as hypothetical proteins or 
proteins of unknown function (DUF2285). JPred (Cuff et al., 1998) and Phyre2 
(http://www.sbg.bio.ic.ac.uk/phyre2) softwares were used to estimate the domain boundaries 
of RovC (Figure 64).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: Bioinformatics analysis of RovC sequence. A) JPred secondary structure annotation of full length 
RovC (Lupas_21, Lupas_14, Lupas_28 are coiled coil predictions; JNetpred-secondary structure prediction- 
helices are shown in red and β-strands in green; JNETCONF-confidence estimated for the prediction). B) 3-D 
structure of the C-terminal region (185-247 aa) of RovC as predicted by the Phyre2 software. 
 
A 
B 
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The N-terminal region of RovC (1-154) has a predicted mixed α/β topology while the C-
terminal region (155-247) is composed of α-helices (Figure 64A). Based on the tertiary 
structure prediction, a DNA binding domain was mapped in the C-terminal region (185-247 
aa) that folds into a helix-turn-helix motif with 50% confidence (template PDB code-3KOR:D) 
(Figure 64B). 
As the DNA binding domain was of special interest, three different N-terminal deletion 
constructs containing the predicted helix-turn-helix motif (D40-L247, S80-L247 and M103-
L247) were designed. 
4.4.1.2 Cloning and expression of RovC in E. coli 
RovC constructs were amplified by PCR using genomic DNA of Y. pseudotuberculosis YPIII 
as a template and cloned (3.2.1-3.2.7) into a modified pCOLA-Duet vector with an N-terminal 
6xHis tag and TEV cleavage site. After verification of inserts by sequencing (3.2.8), bacteria 
were transformed with the plasmid and tested for expression, but none of these constructs 
resulted in soluble protein. In another attempt, RovC (R2-L247; pVK14) fused with 
6xHis_SUMO tag (kindly provided by Prof. Petra Dersch) was tested for expression in E. coli. 
Only a faint band for soluble RovC was observed, while most was found in the insoluble 
fraction. 
Further attempts were made to increase the yield of soluble RovC. One strategy to increase 
the soluble expression is to lower the incubation temperature, which might lead to proper 
folding of the protein (Rosano and Ceccarelli, 2014). Moreover, ionic strength of the lysis 
buffer and presence of detergents also affect the solubility of proteins. Therefore; the 
following variables were investigated, either alone or in combination: 
 
  i)  16°C-20°C post-induction incubation temperature,  
  ii)  150 mM-500 mM NaCl in the lysis buffer, 
  iii) 0.1% Triton X-100 in the lysis buffer,  
  iv)  dYT medium for growing of cells were tested.  
RovC solubility was significantly improved on lowering the post-induction incubation 
temperature to 16°C and increasing NaCl concentration to 500 mM. Changing of LB medium 
to dYT medium also helped in improving the yield of soluble protein (Figure 65). 
4.4.1.3 Culturing and cell disruption 
As described in section 3.3.2-3.3.3, 4 L of dYT + kanamycin + chloramphenicol media was 
inoculated with the overnight culture of pVK14. At an OD600 of 0.6, expression was induced 
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with 120 µM IPTG and the culture was allowed to grow at 16°C, 130 rpm for 21 h. After 
centrifugation and resuspension in lysis buffer, cells were homogenized. 
 
 
.  
 
 
 
 
4.4.1.4 Purification of RovC 
After clearing of the lysate by centrifugation, affinity chromatography was performed. Due to 
the improved solubility at higher ionic strength, NaCl concentration was increased to 500 mM 
in all purification buffers. Protein was further purified by size exclusion chromatography in 
100 mM TRIS pH 8, 500 mM NaCl, 5 mM DTT and 5% glycerol. A 31 kDa band copurified 
with the 42 kDa 6xHis_SUMO_RovC (Figure 66). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: 6xHis_SUMO_RovC purification. A) Coomassie stained gel of RovC Ni-affinity chromatography. P: 
pellet; FT: flow through of the column; W1-W2: wash fraction (washing with 10 and 15 mM imidazole 
respectively); E1-E4: elution fractions (with 100 mM imidazole); M: marker; B) Elution profile of the run on S200 
16/60 column (left); Coomassie stained gel of eluted fractions. Along with 42 kDa band (6xHis_SUMO_RovC), an 
additional band at 31 kDa was also observed (right). Blue bar represents the corresponding elution fractions in 
the chromatogram that were analysed by SDS PAGE. Absorbance of the protein is measured at 280 nm. 
A Ni-affinity 
B Size-exclusion chromtaography 
 
Figure 65: Coomassie stained 15% SDS gel of 6xHis_SUMO tagged RovC test 
expression. Maximum soluble protein yield was obtained at 16°C post induction 
incubation temperature with 120 µM IPTG in dYT medium. In the lysis buffer NaCl 
concentration was increased to 500 mM and 0.1% Triton X-100 was also added. 
Band corresponding to 6xHis_SUMO_RovC is marked with the black arrow. 
         
6xHis_SUMO_RovC 
42 kDa 
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Mass-spectrometry analysis confirmed that both bands (42 and 31 kDa) belonged to RovC. 
To confirm the N-terminal sequence of the smaller fragment, the band was analyzed by 
Edman degradation that identified the sequence as I-E-A-H-R-E-Q-I-G, corresponding to the 
C-terminal end of SUMO tag. The results from Edman degradation reveal a partial 
degradation of the tag, resulting in two species, the 6xHis_SUMO_RovC and the degraded 
variant, partially lacking the 6xHis_SUMO tag. Due to this partial degradation, a 
homogeneous sample was not obtained. 
To circumvent this problem, RovC (M1-L247) was cloned into a modified pCOLA-Duet vector 
(pPS41) with N-terminal 6xHis_SUMO tag and TEV cleavage site. RovC was expressed 
under the same condition as described above. 
Protein was first purified by Ni-affinity chromatography. Elution fractions were pooled and 
TEV protease was added to remove the 6xHis_SUMO tag. To remove the uncleaved 
material, reverse Ni-affinity was performed. Cleavage with the highly specific TEV protease 
also resulted in cleavage of the partially degraded species observed before, resulting in a 
homogenous protein. Final step of purification was performed by size exclusion 
chromatography under the conditions described above (Figure 67). The overall yield of pure 
RovC was about 5 mg/L culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67: 6xHis_SUMO_TEV_RovC purification. A) Coomassie stained gel of RovC Ni-affinity 
chromatography. FT: flow through of the column; W1-W3: wash fraction (washing with 5, 10 and 15 mM imidazole 
respectively); E1-E5: elution fractions (with 100 mM imidazole); M: marker B) Elution fractions were pooled, 
incubated with TEV and loaded on size exclusion column. Elution profile of the run on S200 16/60 column (left); 
Coomassie stained gel of eluted fractions (right). Blue bar represents the corresponding elution fractions in the 
chromatogram that were analysed by SDS PAGE. Absorbance of the protein is measured at 280 nm. 
 
A Ni-affinity 
B Size-exclusion chromatography 
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4.4.2 Crystallization and structure solution 
4.4.2.1 Crystallization of RovC 
Crystallization screening with RovC (M1-L247) was performed at 20°C and 4°C using 
commercially available screens (anion, JCSG I-IV). RovC crystals were obtained under 
several different crystallization conditions. Most promising crystals were obtained with 0.1 M 
TRIS pH 8.5, 3.5 M sodium formate at 4°C with 4 mg/ml of RovC. For cryoprotection, 
reservoir solution was supplemented with an additional 15% glycerol. These crystals 
diffracted to 4 Å in-house (Figure 68A). Crystals were further optimized by designing a 96 
well grid screen around that condition. Single crystals were obtained under the following 
condition-0.1 M TRIS pH 8.3, 3.7 M sodium formate with 3 mg/ml of protein at 4°C (Figure 
68B). 
After optimization, crystals diffracted to 3.8 Å in-house. Several of those crystals were 
dissolved in protein buffer (100 mM TRIS pH 8, 500 mM NaCl, 5 mM DTT, 5% glycerol) and 
loaded on SDS PAGE to confirm the identity of crystals. As a control, RovC (in solution) was 
also loaded on the gel. The protein band was sent for mass spectrometry analysis which 
confirmed that the band in the gel belongs to RovC (Figure 68C). 
 
 
 
 
 
 
 
 
 
 
 
RovC shares no sequence homology with any other protein in the database, hence to solve 
the phase problem, a Se-Met labeled variant of RovC was expressed and purified by Ni-
affinity and size exclusion chromatography (Figure 69). Expression and purification 
conditions were same as described for the native protein. 
Se-Met labeled RovC crystals grew under the same condition as the native crystals. 
  
 
A 
Figure 68: RovC crystals. A) Initial hit B) Optimized crystals C) SDS PAGE analysis of crystals (S=protein in 
solution, C=protein in crystals). 
B C 
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4.4.2.2 Data collection and structure solution 
The data for Selenomethionine (peak wavelength-0.979287 Å) crystal was collected at 
beamline P11 at PETRA III at DESY. The data was indexed, integrated and scaled using the 
XDS program package. Se-Met RovC crystals diffracted to 3.0 Å resolution and belonged to 
space group R32:H. With one molecule in the asymmetric unit, the Matthews 
coefficient VM equals 2.58 Å3/Da, corresponding to a solvent content of 52%. The structure 
was solved by Autosol program in Phenix. Total of four Se sites (out of five) were located in 
one molecule with a figure of merit of 0.37. After an initial round of model building using the 
AutoBuild module in Phenix, a total of 132 out of 247 residues (63 residues in the N-
terminal region and 69 residues in the C-terminal region) were built with Rwork/Rfree of 
34%/41% followed by manual building in Coot. The quality of the electron density was 
however not sufficient to build the complete model. 
With the aim to find crystals with better diffracting properties, further screening of RovC 
against other commercially available screens (Nucleix, Morphius and Midas) were performed. 
Crystals were obtained in the following condition- 0.2 M KCl, 0.01 M MgSO4, 0.01 M MES pH 
5.6, 10% PEG400 at 20°C with 6 mg/ml of RovC. For cryoprotection, reservoir solution was 
supplemented with an additional 20% glycerol. Data for native crystals were collected at 
beamline P11 at PETRA III at DESY. Crystals diffracted to 2.3 Å resolution and belonged to 
space group P321. With one molecule in the asymmetric unit, the Matthews coefficient VM 
equals 2.21 Å3/Da, corresponding to a solvent content of 44%. The structure was solved by 
Molecular Replacement using Phaser MR by using the N- and C-terminal domains of the 
previously build partial model of RovC separately as search models. Phenix AutoBuild was 
used to build the model. In this crystal form, additional electron density was visible, into which 
residues were built manually in Coot. Even though the optimized crystals improved the 
overall quality of the electron density, the quality of the additional electron density was not 
sufficient to assign a sequence, and has thus only been built as poly-Ala model. The statistics 
of the data collection is summarized in Table 29.  
 
 
Figure 69: Purification of the Se-Met variant of RovC. Elution profile of Se-Met RovC on S200 16/60 column 
(left); Coomassie stained gel of eluted fractions (right). Blue bar represents the corresponding elution fractions in 
the chromatogram that were analysed by SDS PAGE. Absorbance of the protein is measured at 280 nm. 
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Table 29: Data collection and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DATA COLLECTION RovC RovC SeMet 
X-ray source DESY PXIII DESY PXIII 
Wavelength [Å] 1.033200 0.979287 
Resolution [Å] 33.44 - 2.30 
(2.38 - 2.30) 
19.40 - 3.00 
(3.10 - 3.00) 
Space group P321 R32 
Cell dimensions  
a, b, c [Å] 
α, β, γ [°] 
 
97.28, 97.28, 46.04 
 
90, 90, 120 
 
97.67,97.67,156.03 
 
90, 90, 120 
Rmerge[%] 8.3 (56.6) 17.8 (267.5) 
Rmeas[%] 9.6 (65.7) 18.1 (271.9) 
CC1/2 [%] 99.6 (69.4) 99.9 (85.8) 
‹I/σ(I)› 9.7 (2.3) 21.46 (2.2) 
 Completeness [%] 99.5 (99.9) 99.7 (99.5) 
 Unique reflections 11309 (1095) 11112 (1039) 
 Redundancy 4.0 (4.0) 30.9 (31.0) 
REFINEMENT   
Resolution [Å] 33.44 - 2.30  
No. of reflections 11306  
Rwork 22.6  
Rfree 28.1  
No. of atoms 1713  
Avg. B factor [Å2] 39.16  
R.m.s. deviations       
Bond length [Å]  
Bond angles [°] 
 
0.008 
0.930 
 
Ramachandran [%] 
(favored/allowed/ 
disallowed) 
96.1/3.9/0.0  
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4.4.2.3 Crystal structure of RovC 
RovC consists of two distinct folded domains (Figure 70), the N-terminal domain, comprising 
residues 1-135 (shown in green) and the C-terminal domain comprising residues 183-247 
(shown in teal). The N-terminal domain consists of three α-helices that are packed against 
three anti-parallel β-strands. These secondary structure features are connected by flexible 
loops that are not well resolved in the crystal structure. The C-terminal domain that adopts a 
helix-turn-helix motif is well defined by its electron density. Residues 136-176 (linker, shown 
in light brown) were built as poly-alanine backbone, because the side-chains were not visible. 
The overall quality of the electron is shown in Figure 71.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 70: Crystal structure of RovC. Domain boundaries of RovC (top) and cartoon representation of RovC 
(bottom). RovC consists of the N-terminal domain (shown in green), linker (shown in light brown) and the C-
terminal domain (shown in teal). Flexible regions that cannot be built are shown as black dotted lines. N and C 
terminus are labeled. 
 
Figure 71: Quality of the electron density. A representative portion of 
the electron density map (2Fo-Fc contoured at 1 σ) showing the quality 
of the electron density. 
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4.4.3 Strategies to alter crystallization behavior of RovC 
The crystal structure contained regions that were not well resolved; therefore, the approach 
was to alter the crystallization behavior of RovC by either modifying surface properties of the 
protein or removing disordered protein regions. With the aim of obtaining new crystal forms or 
better resolution, three different strategies were applied.  
The first approach was to clone, express and purify a set of surface entropy mutants of 
RovC. Using SERp server, three surface entropic residues (54-56EKK, 181-183KEE, 233-
234KK) were identified. Out of the three mutants, K181A/E182A/E183A and K233A/K234A 
were successfully cloned, expressed and purified in large scale (Figure 72). Crystallization 
assays were set up but no new crystal form was obtained. 
 
 
 
 
 
 
 
 
In-situ proteolysis was used as a second approach to rescue crystallization. Out of 12 
different proteases, only EndoproteinaseGluC produced a stable subdomain fragment 
(marked by the dashed box in Figure 73). EndoproteinaseGlu-C was added to RovC at a 
concentration of 1:1000 and 1:10000; 1.5 h prior to setting up of crystallization screens. 
Although RovC crystallized in various conditions, it did not yield well diffracting crystals. 
 
 
 
 
 
 
 
 
 
 
As a third approach, reductive methylation of lysines was performed (Figure 74). 
Crystallization screening was performed with Lys-methylated RovC, however, this approach 
also did not yield good diffracting crystals. 
  
Figure 73: Treatment of RovC with 
different proteases. RovC at a concentration 
of 1 mg/ml was treated with 12 different 
proteases (SU-Subtilisin, PA-Papain, EG-C-
EndoproteinaseGlu-C, AE-Actinase, BR-
Bromelain, CL-Clostripain, α-C-α-
Chymotrypsin, PK-Proteinase-K, TH-
Thermolysin, TR-Trypsin, PE-Pepsin, EL-
Elastase at a concentration of 0.01 mg/ml) 
and incubated for 1.5 h at room temperature. 
 
Figure 72: Purity of purified RovC SER mutants. 
Coommassie stained gel showing purity of mutants after 
size exclusion chromatography. These proteins were 
expressed and purified as described for the wild type 
RovC. 
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Even though different strategies were used, no improvement of the crystal quality compared 
to the crystals obtained with wild type potein could be obtained. 
4.4.4 Oligomeric state of RovC 
4.4.4.1 Multi Angle Light Scattering (MALS) of RovC 
A fully cleaved RovC (without 6xHis_SUMO tag), which has a molecular weight of 29.2 kDa, 
eluted between 60 and 80 ml on S200 16/60 column (Figure 67), suggestive of an oligomeric 
state. An oligomeric state would also be in line with the previous observation, that partially 
truncated 6xHis_SUMO_RovC, lacking the N-terminal 6xHis-tag, still co-eluted with full-
length 6xHis_SUMO_RovC from Ni-affinity resin.  
In order to determine the exact oligomeric state of RovC, size exclusion chromatography 
followed by multi-angle laser light scattering (SEC-MALS) experiment was performed. 
Molecular mass calculation revealed that the molecular weight is 173 kDa, which is close to 
the theoretical mass of the hexamer (175.2 kDa) revealing that RovC assembles as a highly 
stable hexamer in solution (Figure 75), since no additional peaks were observed in the 
elution profile, apart from the hexamer peak.  
 
 
 
 
 
 
 
 
 
 
Figure 74: Lysine methylation of RovC. 
Elution profile of the run on S200 10/30 
column. Absorbance of the protein is 
measured at 280 nm. 
 
 Figure 75: Light scattering chromatogram of RovC. SEC-MALS profile of purified RovC as observed from the 
MALS signal. 
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4.4.4.2 Hexamer in the crystal structure 
In the presented crystal structure, the asymmetric unit contains only one RovC molecule per 
AU (Figure 76A); hence, first dimer (Figure 76B) and then potential hexameric assemblies 
were generated by crystallographic two and three fold (32) symmetry operators. Two 
independent hexameric structures, ring and triskelion shaped were observed in the crystal 
structure (Figure 76C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.4.3 Small Angle X-Ray Scattering analysis of RovC 
To determine how RovC oligomers assemble in solution, SAXS experiment was performed. 
SAXS envelope was constructed without symmetry (P1) and also with symmetry restriction 
(P32 as seen in the crystal structure). Ab initio calculated envelopes were very similar (Figure 
77A, B). Fitting of the calculated scattering curve of RovC with the ring shaped hexamer 
resulted in a chi value of 1.27 which indicates a very good fit to the experimental scattering 
data (Figure 77C). 
  
Figure 76: RovC assemblies generated using the symmetry mates. A) monomer present in the asymmetric 
unit. B) RovC dimer, C) ring shaped hexamer and D) triskelion shaped hexamer generated by applying 
crystallographic symmetry. 
 
A B 
C D 
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4.4.4.4 Structure-guided mutational analysis of RovC 
SAXS data confirmed the ring shaped structure of RovC. To further validate the ring-shaped 
model, a series of point mutations were constructed based on the crystal structure that were 
divided into Set I, Set II and Set III categories (Figure 78). 
 
1) Mutations that disrupt the dimeric interface (Set I) – The dimer interface is formed 
mostly by residues 231-246 of the C-terminal domain (Figure 78 and Figure 79). The 
A237E and G242E mutations that might disrupt the dimeric interface of RovC due to 
replacement of the small/hydrophobic amino acid with a negatively charged side 
chain were designed. 
 
 
 
 
Figure 77: SAXS analysis of RovC. Rigid body fitting of the hexamer into the ab initio determined SAXS 
envelope calculated A) with no symmetry imposed B) with P32 symmetry imposed. C) Fit of the rigid body model 
(red) with the experimental scattering (blue). Quality of the fit is expressed in terms of chi value. 
 
A B 
C 
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2) Mutations that disrupt the ring shaped hexamer (Set II) - In the ring shaped hexamer; 
the interface formed between two dimers is contributed by residues 142-180 that is 
not well defined in the crystal structure. Based on the secondary structure prediction 
(Figure 64), residues 147-152 form a β-strand. Even though the side chains could not 
be assigned for the additional density in the crystal structure, one section adopts a β-
strand conformation that is likely to correspond to region 147-152. Thus, the I150P, 
I150P/Y151P mutations that might disrupt the interface in the ring shaped hexamer by 
destabilizing β-strand structure were designed. These mutations however are solvent 
 
Figure 79: Close-up view of the dimer interface of RovC. Residues that were mutated (Set I) are labeled (only 
in 1 molecule) and shown as sticks with oxygen atoms in red and nitrogen atoms in blue.  
 
Figure 78: Scheme of different mutations introduced in RovC. Regions where mutations are introduced are 
marked with the black circle. 
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exposed in triskelion shaped structure, thus should not influence its stability (Figure 
78 and Figure 80). 
 
 
 
 
 
 
 
 
 
 
 
 
3) Mutation that disrupts the triskelion shaped hexamer (Set III) - The S219E/A220E 
double mutation will introduce six negative charges in the center of the triskelion 
assembly which should destabilize this hexamer. In contrast, these mutations are 
solvent exposed in the ring shaped hexamer and should thus not affect its stability 
(Figure 78 and Figure 81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 81: Close-up view of residues that were mutated in the triskelion shaped assembly. 
Residues that were mutated (Set III) are labeled (only in one molecule) and shown as sticks with oxygen 
atoms in red.  
 
 
Figure 80: Close-up view of the hexamer interface of RovC. 2Fo-Fc map (contoured at 1 σ) showing the β-
strand conformation.  
                                                                                                                                   Results 
 
117 
  
Cloning, expression and purification of mutants 
The above mentioned variants were cloned and mutations were verified by sequencing. Out 
of five different mutants tested for expression, only S219E/A220E and I150P resulted in 
soluble protein (Table 30). 
Table 30: Overview on the solubility of different variants. 
 
RovC variant Hypothetical effect of the mutant Solubility 
Set I mutants   
A237E Should disrupt the dimeric interface Not soluble 
G242E Should disrupt the dimeric interface Not soluble 
Set II mutants   
I150P Should disrupt the ring shaped hexamer Soluble 
I150P/Y151P Should disrupt the ring shaped hexamer Not soluble 
Set III mutant   
S219E/A220E Should disrupt the triskelion shaped hexamer Soluble 
 
Both mutants were expressed and purified in large scale (Figure 82). Expression and 
purification conditions were the same as described for the wild type protein. 
 
 
 
 
 
 
 
 
4.4.4.5 MALS with RovC variants 
To further analyze the effect of mutations on the oligomeric state, MALS was performed. 
Molecular mass calculation revealed that S219E/A220E mutant forms a stable hexamer 
(calculated M.W. - 169 kDa) (Figure 83, shown in red). This result further validated the ring 
shaped model of RovC (Figure 78). For I150P mutant, five peaks were observed on the 
chromatogram (Figure 83, shown in green).  
 
 
 
Figure 82: SDS gel showing purity of RovC mutants. Coomassie 
stained gel showing purified RovC variants. Bands corresponding to 
RovC variants are marked with the black arrow. 
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Molecular mass calculation revealed that 50% of the species form hexamers while the 
remaining form lower and higher order oligomers for which the exact oligomeric state could 
not be calculated with confidence. These results suggest that the I150P mutant, despite of 
being soluble, destabilizes the hexamer and is partially prone to unspecific, higher order 
oligomerization. The solubilty and MALS data, therefore strongly support the model of a 
hexameric ring-shaped structure of RovC in solution. 
4.4.5 RovC interaction with T6SS4 DNA 
4.4.5.1 Microscale thermophoresis  
Vanessa Knittel (Prof. Petra Dersch’s group) could show with electrophoretic mobility shift 
assays and DNAse footprinting assays that RovC binds to the promoter region of T6SS-4 
(minimum binding fragment-38 bp). To further validate the interaction between purified RovC 
and Cy5-labeled T6SS4 DNA, microscale thermophoresis was used. In MST, instead of 38 
bp, 42 bp fragment was used to avoid the influence of Cy5 on binding. Cy5-labeled DNA 
fragment was titrated with increasing concentrations of RovC in 100 mM TRIS pH 8, 500 mM 
NaCl, 5 mM DTT and 0.05%tween. Obtained results confirmed the binding of RovC to the 42 
bp fragment with an experimentally determined affinity constant (Kd) in the range of 11.1 ± 
3.8 µM. Moreover, DNA fragments of different lengths were used to find the minimal binding 
region. On reducing the length of oligonucleotides affinity decreased, which indicated that 
RovC binds to the complete 38 bp fragment (Figure 84). 
  
 
Figure 83: Light scattering chromatogram of RovC variants. Normalized SEC-MALS profile of native RovC 
(in blue), S219E/A220E mutant (red) and I150P mutant (green). 
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4.4.5.2 DNA binding region on RovC 
In order to identify and narrow down the DNA-binding region on RovC, the electrostatic 
potential and conservation has been plotted on the surface of the RovC hexamer. An 
extended basic patch might be involved in interaction with the negatively charged backbone 
and conserved residues might be involved in specific contacts with the target DNA.  
 
1. Electrostatic surface potential of RovC- 
The surface potential of hexameric RovC was calculated in pymol using the generate 
vacuum electrostatics function (Baker et al., 2001). The analysis revealed one basic 
patch (per dimer) on the outer surface of the ring mainly formed by residues 225-240 
present on the helix-turn-helix motif, which represents the potential DNA binding site 
(Figure 85A).  
 
  
 
Figure 84: Interaction of RovC with T6SS4 DNA. A) RovC interaction with different fragments of Cy5 labeled 
DNA. B) MST curves showing the interaction of RovC with different DNA fragments, color scheme as in (A). 
Data shown is the average of duplicate experiments. 
A 
B 
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Figure 85: Potential DNA binding site on RovC. A) Electropotential surface analysis of RovC shown in two 
orientations. Potentials between -74.194 kT/e (red) and + 74.194 kT/e (blue) are color-coded. B) Alignment of 
RovC related proteins (red: 100% conserved amino acids; orange: 80%; yellow: 60%) (WP_049614373-
hypothetical protein from Y. pekkanenii; WP_037397067- hypothetical protein from Serratia; WP_049848866 
hypothetical protein from Trabulsiella odontotermitis; WP_038224070-hypothetical protein from Xenorhabdus 
bovienii; WP_052958275-hypothetical protein from Mesorhizobium sp. LC103) (Alignment generated with 
GeneDoc, (Nicholas et al., 1996)). C) Conserved regions on the surface of RovC shown in two orientations. Color 
scheme as in (B). The dark blue region corresponds to the poly-ala stretch with ill-defined density in the structure, 
to which a conservation could not be mapped onto. 
A 
B 
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2. Sequence conservation of RovC- 
Analysis based on the primary sequence identified six hypothetical proteins in the 
NCBI database that share 45-80% sequence identity with RovC (Figure 85B). These 
proteins are from different Gram-negative bacteria. As the sequence conservation is 
very high, these proteins are likely to adopt a similar fold and possess DNA binding 
function as RovC. The sequence conservation of these proteins was mapped onto the 
structure of RovC. As shown in (Figure 85C), residues 219-240 in the C-terminal 
domain, a region that partially overlaps with the basic patch, are highly conserved 
while the N-terminal domain is less strongly conserved. 
Sulfate ions in the crystal structure 
During the structure refinement, pieces of spherical electron density were observed that likely 
represent sulfate ions because of the crystallization condition containing MgSO4 as 
precipitant. All of the sulfate ions lie on the possible DNA binding site and might mimic DNA 
backbone phosphates (Figure 86). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 86: RovC structure with bound sulfate. A) The electrostatic potential map of RovC showing presence 
of sulfate ions on the positively charged patch. Sulfate ions are shown as spheres with sulfur atoms as yellow 
and oxygen atoms as red. Potentials between -74.194 kT/e (red) and + 74.194 kT/e (blue) are color-coded. B) 
Close-up view of the positively charged residues that are close to sulfate ions in the structure. Residues are 
labeled and shown as sticks with oxygen atoms in red and nitrogen atoms in blue.  
 
A 
B 
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Mutational analysis of DNA binding site 
To precisely analyze the region for DNA binding, site directed mutagenesis of the basic and 
solvent exposed residues (R225, R229 and K56) located on this patch was performed. These 
residues are conserved in RovC sequence as shown in Figure 85B. Apart from the above 
mentioned residues, two non-conserved lysines (K211/K215) present on the helix-turn-helix 
motif were also analyzed for DNA binding (Figure 87). 
 
 
 
 
 
 
 
 
 
 
These residues were mutated to Glutamate. Mutants were cloned, expressed, and purified 
(Figure 88) as described for the wild type protein. 
 
 
 
 
 
 
 
 
 
 
MALS with R225E, R229E, K56E and K211E/K215E variants 
Prior to examining the DNA binding activity of mutants, MALS was performed to ensure that 
the mutations did not affect the hexameric state of protein. As shown in Figure 89, all mutants 
form hexamers in solution. 
  
 
Figure 87: Close-up view of residues that were mutated on the helix-turn-helix motif. Residues that were 
mutated are labeled and shown as sticks with oxygen atoms in red. Sulfate ions are shown as spheres with 
sulfur atoms as yellow and oxygen atoms as red. 
 
Figure 88: SDS gel showing purity of RovC mutants. Coomassie stained gel showing purified RovC mutants. 
Bands corresponding to RovC variants are marked with the black arrow. 
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EMSA 
Mutants that form stable hexamers in solution (R225E, R229E, K56E, K211E/K215E and 
S219E/A220E) were tested for DNA binding in EMSA by Vanessa Knittel. R225E, R229E and 
S219E/A220E completely abolished DNA binding activity while K56E and K211E/K215E 
mutants had no influence on DNA binding suggesting that the DNA binding region lies on the 
conserved basic patch of RovC (discussed in detail in 5.4.3.1).  
4.4.5.4 Co-crystallization of RovC and T6SS4 DNA 
As the mutagenesis studies can identify basic residues involved in interacting with the DNA 
backbone, residues involved in recognition of a specific DNA sequence cannot easily be 
identified by mutagenesis studies. Therefore, co-crystallization of RovC with the 38 bp DNA 
binding fragment was performed using different commercially available screens at 20°C and 
4°C. RovC and DNA were mixed in a molar ratio of 1:1.2 prior to crystallization set-ups. 
However, no co-crystals were obtained.  
As the length of DNA plays a significant role in crystallization of protein-DNA complex 
(Pakotiprapha and Jeruzalmi, 2014), therefore, blunt ended DNA fragments of various 
lengths were used (Table 31). But this approach also did not result in co-crystal formation. 
 
  
 
Figure 89: Light scattering chromatogram of RovC variants. Normalized SEC-MALS profile of native RovC 
(in brown), R225E mutant (green), R229E mutant (dark red), K211E/K215E mutant (blue) and K56E mutant 
(red).  
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Table 31: DNA fragments used for co-crystallization with RovC. 
 
Name Sequence 5'3' 
38 mer ggataaacttattcgcagattttttcacccttcataca 
36 mer gataaacttattcgcagattttttcacccttcatac 
34 mer ataaacttattcgcagattttttcacccttcata 
32 mer taaacttattcgcagattttttcacccttcat 
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5 Discussion 
5.1 InvD from YPIII strain of Y. pseudotuberculosis 
Y. pseudotuberculosis possess several multifunctional adhesins on their surface that are not 
only needed by bacteria for binding to the host cell surface but are also required for efficient 
internalization and colonization. InvD has been recently identified in the YPIII strain of Y. 
pseudotuberculosis (Pisano et al., 2012), but the information on the structure and function 
has remained elusive. Thus, in this study, InvD structure was solved, its host receptor was 
identified and characterized by biochemical and biophysical experiments. 
5.1.1 The BIg12 and BIg13 domains  
InvD consists of 13 BIg domains out of which BIg1-12 are highly repetitive in sequence while 
BIg13 is significantly different from BIg1-12 (Figure 24). Despite the low sequence similarity, 
BIg13 also adopts a β-sandwich fold, similar to BIg12. BIg domains are identified in a variety 
of other bacterial surface proteins such as in Lig proteins from Leptospira interrogans 
(Raman et al., 2010), SiiE from Salmonella enterica (Griessl et al., 2013) and InvA from Y. 
pseudotuberculosis (Hamburger, 1999). These domains have a variety of different functions 
as seen for BIg domains of SiiE that target carbohydrates present on the host cell surface 
(Barlag and Hensel, 2015) or as a linker, to span a certain distance between the outer 
membrane anchor and the C-terminal adhesion domain, as reported for the D1-D3 domains 
of InvA (Hamburger, 1999). BIg12 domain of InvD adopts an I1-set of IgSF fold (Figure 25). 
As BIg1-11 share high sequence similarity with BIg12, they are likely to adopt a similar fold. I-
set of IgSF fold is often seen in other bacterial domains that act as linker (Wang, 2013). In 
contrast, the difference in the sequence of BIg13 domain suggests a special role of this 
domain in bacterial pathogenicity along with the adhesion domain. This was seen in case of 
InvA where D4 domain interacts with the head domain (D5) to form a superdomain 
necessary to bind β1-integrins (Hamburger, 1999). Thus, based on the limited proteolysis 
data of InvD1737/InvD1640 constructs, SAXS and structural data, it can be concluded that 
BIg13 and AD form a functional superdomain with low conformational flexibility, while BIg1-
12 act as spacer modules. 
5.1.2 The adhesion domain of InvD 
Unlike InvB and InvC adhesion domains, InvD AD shares no sequence similarity with the C-
type lectin domain of InvA. The core structure of the InvD AD adopts a β-sandwich fold and 
resembles the C2-set fold with extensive variations and insertions. Comparison of InvD-AD 
topology with BIg12/13 suggests that Yersinia has evolved the AD from its BIg domain to 
carry out a specific function (Figure 30).  
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Sequence analysis of InvD-AD using NCBI BLAST-p identified four structurally 
uncharacterized proteins that share more than 65% sequence identity (similarity 76-97%) 
with the AD of InvD (Figure 90A). All these proteins belong to different strains of the species 
Y. pseudotuberculosis. As considerable sequence similarity exists between InvD AD and the 
above mentioned proteins, these proteins are likely to adopt a similar fold, and thus probably 
fulfill a similar function as that of InvD YPIII adhesion domain. The sequence conservation of 
these proteins was mapped onto the three-dimensional structure of InvD to identify potential 
functional patches with high conservation rate (Figure 90B).  
Two major, highly conserved patches were identified at the top and the bottom of InvD 
structure. The first one is a large surface generated by the C'CFG sheet extending to the 
opposite sheet on strand A and the short antiparallel β-strands insertion between strands B 
and C. The second patch is located at the tip of the molecule and comprises residues of the 
α-helix and the C*/C'* β-turn. The two highly conserved patches are separated by a large 
surface forming a deep cleft in the protein with lower conservation, extending from strands 
C*/C'* to strands E, B and partially A (shown with black dotted lines in Figure 90B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These proteins are likely to provide a similar function as that of InvD, albeit possibly targeting 
different subtypes of the receptor of the same or different hosts, suggesting a broader use of 
this strategy by different zoonotic strains of the Yersinia genus. 
180° 180° 
 
Figure 90: Conservation patches on InvD AD. A) Alignment of InvD related proteins (red: 100% conserved 
amino acids; orange: 80% and yellow: 60%). CNI94919.1, CFV23641.1 and AIN12719.1 belong to different 
strains of Y. pseudotuberculosis; CRG49100.1 belongs to the species Y. wautersii. (Alignment was generated 
with Genedoc, (Nicholas et al., 1996)). B) Conserved regions on the structure of InvD AD as cartoon 
representation (left) and surface representation (right) shown in two orientations. Color scheme as in (A). The 
cleft is indicated with dotted lines. 
A 
B 
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In this deep cleft, some additional electron density was identified (Figure 91). Since InvD 
used for crystallization still contains the hexahistidine-tag, the tag peptide from a symmetry-
related molecule might occupy the position in the cleft resulting in the additional density, to 
which a sequence could however not be assigned to due to poor quality of the density.  
 
 
 
 
 
 
 
 
 
 
5.1.3 InvD interaction with immunoglobulins 
Structural similarity search using InvD AD did not result in any statistically significant match, 
which hampered the assignment of function to InvD AD on the basis of its structural features 
(Figure 31). Therefore, pull down experiments using homogenized extract of mice organs 
were performed which identified antibodies as the potential interaction partner of InvD. 
Further, in vitro panning and interaction assays confirmed that InvD AD specifically targets 
the Fab part of immunoglobulins of the VH3/VK1 subfamily combination with nanomolar to 
low micromolar affinity.  
These results strongly indicate that InvD-Fab interaction is not a classical antigen-antibody 
interaction since,  
i) antibodies isolated after 3rd of panning have common variable heavy (VH) 
and variable light (VL) chain subtypes, but different Complementarity 
Determining Regions (CDRs), 
ii) sequence alignments of VH and VL CDRs indicate broad diversity of CDR 
H3. CDR H3 are largely responsible for antigen specificity as these represent 
unique loops that arise from the hypervariable nature of the VDJ region 
(Figure 92), 
iii) and binding of InvD to specific subtype of the antibody is not dependent on 
prior immune exposure since „unselected libraries“ were used for panning.  
  
 
Figure 91: Electron density in the cleft of InvD-AD. Surface representation of InvD AD with the electron 
density of the tag (Fo-Fc map contoured at 2.5 σ) in the cleft region shown in two orientations.  
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Previous studies have demonstrated that bacterial and viral proteins that target specific 
subtype of the Fab region of immunoglobulins act as B-cell superantigens. Examples are 
staphylococcal Protein A (SpA) from Staphylococcus aureus and gp120 from human 
immunodeficiency virus-1 (HIV) (Townsley-Fuchs et al., 1997), which both target the VH3 
subfamily of Fab (Sasso et al., 1989) and protein L from Peptostreptococcus magnus, which 
binds to VK1, VK3 and VK4 subfamilies (Björck, 1988). These proteins are known to target 
not only the soluble antibodies but also the membrane bound antibodies exposed on B cells 
(Silverman and Goodyear, 2006) and can cause B–cell apoptosis, proliferation or 
overactivation of the classical complement pathway (Gjörloff Wingren et al., 2002; Kozlowski 
et al., 1996; Ruffet et al., 1994; Townsley-Fuchs et al., 1997). 
With the high specificity binding to the VH3/VK1 antibody subfamily combination (Figure 40 
and Figure 41) and binding to the B-cells surface (Figure 38), InvD shares these properties 
with bacterial and viral proteins that act as B-cell superantigens, however there are some 
differences. 
In contrast to classical superantigens, that target more than 5% of the B cell population by 
binding to either VL or VH
 
chain
 
domain of the membrane bound antibody (Silverman and 
Goodyear, 2006), InvD targets a combination of VL
 
and VH,
 
and binds to ~0.5% of murine B-
 
Figure 92: Sequence alignment of antibodies isolated after 3rd round of panning. Alignment of 59 
sequenced VH fragments (from HAL 9+10 libraries) indicates broad diversity in CDR 3 region. Alignment is 
generated with GeneDoc (Nicholas et al., 1996).  
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cell population. Therefore, future experiments are required to understand the biological 
significance of InvD-immunoglobulins interaction. 
In the present study, the roles of InvD to interact with VH3/VK1 fragment of the antibody and 
B cells are established. But, how and at which stage of the infection process InvD targets 
antibodies and/or B cells remain interesting open questions to be answered by future 
experiments. 
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5.2 InvE from IP31758 strain of Y. pseudotuberculosis 
Y. pseudotuberculosis produces different adhesins which are not only essential for bacterial 
uptake but are also needed for efficient colonization in the host. Strain IP31758 of Y. 
pseudotuberculosis is responsible for Far East scarlet–like fever and also leads to toxic 
shock syndrome, which is not commonly seen for pseudotuberculosis infections (Eppinger et 
al., 2007). A novel Invasin, InvE has been identified in this strain. So far, there has been no 
report on the structural and functional characterization of InvE. In this study, the three 
dimensional structure of InvE adhesion domain along with the two BIg domains was 
determined by X-ray crystallography and its structural characteristics are discussed.  
5.2.1 The BIg20 and BIg21 domains  
InvE consists of 21 BIg domains, out of which BIg1-20 share high sequence similarity while 
BIg21 is significantly different from BIg1-20 (Figure 52). Despite their weak sequence 
similarity, both BIg20 and BIg21 adopt an IgSF fold. BIg20 belongs to the I1–set while BIg21 
is categorized in the I2 set of IgSF fold (Figure 53). I-set of Ig-like fold generally acts as a 
linker to span a certain distance and present the ligand binding domain on the cell surface 
(Wang, 2013). Comparison of BIg21 with other Ig-like domains of InvA and InvE reveals a 
unique conformation (Figure 56), important for its interaction with the AD. Structural and 
sequence difference in the last Ig like domain suggests its role in bacterial pathogenicity 
along with the AD, as seen with InvA where D4-D5 domain interface spans significantly 
larger area required to form a superdomain necessary to bind β1-integrins (Hamburger et al., 
1999). Based on the limited proteolysis, SAXS and structural data, it is evident that in the rod 
shaped structure of InvE, BIg21 and AD form a functional superdomain with low 
conformational flexibility, while BIg1-20 act as spacer modules.  
5.2.2 The adhesion domain  
Structure based search of InvE adhesion domain using PDBefold resulted in the best fit with 
the CTLDs of Intimin from EPEC/EHEC and InvA from Y. pseudotuberculosis.  
Both Intimin and InvA are ~900 aa protein, consisting of the N-terminal β–barrel domain, 
followed by Ig like domains and the CTLD. Crystal structure of InvA reveals four Ig like 
domains (D1-D4) and the C-terminal domain (D5) while Intimin comprises three Ig like 
domains (D0-D2) and the C-terminal domain (D3) (Hamburger et al., 1999; Luo et al., 2000; 
Yi et al., 2010). During the infection process, Intimin targets the translocated intimin receptor 
(Tir), which is exported by the bacteria and integrated into the host cell plasma membrane 
(Kenny et al., 1997), whereas InvA targets β1-integrins on the host cell membrane, mediating 
efficient cellular uptake of the pathogen (Alrutz et al., 2001; Isberg et al., 1987).  
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InvE AD shares high structural similarity (Z score>8.5) with the adhesion domain of InvA and 
Intimin (Figure 93A, B) despite less than 17% sequence identity (Figure 93C). When InvE-
CTLD is superimposed on the adhesion domain of InvA (PDB ID-1cwv:A) and the adhesion 
domain of Intimin (PDB ID-3ncx:A), the rmsd is 2.5 Å and 2.2 Å, respectively. 
 
 
 
 
 
However, the major structural differences among them occur at the N-terminus which 
includes: presence of strand β0, wedge domain and adaptor ring in InvE AD, whereas InvA 
and Intimin lack these elements (Figure 93A, B). While the AR in InvE appears to stabilize 
the overall rod-shaped structure and link the BIg21 to AD as shown in Figure 57A, the 
function of the WD is at this stage less clear.  
Another difference among them is the relative orientation of the adhesion domains to the 
residual part of the protein. InvA and Intimin share a similar orientation while the orientation 
of InvE AD is different as shown in Figure 94.  
  
A B i) ii) 
C 
Figure 93: Structural and sequence alignment of InvE AD. A) Cartoon representation of InvE AD with β-
strands and α-helices labeled (color scheme as in Figure 59). B) Structural comparison of InvE AD with other 
structurally similar proteins. Superposition of InvE AD (color scheme as in Figure 59) with (in yellow) i) Intimin 
adherence protein (PDB ID-3ncx:A) and ii) InvA (PDB ID- 1cwv:A). C) Sequence alignment of InvE AD (InvE) 
with Intimin adherence protein (3ncx) and InvA (1cwv). (100% conserved amino acids are marked in red and 
80% in orange). Alignment is generated with GeneDoc (Nicholas et al., 1996). 
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As described above, the CTLDs of both InvA and Intimin promote bacterial adherence.  
1. In InvA, the integrin binding site is formed by polar and charged residues located on 
helix α1 and the loop followed by it (Hamburger et al., 1999) (Figure 95B). While InvE 
AD lacks cluster of residues required for integrin binding and contains mainly 
hydrophobic residues (Figure 95C).  
 
 
 
 
 
 
 
 
 
 
  
Figure 95: Close-up view of the Integrin binding site in InvA and its comparison with InvE. 
A) Structural overlay of InvA (PDB ID-1CWV:A) and InvE adhesion domain (color scheme as shown in Figure 
93A). B) Residues involved in binding integrin are shown on the structure of InvA and C) the corresponding 
residues in InvE AD are shown. These residues are shown as sticks with sulfur atoms in yellow, oxygen atoms in 
red and nitrogen atoms in blue. 
 
 
A B C 
Figure 94: Orientation of InvE AD as compared to InvA and Intimin. Structural overlay of InvE 
(BIg20/BIg21/InvE AD, in gray) with (in light blue) A) Intimin (D1/D2/Intimin AD) and B) InvA (D3/D4/InvA AD). 
 
A B 
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2. Structural superposition of EPEC Intimin-Tir structure (PDB ID-1f02) with InvE AD 
shows that when Intimin is replaced by InvE in the complex structure, steric clashes 
arise (marked with a black dotted circle in Figure 96C). Furthermore, InvE lacks the 
short helix (marked with a black arrow in Figure 96B) that is involved in Tir binding in 
Intimin (Luo et al., 2000) (Figure 96B, C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus, despite the overall structural similarity of the adhesion domain of InvE to InvA and 
Intimin, it appears that the AD of InvE has evolved to target a distinct receptor. 
InvE AD lacks the cluster of residues required for binding to Ca2+ and also motifs such as 
EPN, QPD and WND that are responsible for the specificity of sugar recognition (Zelensky 
and Gready, 2005).  
The identification of CTLD in InvE suggests its role in targeting a specific receptor on the host 
cell. The C-type lectin fold is at the core of many proteins with a wide range of functions 
including adhesion, signaling and cell-cell recognition (Zelensky and Gready, 2005), which 
hampers the assignment of function to InvE AD on the basis of its structural features. 
  
Figure 96: Close-up view of Intimin-Tir interaction interface and its comparison with InvE. 
A) Structural overlay of EPEC Intimin-Tir structure (PDB ID-1f02) (Intimin in yellow and Tir in light pink) with InvE 
AD (color scheme as in Figure 93A). B) Close-up view of Intimin-Tir and C) InvE AD-Tir interaction interface. 
Helix is marked with a black arrow in B. Black dotted circle in panel C represents the steric clashes in between 
InvE and Tir. 
 
A B 
C 
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5.3 YadApstb 
YadApstb and YadAent belong to the trimeric autotransporter family and share high sequence 
homology among themselves, however they differ in their pathogenicity. The difference in 
their virulence behavior is due to the presence of an additional 31 aa in YadApstb head region, 
that constitutes the ‘’uptake domain’’. Deletion of the 31 aa motif abolishes fibronectin binding 
and the molecule preferentially binds to collagen (Heise and Dersch, 2006). But the structural 
basis for this functional transition is not known. 
The structure of the head domain of YadApstb is solved in this work and compared with 
YadAent. The overall architecture of both proteins is similar consisting of β-roll trimeric 
structure (Figure 63). Both have NSVAIG-x-S motif required for collagen binding (Nummelin 
et al., 2004). However, the 31 aa region in YadApstb could not be completely built which 
indicates that this region is highly flexible. Nonetheless, the insertion was identified to be 
located at the tip of trimeric structure (Figure 97) which might modify the surface of the tip 
region of YadApstb in comparison to YadAent, which is likely to result in the changed binding 
specificity from collagen in YadAent to fibronectin in YadApstb. Even though the crystal 
structure has been solved, with the current data, it is difficult to give a detailed answer to the 
question on target specificity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Figure 97: Top view onto the tip of YadApstb. Structured parts of the 31 aa insertion are shown in cyan, 
orange and yellow (left) on the cartoon model, (right) and surface representation. 
 
                                                                                                                             Discussion 
 
135 
  
5.4 RovC 
Expression levels of various virulence factors in Yersinia are controlled by complex 
regulatory networks. The regulation is achieved at transcriptional, post-transcriptional and 
translational level by several proteins and RNAs (Erhardt and Dersch, 2015). One of these is 
RovC that regulates T6SS4 and Csr systems of Yersinia. Role of RovC in virulence has been 
established by the group of Prof. Petra Dersch (dissertation Stephanie Christine Seekircher, 
2014/Vanessa Knittel, unpublished data), but the details on the structure of RovC and the 
regulatory mechanism were not known. In order to gain insights into the molecular 
mechanism of RovC, its structure was solved and further characterized using biophysical and 
biochemical methods. 
5.4.1 Hexameric ring shaped structure of RovC 
In this study, the crystal structure of RovC was determined to 2.3 Å resolution. RovC is 
composed of the N-terminal domain, linker and the C-terminal domain. Further, SEC-MALS 
data revealed that RovC assembles as a hexamer in solution. Although, the determined 
structure contained one molecule in the asymmetric unit, hexameric RovC was generated by 
crystallographic symmetry in which the three dimers are arranged to form a ring like 
structure. The ring shaped model was further validated by SAXS and mutational studies 
(S219/A220 and I150P mutants) using SEC-MALS.  
RovC hexameric interface (Interface I as shown in Figure 98) forming the ring is formed 
solely by the N-terminal domain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 98: RovC hexameric and dimeric interface. The hexameric interface (interface I) (left) and the dimer 
interface (interface II) (right) are marked with a black box. 
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The interface and the linker region were partially built as poly-alanine chain into the electron 
density which precludes the possibility of making detailed interpretations regarding its 
structural organization and interface arrangement. This also indicates that the interface might 
allow for minor flexibility between different subunits.  
RovC dimer interface (Interface II as shown in Figure 99) was calculated by PISA. The 
interface is formed by 12 N-terminal and 16 C-terminal residues (per monomer) comprising 
an interface area of 1142.5 Å2 (formed by 14 hydrogen bonds and 2 salt bridges). 
Additionally, a network of hydrophobic interactions across the dimer interface were analyzed 
using the DIMPLOT module of LigPlot+ (Laskowski and Swindells, 2011) as shown in Figure 
99. 
 
 
 
 
All of the mutants with dimerization interface mutations resulted in insoluble protein. I150P 
mutant, which was designed to disrupt the ring formation, resulted in the formation of 
different order oligomers, while the double mutant I150P/Y151P resulted in insoluble protein. 
This indicates that the hexamer formation is critically important since any mutation designed 
to disrupt the dimeric or hexameric interface resulted in insoluble protein or unstable 
hexamer.  
5.4.2 Structural similarity search with DALI 
The N and C-terminal domains of RovC were separately submitted to the DALI server (Holm 
and Rosenstrom, 2010), as no structures were found that shared significant similarity with the 
full length RovC.  
 
Figure 99: Dimplot analysis of the dimeric interface of RovC. Hydrogen bonds are shown by green dashed 
lines and spoked arcs represent hydrophobic interactions. Residues that belong to chain A are labeled in blue 
while chain B residues are in red. 
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For the N–terminal domain, no significant match (Z score<2.8) was obtained with the top hits 
being lactoylglutathione lyase (PDB ID-2qh0:A), an enzyme that catalyzes the isomerization 
of the hemithioacetal (Thornalley, 2003) and Bleomycin acetyltransferase (PDB ID-2zw5:A), 
an enzyme that inactivates Bleomycin using acetyl-coenzymeA (Oda et al., 2010). Structural 
superposition of the N-terminal domain of RovC with these proteins however shows that 
there is no similarity in topology or fold with a high rmsd>4.5 Å, indicating that this domain 
adopts a unique fold (Figure 100).  
 
 
 
 
 
 
 
 
 
 
In contrast, DALI search for the C-terminal domain revealed substantial similarity (Z score>6) 
with two DNA binding proteins from Mycobacterium tuberculosis, RNA polymerase sigma 
factor (PDB ID-3hug: A) (Thakur et al., 2010) and two component transcriptional regulatory 
protein  (PDB ID-3c57:B) (Wisedchaisri et al., 2008).  
The superposition of the C-terminal domain of RovC with these proteins is shown in Figure 
101. All of them contain a helix-turn-helix topology suggesting that RovC might be a member 
of the helix-turn-helix family of DNA binding proteins. 
  
 
Figure 100: Comparison of the N-terminal domain of RovC with other structurally similar proteins  A) i) 
RovC N-terminal domain (in green) was superimposed with (in orange): ii) lactoylglutathione lyase (PDB code-
2qh0:A), iii) Bleomycin acetyltransferase (PDB code-2zw5:A). B) Sequence alignment of RovC N-terminal 
domain (RovC_N-ter) with lactoylglutathione lyase (2qh0:A) and Bleomycon acetyltransferase (2zw5:A). (100% 
conserved amino acids are marked in red and 80% in orange). Alignment is generated with GeneDoc (Nicholas 
et al., 1996). 
A 
B 
i) ii) iii) 
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5.4.3 RovC-T6SS4 interaction 
The DNA binding activity of RovC protein has been characterized in vitro by different 
approaches. Purified RovC showed robust DNA binding activity in EMSA and DNase 
footprinting assay (Vanessa Knittel, unpublished data). Further with MST, Kd of 11 µM was 
determined between the 42 bp fragment and RovC (Figure 84). The affinity dropped 
substantially on reducing the length of the DNA to shorter fragments, indicating that the 38 bp 
is the minimal DNA binding fragment. Generally, very high affinities (in the nanomolar range) 
are observed with proteins that target specific DNA sequences (Strauch, 2001). Although the 
reason for the moderate affinity between RovC and the 42 bp fragment is not known, high 
salt concentration in the protein buffer (500 mM NaCl) might be the cause (Lohman, 1986; 
Record et al., 1985). However, high salt was prerequisite for the stability of RovC in solution, 
so the effect of salt could not be tested on the strength of the interaction. 
To determine the stoichiometry of RovC-DNA interaction, stoichiometric titration experiment 
was performed with MST (as described in (Jerabek-Willemsen et al., 2014)). In contrast to 
equilibrium titrations, where the concentration of one of the interaction partner is kept well 
below the Kd, in stoichiometric titrations, concentration of both protein and DNA should be 
atleast 10-15 fold higher than the Kd to ensure saturation binding. However, for RovC-DNA 
interaction, for which the Kd of 11 µM was determined, concentration of atleast 100 µM of 
 
A 
B 
Figure 101: Comparison of the C-terminal domain of RovC with other structurally similar proteins. A) i) 
RovC C-terminal domain (in blue) was superimposed with (in orange): ii) two component transcriptional regulatory 
protein (PDB code-3c57:B) (rmsd 2.1 Å), iii) RNA polymerase sigma factor (PDB code-3hug:A) (rmsd 3.4 Å). B) 
Sequence alignment of RovC C-terminal domain (RovC_C-ter) with two component transcriptional regulatory 
protein (3c57:B) and RNA polymerase sigma factor (PDB code-3hug:A). (100% conserved amino acids are marked 
in red and 80% in orange). Alignment is generated with GeneDoc (Nicholas et al., 1996). 
i) ii) iii) 
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labeled DNA was required, which was technically not possible with MST. Therefore, further 
experiments are required to determine the ratio of DNA to RovC in the complex. 
5.4.3.1 DNA binding region on RovC 
The conserved basic patch in the C-terminal domain of RovC, forming the outer surface of 
the oligomeric ring, represents the probable ds DNA binding site (Figure 85). In order to 
identify if the amino acid residues of this patch are essential for DNA-binding activity, 
mutational analysis has been performed. Mutants R225, R229, and S219/A220 were found to 
completely abolish the DNA binding activity and at the same time retained the hexameric 
structure. On the other hand K56E and K211E/K215E mutants had no influence on DNA 
binding. Even though K56 is located in the basic patch, the side chain forms a salt bridge 
with D23 (Figure 102), precluding interaction with the DNA-phosphate backbone. This in turn 
might explain why the mutation had no effect on DNA binding. 
 
 
 
 
 
 
 
RovC C-terminal domain contains a helix-turn-helix motif formed by residues 200-219. This 
motif is generally known to bind in the major groove of DNA and responsible for making base 
specific recognition contacts with DNA (Garvie and Wolberger, 2001).  
The double mutant K211E/K215E present on the helix-turn-helix motif (Figure 87) had no 
influence on DNA binding activity indicating that in RovC, this motif is not required for 
interacting with DNA. Together, these results strongly indicate that the conserved basic patch 
of dimeric RovC constitutes the DNA binding region. Additionally, it suggests that RovC does 
not utilize the helix-turn-helix motif for DNA-interaction in the manner observed in classical 
helix-turn-helix DNA-binding (insertion of one helix into the major groove), but rather as 
structural element for dimerization and formation of the basic patch.   
 
Figure 102: Salt bridge formation in 
between K56 and D23. Close-up view of the 
salt bridge formation in between K56 and 
D23. These two residues are shown as sticks 
with oxygen atoms in red and nitrogens in 
blue. Sulfate ions are shown as spheres with 
sulfur atoms as yellow and oxygen atoms as 
red.The black dashed line indicates the salt 
bridge. 
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5.4.4 A model for DNA binding 
In the crystal structure, four sulfate ions bind to this basic patch of the dimeric RovC structure 
(Figure 86). Very often sulfate ions mimic the negatively charged phosphate backbone of 
DNA.  
By taking into account the mutagenesis data, the basic patch and position of the sulfate ions, 
a 21 bp ds B-DNA molecule was manually docked to the surface of RovC. As seen in Figure 
103, the 21 bp DNA fragment binds on the side of the hexameric ring. The DNA fragment fits 
well in the positively charged patch of RovC and the position of phosphate ions overlaps very 
well with sulfates present on that patch.  
 
 
 
 
 
 
 
 
 
Although a 21 bp fragment was docked, but the actual recognition sequence is 38 bp as 
determined by footprinting assay. Thus, with the current data, a model could be proposed in 
which hexameric RovC binds to the 38 bp DNA very specifically (Figure 104) and then 
potentially uses additional sites to bind additional sections of the DNA or a longer fragment of 
DNA wraps around RovC (Figure 104). However, more data are required for a more detailed 
prediction. 
 
 
 
Figure 103: Docked model of protein-DNA complex. Electropotential representation of RovC with the 21 bp B-
DNA fragment (PDB ID: 5sy7) docked onto the surface of RovC shown in two different orientations. Potentials 
between -74.194 kT/e (red) and + 74.194 kT/e (blue) are color-coded. Sulfate ions are shown as spheres with 
sulfur atoms as yellow and oxygen atoms as red. 
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5.4.5 Possible mechanisms for transcriptional activation 
As already mentioned RovC shares no structural and sequence similarity with any other 
known transcriptional activator. Hence, the detailed mechanism by which RovC activates 
transcription remains elusive. Binding of RovC to T6SS4 promoter can result in activation of 
expression by one of the following mechanisms- 
1. By acting as an antirepressor. One example for this is RovA protein. inv gene in Y. 
pseudotuberculosis is repressed by H-NS nucleoid associated protein. Binding of 
RovA to inv promoter causes the displacement of H-NS from the silencing element, 
leading to expression of Invasin (Lee et al., 2012; Stoebel et al., 2008). 
2. By altering the conformation of the promoter. This is seen in case of MerR type 
activators. Binding of transcriptional activator changes the conformation of the 
promoter that enables RNA Polymerase to initiate transcription (Browning and Busby, 
2004). 
3.  As a direct transcriptional activator as seen for cAMP receptor protein. Activator 
binds to the promoter element and initiates transcription by recruiting RNA 
polymerase to the promoter (Busby and Ebright, 1999). 
Which of these mechanisms RovC potentially uses to trigger expression of T6SS, remains an 
interesting question that needs to be answered in future experiments. 
 
 
Figure 104: A model for DNA binding. 
Hexameric RovC (shown as surface) binds 
to the 38 bp DNA fragment (in blue) very 
specifically and then might target other 
regions of DNA (in gray) by using 
additional sites present on its surface. 
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6 Summary and outlook 
6.1 InvD 
YPIII strain of Y. pseudotuberculosis expresses four Invasins, which are InvA, InvB, InvC and 
InvD (Pisano et al., 2012). So far, details on the regulation, structure and function of InvD 
have been elusive. In this project, the role of InvD has been elucidated biochemically and 
structurally. Crystal structure of InvD adhesion domain along with the two Ig-like domains 
was solved to 2.6 Å resolution. Structural analysis revealed that the adhesion domain adopts 
a distinct Ig-like fold evolved from its BIg domains. By phage display panning, in vitro 
interaction assays and ex vivo experiments, the role of InvD in binding VH3/VK1 fragment of 
the antibody and B-cells was established. However, the biological significance of the 
immunoglobulins binding of InvD, the subgroup specificity and interaction with B-cells is 
presently unknown.  
In this context, co-crystallization of InvD with VH3/VK1 antibody will be required to 
characterize details regarding the InvD-Fab interaction and identify determinants of binding 
specificity. In vivo and cell-culture based experiments are needed to be performed to 
determine the role of InvD in virulence caused by Yersinia. 
6.2 InvE 
InvE is the newly identified Invasin in the IP31758 strain of Y. pseudotuberculosis. The aim of 
this study was to determine the three dimensional structure of InvE adhesion domain and 
analyze its function in the context of virulence in Yersinia. For that purpose, InvE construct 
comprising the two N-terminal BIg domains along with the adhesion domain was expressed, 
purified and crystallized. The three‐dimensional structure of InvE was determined to 1.7 Å 
resolution by SAD and analyzed in solution by SAXS. The two N-terminal domains of InvE 
adopt a fold which is characteristic of the IgSF fold while the AD shows significant structural 
resemblance to the CTLDs of InvA and Intimin. Despite their high overall structural similarity, 
InvE AD does not share any sequence or structural resemblance to the Tir/integrin binding 
site of Intimin/InvA giving rise to the notion that InvE targets a distinct receptor in the host 
system.  
Possible roles for InvE in immune evasion or colonization remain to be experimentally 
determined. As Invasins generally target cell surface receptors, binding of InvE to lipids, 
proteins or carbohydrates should be tested. In addition to that, binding of InvE to different cell 
lines such as epithelial, T and B cell lines needs to be analyzed. This experiment would give 
a strong indication of whether InvE targets a cell surface receptor. Once the receptor is 
identified, it would be interesting to co-crystallize it in complex with InvE to further understand 
the mechanism of action. 
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6.3 YadApstb 
YadA is a “lollipop” shaped protein on the cell surface of Y. pseudotuberculosis and Y. pestis 
(Hoiczyk et al., 2000). The aim of this project was to provide the structural basis for the 
functional transition by solving the structure of YadApstb and to compare it with YadAent 
structure (Nummelin et al., 2004). For that purpose, the head domain of YadApstb was cloned, 
expressed, purified and crystallized. YadApstb structure was solved to 2.3 Å resolution. 
However, detailed information on the architecture of insertion could not be obtained due to 
high flexibility of that region.  
In this context, co-crystallization of the head domain of YadApstb with fibronectin will shed light 
on its functional specificity and also stabilize the highly flexible 31 aa region. However, which 
domain of fibronectin is involved in interaction with YadApstb is not known. In this context, 
testing binding of different domains of fibronectin with YadApstb needs to be performed. In 
addition, SAXS analysis of the head domain of YadAent and YadApstb might provide further 
insight into differences in the tip region. 
6.4 RovC 
RovC is a transcriptional regulator of Yersinia that activates T6SS4 system (dissertation 
Stephanie Christine Seekircher, 2014/Vanessa Knittel, unpublished work). The aim of this 
project was to elucidate the role of RovC biochemically and structurally. For that purpose, full 
length RovC was over-expressed, purified and crystallized. The three‐dimensional structure 
of RovC was determined to 2.3 Å resolution and analyzed in solution by SAXS. The N-
terminal domain of RovC adopts a distinct fold while the C-terminal domain contains a helix-
turn-helix motif. SAXS reveals a hexameric ring shaped structure of RovC, which was 
strongly supported by MALS and site-directed mutagenesis studies. With MST, the affinity 
between RovC and T6SS4 DNA fragment was determined. Further with structural and 
mutational analysis, it was shown that R225, R229 and S219/A220 are residues crucial for 
DNA binding, giving rise to the notion that the DNA binding site is present on the surface of 
the hexamer. Finally, based on the data obtained, a model was proposed for RovC-mediated 
DNA-binding in which DNA wraps around the surface of hexameric RovC. 
Initial attempts that were made to co-crystallize RovC with T6SS4 DNA were not successful. 
Future work should focus on the crystallization of RovC in complex with T6SS4 DNA. The co-
crystal structure with DNA will provide detailed insights into the mechanism of action of 
RovC, especially into structural elements involved in the recognition of the specific T6SS-4 
DNA-sequence. In this context, testing binding of different fragments of T6SS4 DNA with 
RovC needs to be performed. Further, SAXS analysis of RovC-DNA complex could also shed 
light onto the mode of DNA binding. In addition, RovC mutants that have been used in this 
study should also be analyzed in vivo, to analyze their physiological relevance. 
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8 Appendix 
8.1 Abbreviations 
List of abbreviations 
~ Approximate 
∞ Infinite 
°C degree Celsius 
µg Microgram 
µl Microliter 
µM Micromolar 
α-C α-Chymotrypsin 
βME β-mercaptoethanol 
aa amino acids 
AE Actinase 
Ail Adherence and Invasion Locus 
AP alkaline phosphatase 
AU asymmetric unit 
BCIP 5-bromo 4-chloro 3’indolylphosphate 
BIg bacterial immunoglobulin-like 
bp base pairs 
BR Bromelain 
CV column volume 
CL Clostripain 
CTLD C-type lectin-like domain 
Csr carbon storage regulator 
Da Dalton; 1Da = 1g/mol 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonucleosid-triphosphate 
DTT Dithiothreitol 
dYT double Yeast Trypton Broth  
ECM extracellular matrix 
E.coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EG-C EndoproteinaseGlu-C 
EHEC enterohemorrhagic E.coli 
EL Elastase 
EMSA electrophoretic mobility shift assay 
EPEC enteropathogenic E.coli  
ESRF European Synchrotron Radiation Facility 
FAE follicle-associated epithelium 
h Hour 
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HEp-2 human epithelial type-2 
Ifp Intimin family protein 
IgSF immunoglobulin superfamily 
Ilp Intimin/Invasin-like protein 
IM inner membrane 
InvA Invasin 
InvB-E Invasin(B-E) 
IPTG isopropyl-β-D-thiogalactopyranoside 
JCSG Joint Center for Structural Genomics 
Kd dissociation constant 
L liter 
LB Luria Bertani 
M molar 
MALDI-TOF matrix assisted laser desorption ionization-time of flight 
min minute 
ml mililiter 
mM milimolar 
MR-SAD molecular replacement with single wavelength anomalous 
dispersion 
MS mass spectrometry 
MWCO molecular weight cut off 
NCBI National Centre for Biotechnology Informatin 
Ni-NTA nickel-nitrilotriacetic acid 
nM nanomolar 
OD600 optical density at wavelength of 600 nm 
OM outer membrane 
o/n overnight 
PA Papain 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PCR Polymerase chain reaction 
PDB Protein Data Bank 
PE Pepsin 
PK Proteinase-K 
Pla Plasminogen activator 
PMSF phenylmethanesulfonylfluoride 
PVDF polyvinyl difluoride 
pYV plasmid for Yersinia virulence 
RFU relative fluorescence unit 
rmsd root main square deviation 
RovC regulator of virulence associated with CsrC 
rpm revolutions per minute 
s second 
S75 superdex 75 (gel filtration column) 
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S200 superdex 200 (gel filtration column) 
SAXS small angle x-ray scattering 
SDS  sodium dodecyl sulftae 
SEC-MALS Size exclusion chromatography with multi angle light scattering 
Se-Met seleno-methionine 
SER Surface Entropy Reduction 
SOC super optimal broth with catabolite repression 
SU Subtilisin 
T(1-6)SS Type (1-6) secretion system 
TEMED tetramethylethylenediamine 
TH Thermolysin 
Tris tris(hydroxymethyl)aminomethane  
VH variable heavy 
VL variable light 
(v/v) volume per volume 
(w/v) weight per volume 
Y.  Yersinia  
YadA Yersinia adhesin A 
Yop Yersinia outer proteins 
 
Abbreviations for amino acids 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartate/Aspartic acid 
E Glu Glutamate/Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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8.2 Supplementary table 
8.2.1 Glycan binding analysis of InvD 
Chart 
Number 
Structure on Masterlist AvgMeanS-B 
w/o MIN/MAX 
StDev %CV 
1 Gala-Sp8 3 3 92 
2 Glca-Sp8 23 26 111 
3 Mana-Sp8 8 7 87 
4 GalNAca-Sp8 8 4 43 
5 GalNAca-Sp15 5 2 51 
6 Fuca-Sp8 22 17 79 
7 Fuca-Sp9 10 9 89 
8 Rhaa-Sp8 17 14 82 
9 Neu5Aca-Sp8 4 3 69 
10 Neu5Aca-Sp11 20 29 146 
11 Neu5Acb-Sp8 29 21 73 
12 Galb-Sp8 61 39 64 
13 Glcb-Sp8 4 4 124 
14 Manb-Sp8 3 2 49 
15 GalNAcb-Sp8 30 25 82 
16 GlcNAcb-Sp0 7 6 77 
17 GlcNAcb-Sp8 9 10 101 
18 GlcN(Gc)b-Sp8 1 1 165 
19 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAca-Sp8 16 3 21 
20 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAc-Sp14 13 3 24 
21 GlcNAcb1-6(GlcNAcb1-4)(GlcNAcb1-3)GlcNAc-Sp8 17 10 62 
22 6S(3S)Galb1-4(6S)GlcNAcb-Sp0 5 3 62 
23 6S(3S)Galb1-4GlcNAcb-Sp0 19 6 31 
24 (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 26 10 39 
25 (3S)Galb1-4Glcb-Sp8 4 4 94 
26 (3S)Galb1-4(6S)Glcb-Sp0 14 11 81 
27 (3S)Galb1-4(6S)Glcb-Sp8 -1 2 -143 
28 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp8 3 7 274 
29 (3S)Galb1-3GalNAca-Sp8 6 2 38 
30 (3S)Galb1-3GlcNAcb-Sp0 13 15 114 
31 (3S)Galb1-3GlcNAcb-Sp8 3 8 315 
32 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp0  5 4 75 
33 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8 3 3 111 
34 (3S)Galb1-4(6S)GlcNAcb-Sp0 28 20 72 
35 (3S)Galb1-4(6S)GlcNAcb-Sp8 23 12 51 
36 (3S)Galb1-4GlcNAcb-Sp0 12 2 15 
37 (3S)Galb1-4GlcNAcb-Sp8 4 4 125 
38 (3S)Galb-Sp8 2 2 72 
39 (6S)(4S)Galb1-4GlcNAcb-Sp0 0 4 ### 
40 (4S)Galb1-4GlcNAcb-Sp8 18 32 175 
41 (6P)Mana-Sp8 7 13 189 
42 (6S)Galb1-4Glcb-Sp0 13 25 184 
43 (6S)Galb1-4Glcb-Sp8 7 6 83 
44 (6S)Galb1-4GlcNAcb-Sp8 -2 7 -411 
45 (6S)Galb1-4(6S)Glcb-Sp8 20 13 65 
46 Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 4 6 144 
47 (6S)GlcNAcb-Sp8 13 8 58 
48 Neu5,9Ac2a-Sp8 12 25 202 
49 Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8 7 14 183 
50 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 8 98 
51 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 8 6 76 
52 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 23 15 65 
53 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 7 6 86 
54 Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 
20 23 114 
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55 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
8 15 187 
56 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Man-a1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
24 21 88 
57 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 
24 14 59 
58 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 19 19 104 
59 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 12 8 70 
60 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 3 5 153 
61 Fuca1-2Galb1-3GalNAca-Sp8 8 5 63 
62 Fuca1-2Galb1-3GalNAca-Sp14 7 5 73 
63 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 14 7 50 
64 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 18 28 155 
65 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 6 3 54 
66 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 19 6 33 
67 Fuca1-2Galb1-3GlcNAcb-Sp0 9 8 86 
68 Fuca1-2Galb1-3GlcNAcb-Sp8 3 5 152 
69 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 11 5 46 
70 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 
10 1 11 
71 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 19 17 87 
72 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 1 10 653 
73 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 4 259 
74 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 2 24 
75 Fuca1-2Galb1-4GlcNAcb-Sp0 12 12 107 
76 Fuca1-2Galb1-4GlcNAcb-Sp8 12 12 106 
77 Fuca1-2Galb1-4Glcb-Sp0 7 3 42 
78 Fuca1-2Galb-Sp8 10 9 92 
79 Fuca1-3GlcNAcb-Sp8 9 5 52 
80 Fuca1-4GlcNAcb-Sp8 22 18 84 
81 Fucb1-3GlcNAcb-Sp8 19 14 75 
82 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 10 3 36 
83 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 16 22 141 
84 (3S)Galb1-4(Fuca1-3)Glcb-Sp0 6 2 36 
85 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 4 2 65 
86 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 6 5 84 
87 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 3 7 204 
88 GlcNAcb1-3Galb1-3GalNAca-Sp8 2 3 155 
89 GalNAca1-3(Fuca1-2)Galb-Sp8 8 6 78 
90 GalNAca1-3(Fuca1-2)Galb-Sp18 39 36 92 
91 GalNAca1-3GalNAcb-Sp8 10 9 90 
92 GalNAca1-3Galb-Sp8 3 3 102 
93 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 17 13 73 
94 GalNAcb1-3GalNAca-Sp8 6 1 23 
95 GalNAcb1-3(Fuca1-2)Galb-Sp8 26 32 121 
96 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 6 10 151 
97 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 10 13 124 
98 GalNAcb1-4GlcNAcb-Sp0 10 15 158 
99 GalNAcb1-4GlcNAcb-Sp8 31 41 133 
100 Gala1-2Galb-Sp8 25 24 95 
101 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 5 2 44 
102 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8 5 3 57 
103 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 6 2 29 
104 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp8 25 27 110 
105 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 9 5 53 
106 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 5 5 102 
107 Gala1-3(Fuca1-2)Galb-Sp8 16 20 128 
108 Gala1-3(Fuca1-2)Galb-Sp18 30 37 124 
109 Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 7 7 101 
110 Gala1-3GalNAca-Sp8 29 12 43 
111 Gala1-3GalNAca-Sp16 14 14 98 
112 Gala1-3GalNAcb-Sp8 9 6 71 
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113 Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 29 14 47 
114 Gala1-3Galb1-3GlcNAcb-Sp0 11 6 57 
115 Gala1-3Galb1-4GlcNAcb-Sp8 10 6 62 
116 Gala1-3Galb1-4Glcb-Sp0 17 19 112 
117 Gala1-3Galb1-4Glc-Sp10 2 5 225 
118 Gala1-3Galb-Sp8 18 14 82 
119 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 5 6 122 
120 Gala1-4Galb1-4GlcNAcb-Sp0 5 3 54 
121 Gala1-4Galb1-4GlcNAcb-Sp8 4 5 114 
122 Gala1-4Galb1-4Glcb-Sp0 11 7 64 
123 Gala1-4GlcNAcb-Sp8 9 9 107 
124 Gala1-6Glcb-Sp8 7 5 70 
125 Galb1-2Galb-Sp8 11 6 55 
126 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 21 17 82 
127 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 21 21 97 
128 Galb1-3(Fuca1-4)GlcNAc-Sp0  19 12 66 
129 Galb1-3(Fuca1-4)GlcNAc-Sp8  12 6 54 
130 Fuca1-4(Galb1-3)GlcNAcb-Sp8 3 7 208 
131 Galb1-4GlcNAcb1-6GalNAca-Sp8 8 10 128 
132 Galb1-4GlcNAcb1-6GalNAc-Sp14 9 7 70 
133 GlcNAcb1-6(Galb1-3)GalNAca-Sp8  15 26 177 
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp14 5 3 59 
135 Neu5Aca2-6(Galb1-3)GalNAca-Sp8 10 8 79 
136 Neu5Aca2-6(Galb1-3)GalNAca-Sp14 26 3 10 
137 Neu5Acb2-6(Galb1-3)GalNAca-Sp8 15 12 76 
138 Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 4 8 178 
139 Galb1-3GalNAca-Sp8 35 55 158 
140 Galb1-3GalNAca-Sp14 21 8 38 
141 Galb1-3GalNAca-Sp16 6 4 74 
142 Galb1-3GalNAcb-Sp8 15 13 90 
143 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 15 11 72 
144 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 19 16 84 
145 Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 35 20 57 
146 Galb1-3Galb-Sp8 10 3 33 
147 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 15 6 37 
148 Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 10 11 115 
149 Galb1-3GlcNAcb-Sp0 13 12 90 
150 Galb1-3GlcNAcb-Sp8 7 10 141 
151 Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 4 156 
152 Galb1-4(Fuca1-3)GlcNAcb-Sp8 17 20 123 
153 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 15 5 35 
154 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-
Sp0 
15 6 44 
155 Galb1-4(6S)Glcb-Sp0 8 5 65 
156 Galb1-4(6S)Glcb-Sp8 13 23 170 
157 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 23 22 96 
158 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 3 4 117 
159 Galb1-4GlcNAcb1-3GalNAca-Sp8 14 9 65 
160 Galb1-4GlcNAcb1-3GalNAc-Sp14 23 20 87 
161 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 17 14 85 
162 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 2 102 
163 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 10 4 40 
164 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 7 4 50 
165 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8 8 7 86 
166 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 16 18 112 
167 Galb1-4GlcNAcb1-6(Galb1-3)GalNAc-Sp14 4 6 165 
168 Galb1-4GlcNAcb-Sp0 3 4 140 
169 Galb1-4GlcNAcb-Sp8 18 9 49 
170 Galb1-4GlcNAcb-Sp23 2 3 129 
171 Galb1-4Glcb-Sp0 16 25 150 
172 Galb1-4Glcb-Sp8 13 6 43 
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173 GlcNAca1-3Galb1-4GlcNAcb-Sp8 3 8 289 
174 GlcNAca1-6Galb1-4GlcNAcb-Sp8 10 9 86 
175 GlcNAcb1-2Galb1-3GalNAca-Sp8 35 9 26 
176 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 33 31 94 
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 6 9 144 
178 GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAcb-Sp8 3 3 105 
179 GlcNAcb1-3GalNAca-Sp8 9 2 17 
180 GlcNAcb1-3GalNAca-Sp14 9 5 56 
181 GlcNAcb1-3Galb-Sp8 6 12 208 
182 GlcNAcb1-3Galb1-4GlcNAcb-Sp0 20 22 109 
183 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 10 18 180 
184 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 2 49 
185 GlcNAcb1-3Galb1-4Glcb-Sp0 8 9 108 
186 GlcNAcb1-4-MDPLys 41 25 62 
187 GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 4 9 229 
188 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 33 21 65 
189 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 10 9 90 
190 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 4 4 103 
191 GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 15 11 75 
192 GlcNAcb1-6GalNAca-Sp8 22 19 87 
193 GlcNAcb1-6GalNAca-Sp14 7 3 48 
194 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 42 25 60 
195 Glca1-4Glcb-Sp8 1 3 495 
196 Glca1-4Glca-Sp8 6 1 21 
197 Glca1-6Glca1-6Glcb-Sp8 4 3 65 
198 Glcb1-4Glcb-Sp8 3 9 289 
199 Glcb1-6Glcb-Sp8 16 8 52 
200 G-ol-Sp8 2 4 155 
201 GlcAa-Sp8 5 10 213 
202 GlcAb-Sp8 7 3 39 
203 GlcAb1-3Galb-Sp8 19 14 74 
204 GlcAb1-6Galb-Sp8 11 22 192 
205 KDNa2-3Galb1-3GlcNAcb-Sp0 -4 8 -210 
206 KDNa2-3Galb1-4GlcNAcb-Sp0 7 3 44 
207 Mana1-2Mana1-2Mana1-3Mana-Sp9 14 11 75 
208 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana-Sp9 12 2 18 
209 Mana1-2Mana1-3Mana-Sp9 12 6 55 
210 Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 
5 4 83 
211 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 
8 6 74 
212 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 
16 11 70 
213 Mana1-6(Mana1-3)Mana-Sp9 10 5 51 
214 Mana1-2Mana1-2Mana1-6(Mana1-3)Mana-Sp9 10 7 65 
215 Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 7 8 112 
216 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 7 7 105 
217 Manb1-4GlcNAcb-Sp0 2 10 434 
218 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 16 16 103 
219 (3S)Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8  16 16 101 
220 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 5 3 48 
221 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8 5 12 272 
222 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0 17 12 69 
223 Neu5Aca2-3Galb1-3GalNAca-Sp8 36 15 42 
224 Neu5Aca2-3Galb1-3GalNAca-Sp14 15 8 57 
225 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 4 4 112 
226 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 20 20 100 
227 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 11 17 155 
228 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 4 5 122 
229 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 13 13 99 
230 Neu5Aca2-3(6S)Galb1-4(Fuca1-3)GlcNAcb-Sp8 5 4 72 
231 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 6 4 71 
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232 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 13 15 120 
233 GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 5 7 127 
234 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 9 5 58 
235 Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 19 25 129 
236 Neu5Aca2-3GalNAca-Sp8 30 19 62 
237 Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 22 6 29 
238 Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 7 11 163 
239 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 6 3 46 
240 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 27 12 44 
241 Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 19 12 61 
242 Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 20 12 59 
243 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 3 2 63 
244 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 16 22 139 
245 Neu5Aca2-3Galb-Sp8 4 3 83 
246 Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 13 18 146 
247 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3 2 66 
248 Fuca1-2(6S)Galb1-4Glcb-Sp0 8 6 73 
249 Neu5Aca2-3Galb1-3GlcNAcb-Sp0 10 11 109 
250 Neu5Aca2-3Galb1-3GlcNAcb-Sp8 6 4 69 
251 Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 9 11 129 
252 Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 17 9 51 
253 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 
8 18 220 
254 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 5 3 58 
255 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 5 7 125 
256 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 7 3 43 
257 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 14 1 9 
258 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6 6 95 
259 Neu5Aca2-3Galb1-4GlcNAcb-Sp0 18 11 60 
260 Neu5Aca2-3Galb1-4GlcNAcb-Sp8 35 30 87 
261 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 18 11 63 
262 Fuca1-2Galb1-4(6S)Glcb-Sp0 15 10 66 
263 Neu5Aca2-3Galb1-4Glcb-Sp0 19 20 106 
264 Neu5Aca2-3Galb1-4Glcb-Sp8 20 20 97 
265 Neu5Aca2-6GalNAca-Sp8 5 4 71 
266 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 0 4 -762 
267 Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 19 21 108 
268 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 7 7 93 
269 Neu5Aca2-6Galb1-4GlcNAcb-Sp8 21 20 95 
270 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 
10 5 52 
271 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 30 14 46 
272 Neu5Aca2-6Galb1-4Glcb-Sp0 3 1 31 
273 Neu5Aca2-6Galb1-4Glcb-Sp8 19 16 86 
274 Neu5Aca2-6Galb-Sp8 10 13 130 
275 Neu5Aca2-8Neu5Aca-Sp8 13 5 38 
276 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 12 10 81 
277 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 6 3 55 
278 Neu5Acb2-6GalNAca-Sp8 10 9 84 
279 Neu5Acb2-6Galb1-4GlcNAcb-Sp8 12 8 63 
280 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 2 5 246 
281 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 11 11 99 
282 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 2 6 283 
283 Neu5Gca2-3Galb1-4GlcNAcb-Sp0 14 11 76 
284 Neu5Gca2-3Galb1-4Glcb-Sp0 24 33 141 
285 Neu5Gca2-6GalNAca-Sp0 8 18 228 
286 Neu5Gca2-6Galb1-4GlcNAcb-Sp0 7 6 85 
287 Neu5Gca-Sp8 13 9 64 
288 Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 18 7 42 
289 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 11 4 34 
290 Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0  18 9 50 
291 Galb1-4(Fuca1-3)(6S)Glcb-Sp0 30 18 61 
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292 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 4 3 64 
293 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 4 11 259 
294 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0        4 4 101 
295 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 9 6 67 
296 4S(3S)Galb1-4GlcNAcb-Sp0 43 42 96 
297 (6S)Galb1-4(6S)GlcNAcb-Sp0 4 3 69 
298 (6P)Glcb-Sp10 7 2 34 
299 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14 29 18 63 
300 Galb1-3Galb1-4GlcNAcb-Sp8 18 12 66 
301 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 
14 15 109 
302 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 16 19 123 
303 GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 22 11 52 
304 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 8 6 79 
305 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 10 3 26 
306 GalNAcb1-3Galb-Sp8 25 9 37 
307 GlcAb1-3GlcNAcb-Sp8 12 10 80 
308 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 
9 3 27 
309 GlcNAcb1-3Man-Sp10 8 11 135 
310 GlcNAcb1-4GlcNAcb-Sp10 10 7 71 
311 GlcNAcb1-4GlcNAcb-Sp12 31 23 75 
312 MurNAcb1-4GlcNAcb-Sp10 14 5 35 
313 Mana1-6Manb-Sp10 37 14 37 
314 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 17 19 118 
315 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Mana-Sp9 9 4 48 
316 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Mana-Sp9 8 9 121 
317 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 21 27 133 
318 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
8 5 62 
319 Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp12 
2 8 393 
320 Neu5Aca2-8Neu5Acb-Sp17 7 5 72 
321 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 6 5 79 
322 Neu5Gcb2-6Galb1-4GlcNAc-Sp8 38 14 36 
323 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp19 
22 11 50 
324 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
13 13 97 
325 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
7 2 22 
326 Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 
7 5 70 
327 Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 16 17 106 
328 Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 16 17 106 
329 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 13 12 93 
330 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 39 35 89 
331 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 15 22 144 
332 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 9 7 78 
333 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 6 4 65 
334 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 11 129 
335 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 62 11 19 
336 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAc-Sp14 16 28 181 
337 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 7 144 
338 GlcNAca1-4Galb1-4GlcNAcb-Sp0 8 2 26 
339 GlcNAca1-4Galb1-3GlcNAcb-Sp0 6 3 42 
340 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 13 9 65 
341 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-
Sp0 
70 9 12 
342 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 27 27 102 
343 GlcNAca1-4Galb1-3GalNAc-Sp14 22 22 103 
344 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 5 5 100 
345 Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 6 4 68 
346 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 4 4 89 
                                                                                                                                 Appendix 
 
163 
  
347 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 1 3 393 
348 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 3 4 108 
349 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 4 1 33 
350 Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 41 33 79 
351 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 54 33 62 
352 Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 
24 18 77 
353 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 
28 20 72 
354 (6S)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 7 5 75 
355 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 13 7 58 
356 KDNa2-6Galb1-4GlcNAc-Sp0 14 21 145 
357 KDNa2-3Galb1-4Glc-Sp0 -1 3 -220 
358 KDNa2-3Galb1-3GalNAca-Sp14 28 25 88 
359 Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 
32 9 28 
360 Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 
39 22 56 
361 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAb-Sp20 
80 32 40 
362 Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 
15 8 49 
363 Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 3 8 222 
364 Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-6(Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
39 12 30 
365 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 3 5 189 
366 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 9 5 52 
367 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 14 16 119 
368 Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 
0 14 ### 
369 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 
15 8 55 
370 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 
9 6 60 
371 Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 
81 24 30 
372 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 
14 11 77 
373 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 
7 5 65 
374 Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-2Mana1-3(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 
60 40 67 
375 Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 4 1 36 
376 Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 4 7 163 
377 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 6 7 106 
378 GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAc-Sp12 
22 21 98 
379 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0 14 14 95 
380 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 3 12 393 
381 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp0 5 4 82 
382 Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21  12 18 148 
383 Galb1-4GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 26 20 78 
384 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 5 11 228 
385 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21  7 6 78 
386 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-4(Galb1-
4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
4 6 146 
387 GlcNAcb1-2Mana1-6(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 
12 6 55 
388 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 10 7 63 
389 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 5 3 70 
390 Galb1-3GlcNAcb1-3GalNAca-Sp14 11 6 55 
391 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14 61 37 60 
392 GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 12 8 65 
393 Gala1-3Galb1-3GlcNAcb1-2Mana1-6(Gala1-3Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp19 
20 8 41 
394 Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19 
36 16 45 
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395 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp19 
38 29 75 
396 GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 25 16 63 
397 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 5 3 66 
398 Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 23 16 68 
399 Fuca1-2Galb1-4GlcNAcb1-3GalNAca-Sp14 4 3 72 
400 Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 8 12 159 
401 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 14 7 51 
402 Gala1-4Galb1-3GlcNAcb1-2Mana1-6(Gala1-4Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 
17 17 99 
403 Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp24 
8 3 41 
404 Gala1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 14 4 25 
405 Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 12 4 31 
406 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 33 48 145 
407 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 4 2 47 
408 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 7 10 152 
409 Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 16 20 122 
410 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 15 7 47 
411 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 8 9 118 
412 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 2 6 296 
413 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 6 3 44 
414 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 5 2 54 
415 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 57 40 70 
416 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 7 6 91 
417 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 25 10 39 
418 Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
14 12 84 
419 Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
24 18 73 
420 GlcNAcb1-2(GlcNAcb1-6)Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp19 
14 12 88 
421 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 5 3 65 
422 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 6 6 91 
423 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 12 10 87 
424 Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14 10 10 102 
425 Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
48 23 47 
426 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
15 5 32 
427 Galb1-3GlcNAcb1-6(Galb1-3GlcNAcb1-2)Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 
15 13 87 
428 Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 10 8 77 
429 Fuca1-3GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 19 8 44 
430 GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 
6 6 100 
431 GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 
4 5 128 
432 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 
8 7 89 
433 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 
0 6 ### 
434 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 
3 6 210 
435 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 
8 9 101 
436 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 
11 7 59 
437 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-
4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 
10 6 59 
438 Galb1-4Galb-Sp10 9 1 7 
439 Galb1-6Galb-Sp10 12 4 36 
440 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 5 4 72 
441 GalNAcb1-6GalNAcb-Sp8 18 10 55 
442 (6S)Galb1-3GlcNAcb-Sp0 16 14 88 
443 (6S)Galb1-3(6S)GlcNAc-Sp0 34 36 108 
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444 Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2(Fuca1-2Galb1-
4GlcNAcb1-4)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
42 30 72 
445 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
4(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
12 10 84 
446 Galb1-4(Fuca1-3)GlcNAcb1-6GalNAc-Sp14 6 3 46 
447 Galb1-4GlcNAcb1-2Mana-Sp0 11 8 72 
448 Fuca1-2Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)GalNAc-Sp14 31 20 65 
449 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3)GalNAc-
Sp14 
44 28 65 
450 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6(GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
3)GalNAc-Sp14 
23 18 79 
451 Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 7 3 43 
452 GalNAcb1-4Galb1-4Glcb-Sp0 10 5 48 
453 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
34 13 40 
454 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
23 8 35 
455 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 19 16 81 
456 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-
3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 
38 23 61 
457 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 
20 18 92 
458 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
3 1 43 
459 Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-
4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
15 16 113 
460 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-
4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
9 9 96 
461 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-
4)(Neu5Aca2-3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 
28 11 41 
462 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
9 7 75 
463 Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-
4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
11 5 43 
464 Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-
4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 
14 10 74 
465 Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-
4)(Neu5Aca2-6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 
17 11 62 
466 Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8 16 21 128 
467 Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 34 23 67 
468 Glca1-6Glca1-6Glca1-6Glcb-Sp10 14 19 136 
469 Glca1-4Glca1-4Glca1-4Glcb-Sp10 8 3 42 
470 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 17 12 71 
471 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
25 10 42 
472 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 
22 5 21 
473 Neu5Aca2-3Galb1-3GlcNAcb1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2)Mana1-6(Neu5Aca2-
3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 
0 5 ### 
474 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 
8 9 115 
475 Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp21 
17 10 60 
476 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp21 3 4 139 
477 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0 83 53 64 
478 Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14 20 10 51 
479 Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14 14 6 42 
480 Neu5Aca2-6Galb1-4 GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3)GalNAca-Sp14 1 3 181 
481 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
38 29 76 
482 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
8 2 31 
483 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 11 6 56 
484 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
17 12 74 
485 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-3GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 
1 4 306 
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486 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3)Galb1-4Glc-
Sp21 
8 1 19 
487 Galb1-3GlcNAcb1-6GalNAca-Sp14 7 8 124 
488 Gala1-3Galb1-3GlcNAcb1-6GalNAca-Sp14 9 8 85 
489 Galb1-3(Fuca1-4)GlcNAcb1-6GalNAca-Sp14 8 3 30 
490 Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14 9 8 88 
491 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0 0 5 ### 
492 Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6(Neu5Aca2-3Galb1-3)GlcNAcb1-3)Galb1-
4Glc-Sp21 
6 6 100 
493 Fuca1-2Galb1-4GlcNAcb1-6GalNAca-Sp14 6 2 40 
494 Gala1-3Galb1-4GlcNAcb1-6GalNAca-Sp14 9 12 133 
495 Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 13 6 47 
496 Fuca1-2(6S)Galb1-3GlcNAcb-Sp0 17 22 127 
497 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAca-Sp14 11 7 61 
498 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0 8 6 78 
499 Fuca1-2Galb1-3(6S)GlcNAcb-Sp0 23 15 63 
500 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 14 7 46 
501 Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 6 5 79 
502 GalNAcb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 6 3 59 
503 (3S)GalNAcb1-4(Fuca1-3)GlcNAcb-Sp8 24 13 52 
504 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)GalNAca-Sp14 21 13 61 
505 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 2 2 138 
506 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 
5 2 43 
507 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)Galb1-4GlcNAcb1-4(Gal 
b1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 
13 19 149 
508 Galb1-3GlcNAca1-3Galb1-4GlcNAcb-Sp8  11 12 114 
509 Galb1-3(6S)GlcNAcb-Sp8  22 14 63 
510 (6S)(4S)GalNAcb1-4GlcNAc-Sp8 6 3 44 
511 (6S)GalNAcb1-4GlcNAc-Sp8  9 7 72 
512 (3S)GalNAcb1-4(3S)GlcNAc-Sp8 79 30 38 
513 GalNAcb1-4(6S)GlcNAc-Sp8  30 27 87 
514 (3S)GalNAcb1-4GlcNAc-Sp8  21 23 107 
515 (4S)GalNAcb-Sp10 8 1 9 
516 Galb1-4(6P)GlcNAcb-Sp0  4 8 192 
517 (6P)Galb1-4GlcNAcb-SP0  9 5 49 
518 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAc-Sp14 12 12 99 
519 Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 18 26 139 
520 Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 5 2 42 
521 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana-Sp0 3 2 73 
522 GalNAca1-3(Fuca1-2)Galb1-4 GlcNAcb1-2Mana-Sp0 11 10 86 
523  Galb1-3GlcNAcb1-2Mana-Sp0 13 8 60 
524 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14 44 28 62 
525 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 14 6 41 
526 Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 7 6 82 
527 GalNAcb1-4GlcNAcb1-2Mana-Sp0 10 13 127 
528 Neu5Aca2-3Galb1-3GalNAcb1-4Galb1-4Glcb-Sp0 12 12 96 
529 GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAc-Sp21 
6 11 169 
530 Galb1-4GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 
2 3 123 
531 Galb1-4GlcNAcb1-2 Mana1-6(Galb1-4GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 
11 7 63 
532 Fuca1-4(Galb1-3)GlcNAcb1-2 Mana-Sp0 9 9 108 
533 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 6 6 97 
534 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAc-Sp0 1 2 211 
535 GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 25 28 112 
536 Gala1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 25 8 33 
537 Galb1-3GalNAcb1-3Gal-Sp21 9 9 96 
538 GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
14 13 93 
539 GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
38 9 24 
540 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1- 1017 152 15 
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2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
541 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 
37 6 16 
542 Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Gca2-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 
28 48 172 
543 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 
9 9 105 
544 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
551 41 7 
545 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
41 8 19 
546 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
175 95 54 
547 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 
21 8 37 
548 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
35 21 59 
549 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
27 21 77 
550 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp25 
6 3 62 
551 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 3 4 166 
552 Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 6 8 137 
553 Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 2 5 198 
554 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 25 18 70 
555 Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 16 7 44 
556 Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 8 6 71 
557 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-2Man a1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24 
14 11 73 
558 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Mana1-4GlcNAcb1-
4GlcNAc-Sp24 
39 40 102 
559 Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp24 
125 67 53 
560 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-3)GalNAca-Sp14 19 24 126 
561 GalNAcb1-3GlcNAcb-Sp0  9 6 75 
562 GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb-Sp0  28 20 72 
563 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
11 6 50 
564 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
10 10 100 
565 GlcNAb1-3Galb1-3GalNAc-Sp14 22 13 61 
566 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 20 13 64 
567 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 
19 6 34 
568 (3S)GlcAb1-3Galb1-4GlcNAcb1-3Galb1-4Glc-Sp0 6 7 111 
569 (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 15 10 65 
570 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
53 12 23 
571 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 
29 19 66 
572 Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glc-Sp21 14 14 105 
573 GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
13 6 47 
574 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
71 28 39 
575 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
114 52 46 
576 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 
47 13 29 
577 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
53 10 19 
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3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
578 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
34 11 33 
579 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 
20 14 71 
580 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp19 
18 12 65 
581 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 
101 10 10 
582 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
264 27 10 
583 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
122 29 23 
584 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
70 6 8 
585 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
49 30 61 
586 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 
14 7 53 
587 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 
53 60 113 
588 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 107 97 91 
589 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 89 9 10 
590 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 
104 36 35 
591 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 10 7 68 
592 GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 11 12 106 
593 GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 10 7 74 
594 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 6 2 39 
595 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3)GalNAca-Sp14 
11 5 48 
596 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 12 8 68 
597 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 8 14 180 
598 Galb1-4GlcNAcb1-3Galb1-3GalNAca-Sp14 20 16 77 
599 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 21 26 122 
600 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 21 15 71 
601 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 58 48 83 
602 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
26 2 9 
603 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 15 11 73 
604 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3)GalNAca-Sp14 
42 25 61 
605 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
69 108 155 
606 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
42 6 14 
607 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 
0 3 ### 
608 GlcNAcb1-3Fuca-Sp21 6 2 27 
609 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp21 30 26 87 
Chart number indicates the glycan number; Structure on masterlist indicates the name of the glycan; 
AvgMeanS-B w/o MIN/MAX indicates the average RFU value from the replicates; St Dev indicates the Standard 
deviation; %CV is 100 * St.Dev/Mean. 
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